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ABSTRACT 
Despite intense interest in the proteolysis of Amyloid Precursor Protein (APP) in 
Alzheimer’s disease (AD), how the normal processing and function of this type I receptor-like 
glycoprotein is regulated remains ill-defined.  APP is reported to function in neurodevelopment, 
including migration of neuronal precursor cells into the cortical plate. In recent years, several 
candidate ligands for APP, including F-spondin, Reelin, β1 Integrin, Contactins, and Lingo-1 have 
been reported. However, a cognate ligand for APP that regulates its function or processing has 
yet to be widely confirmed in multiple laboratories.  
First, in an unbiased approach to reveal novel ligands, Pancortin was identified by a 
mass spectrometry-based screen for factors that bind to the APP ectodomain in rodent brain. 
Each of the Pancortin isoforms was confirmed to interact with APP. However, only specific 
Pancortin isoforms reduced β-secretase but not α-secretase cleavage of endogenous APP. Using 
in utero electroporation to overexpress or knockdown Pancortin isoforms in rodent cortex, a 
previously unidentified role for Pancortin in cortical cell migration with evidence for a 
functional interaction with APP was discovered.  
Next, I developed new assays in an effort to confirm a role for one or more of the 
published candidate ligands in regulating APP ectodomain shedding in a biologically relevant 
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context.   A comprehensive quantification of APPsα and APPsβ, the immediate products of 
secretase processing, in both non-neuronal cell lines and primary neuronal cultures expressing 
endogenous APP yielded no evidence that any of these published candidate ligands stimulate 
ectodomain shedding.  Rather, Reelin, Lingo-1 and Pancortin emerged as the most consistent 
ligands for significantly inhibiting ectodomain shedding.  
These studies clarify mechanisms regulating the function and processing of APP, which is 
needed to understand consequences of chronically altering APP proteolysis to treat AD and to 
develop new potential drug targets. 
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The Biology of Amyloid Precursor Protein 
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Importance of APP to human health 
Alzheimer’s disease 
Amyloid Precursor Protein (APP) was identified just over 25 years ago (Goldgaber et al, 
1987; Kang et al, 1987; Tanzi et al, 1987).  Since then, a central role for APP in the pathogenesis 
of Alzheimer’s disease (AD) has been established. APP is processed via regulated 
intramembrane proteolysis to generate, amount other fragments, the amyloid-beta peptide 
(Aβ) (reviewed in (De Strooper & Annaert, 2000). Aβ aggregates to form amyloid deposits in 
brain parenchyma and its microvasculature during aging and in AD(Glenner & Wong, 1984; 
Masters et al, 1985). These extracellular Aβ plaques along with neurofibrillarly tangles of 
hyperphosphorylated Tau are the pathological hallmarks found in post-mortem AD brain. A vast 
number of biochemical and in vivo animal studies provide solid evidence that Aβ at least in part 
initiates a cascade resulting in synaptic dysfunction, neurodegeneration, and ultimately 
memory impairment in AD (reviewed in (Hardy & Selkoe, 2002)). These neurotoxic effects of Aβ 
are often attributed to various oligomeric assembly forms of the peptide (Lesné et al, 2013; 
Shankar et al, 2007).  
The strongest evidence implicating APP in AD comes from genetic studies of rare, early-
onset, familial cases of the disease. Over 200 dominantly inherited missense mutations have 
been identified in either the APP gene or Presenilin-1 or 2 genes (subunits of the γ-secretase 
complex that cleaves APP to generate Aβ) (reviewed in(Tanzi, 2012)).  Mutations within APP are 
known to lead to either increase Aβ production, Aβ aggregation, or Aβ42/AP40 ratios. For 
example, the ‘Swedish’ mutation (which will be briefly used in Chapter 3) resides near the β-
secretase cleavage site of APP and elevates Aβ levels by enhancing β-secretase cleavage of APP 
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(Citron et al, 1992; Mullan et al, 1992). The ‘London’ V717I mutation (studied in Appendix 2) 
resides within the transmembrane domain of APP near the γ-secretase cleavage site and leads 
to increased Aβ42/40 ratio (Goate et al, 1991; Tamaoka et al, 1994).  
As a result, intensive efforts are underway to enhance Aβ clearance or to chronically 
inhibit β- or γ-secretase cleavage of APP to prevent Aβ generation as rational approaches to the 
treatment and prevention of AD (reviewed in(Selkoe, 2011). In fact, such therapeutic strategies 
are currently in patient trials. Nevertheless, the fundamental biological function of APP has not 
been definitively established. Elucidating the physiological function of APP and the role 
proteolytic processing plays in these functions would help better understand potential side-
effects of reducing APP processing to treat AD. Further, identifying the precise molecular 
mechanisms that regulate APP processing—for example, a ligand which triggers the initial 
cleavage event-- could yield novel, biologically relevant drug targets for AD.  
The APP family 
APP family members 
Much of the difficulty in elucidating the precise function of APP has been attributed to 
functional redundancy and compensation by its conserved family members. In mammals, two 
homologues for APP, termed amyloid precursor-like protein 1 (APLP1) and APLP2 share 56% 
and 68% amino acid sequence homology to APP, respectively (Slunt et al, 1994; Wasco et al, 
1993; Wasco et al, 1992). APP orthologs have also been identified in non-mammalian species 
including  appa and appb in zebrafish with 70% homology (Musa et al, 2001), APP-like (APPL)  in 
Drosophila melanogaster with 43% homology (Luo et al, 1990; Rosen et al, 1989), and APL-1 in 
Caenorhabditis elegans with 46% homology (Daigle & Li, 1993)(reviewed in(Walsh et al, 2007)).  
3
Structure  
APP is an integral type I transmembrane glycoprotein. With a large extracellular domain 
(accounting for at least 88% of the total protein mass (Gralle & Ferreria, 2007), a single 
transmembrane domain, and three lysine residues in a short cytoplasmic tail, APP has been 
predicted to be a cell-surface receptor since its initial discovery (Kang et al, 1987). While the 
crystal structure of entire full-length APP or its ectodomain have not been solved despite 
multiple attempts, individual domains of the protein have been structurally characterized  
(reviewed in (Gralle & Ferreria, 2007)). These structural studies predict the ectodomain has 
regions of flexibility enabling it to undergo multiple conformation changes, which may have 
interesting implications for a putative APP ligand (Botelho et al, 2003; Gralle et al, 2002; Gralle 
& Ferreria, 2007). The flexibility of the APP ectodomain may allow it to recognize multiple 
ligands with high specificity. Binding of such a ligands could induce a conformational changes to 
stabilize the ectodomain or expose the α- or β- secretase cleavage sites, thus promoting 
ectodomain shedding  (reviewed in (Gralle & Ferreria, 2007)).  
The APP ectodomain can be characterized in terms of three major regions: the E1, 
acidic, and carbohydrate regions (Figure 1.1.) (reviewed in (Reinhard et al, 2005)). The reported 
binding of candidate ligands are not confined to a specific region of the APP ectodomain, rather 
protein-protein interactions have been reported within each of these domains.  The amino-
terminal E1 region, to which Reelin (Hoe et al, 2009) and CNTN4 (Osterfield et al, 2008) (as well 
as Pancortin in studies presented in Chapter 2) are reported to interact, consists of the growth 
factor-like domain (GFLD) followed by the copper-binding domain (CuBD). The GFLD, enriched 
with cysteines, contains disulfide bonds, a heparin binding site, and a hydrophobic surface 
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patch. These types of hydrophobic regions are generally known to be important sites for 
protein-protein interactions (Rossjohn et al, 1999). While several candidate ligands (Reelin, 
CNTNs, Pancortins) have been reported to bind a region of APP that includes this patch (Hoe et 
al, 2009; Osterfield et al, 2008; Rice et al, 2012)), its importance for ligand binding is not clear 
but should be considered. Linking the E1 region to the carbohydrate region is an acidic region, 
which is one flexible region that does not participate in any secondary structure. This is 
followed by the Kunitz-type protease inhibitor (KPI) domain and OX2 domain, which is removed 
through alternative splicing in some isoforms (described in more detail in the next section). The 
KPI domain has been shown to inhibit multiple serine proteases in vitro (Sinha et al, 1990) and 
to be involved in the coagulation cascade in human plasma (Smith et al, 1990; van Nostrand et 
al, 1990). The carbohydrate region, which contains a heparin binding site and 2 glycosylation 
sites, consists of the E2/central APP domain (CAPPD) and an unstructured linker domain. The 
E2/CAPPD, to which the candidate ligand F-spondin (Ho & Sudhof, 2004) has been reported to 
interact, contains an RERMS sequence with proposed trophic functions(Li et al, 1997; Ninomiya 
et al, 1993). The Aβ region resides partly within the extracellular linker sequence and partly 
within the transmembrane domain. The transmembrane domain is followed by a small 
cytoplasmic tail known as the APP intracellular domain (AICD), which contains phosphorylation 
sites  and an YENPTY sequence implicated in intracellular interactions (Kerr & Small, 2005).  
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Figure 1.1 Structure and isoforms of APP.  
The APP ectodomain is composed of the E1, Acidic, and Carbohydrate domains, each with 
multiple subdomains. Alternative splicing of APP leads to multiple isoforms, including 
APP770, APP751, APP695, and APP733 (also termed appican).  
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The structural similarities and differences of the APP family members may provide 
critical insights to both their redundant and separate functions. APP, APLP-1 and -2 have an 
almost entirely conserved intracellular domain, including the NPXY internalization motif (Walsh 
et al, 2007). Within the ectodomains of the APP family members, the E1 and E2 regions are also 
quite conserved; however, the juxtamembrane regions including the Aβ sequence are highly 
divergent (Walsh et al, 2007). Thus, the AD-relevant Aβ peptide is unique to APP.  Recently, 
evidence has begun to suggest that these structural similarities enable the APP family members 
to form both homo- and heter-dimerization in cis and trans. Multiple sites of interaction have 
been described including a requirement of the E1 region for APP and APLP2 dimerization and 
the requirement of the E2 region for dimerization of APLP1 (Kaden et al, 2009; Soba et al, 
2005). A GxxxG motif within the transmembrane domain has been reported to be a third site 
for stabilization of APP dimers (Munter et al, 2007).  
Expression 
In mammals, the APP gene, containing 19 exons, is expressed as multiple isoforms 
through alternative splicing (Figure 1.1) (Yoshikai et al, 1990). The APP700 isoform results from 
the non-spliced transcript; whereas, APP751 results from splicing of exon 8 containing the OX2 
sequence, and APP695 results from splicing of both exons 7 and 8 which removes the KPI 
domain as well as the OX2 sequence.  In addition to these three main isoforms, the APP733 
isoform often termed ‘appican’ is generated by splicing of exon 15 to yield a consensus 
sequence for the attachment of chondroitin sulfate chains at the exon 14-16 fusion site just n-
terminal to the Aβ sequence(Pangalos et al, 1995). APLP2, but not APLP1, undergoes alternative 
splicing to generate similar isoforms as APP (Lenkkeri et al, 1998). 
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While APP is enriched in neuronal tissues, it is also expressed ubiquitously throughout 
non-neural tissues. APP695 is the predominant isoform in neuronal tissue, and APP770 and 
APP751 are the predominant isoforms in non-neuronal tissues but are also expressed in the 
brain (Ohyagi et al, 1990; Sisodia et al, 1993). APP733 is expressed primarily in astrocytes. The 
Like APP, APLP2 is ubiquitously expressed but enriched in neurons; whereas, APLP1 is expressed 
almost exclusively by neurons (Lorent et al, 1995). Expression levels of each of the APP family 
members increase progressively over embryonic development (Lorent et al, 1995).  Within the 
embryonic cortex, evidence suggests that APP family members may differ in their expression 
patterns.  APP is reported to be expressed throughout the cortical plate (CP) and in a subset of 
cells in the intermediate (IZ) and ventricular (VZ) zones; whereas APLP1 expression is reported 
to be more confined to the VZ and subventricular zone (SVZ) and APLP1 to the CP (López-
Sánchez et al, 2005; Young-Pearse et al, 2007). Within neurons, APP is localized in neurites to 
growth cones and at both presynaptic and postsynaptic terminals (Sabo et al, 2003; Yamazaki et 
al, 1997). 
Trafficking and proteolytic processing of APP 
Amyloidogenic and non-amyloidogenic processing pathways 
APP undergoes sequential proteolytic processing during normal cell metabolism  (Figure 
1.2) (Haass et al, 1992). Two distinct processing pathways can lead to either the generation of 
Aβ (the amyloidogenic pathway) or preclude Aβ generation (the non-amyloidogenic pathway) 
(reviewed in(De Strooper & Annaert, 2000). In the amyloidogenic pathway, the initial cleavage 
event is performed by β-secretase primarily between Met596 and Asp597 (APP695 numbering) 
8
but also to a lesser degree between Tyr606 and Glu607.  This results in shedding of the large 
APP ectodomain, releasing a fragment termed APPsβ. The remaining C-terminal fragment 
(CTFβ) of 99 amino acids is then cleaved by γ-secretase. Cleavage of CTFβ by γ-secretase 
releases Aβ into the luminal/extracellular space and AICD into the cytoplasm. The non-
amyloidogenic pathway is quite similar except the initial cleavage event is performed by α-
secretase between Lys612 and Leuc613 within the Aβ sequence, thereby preventing Aβ 
generation.  APPsα is shed into the extracellular space and CTFα of 83 amino acids is retained in 
the membrane. CTFα is cleaved by γ-secretase to release p3 into the luminal/extracellular space 
and AICD into the cytoplasm.  APLP-1 and -2 undergo similar sequential proteolytic processing 
as APP, but it does not result in generation of an Aβ peptide due to sequence differences. 
Recently, an additional cleavage event has been proposed, in which a yet unknown protease 
further cleaves APPsβ to generate a 35kDa fragment termed N-APP (Nikolaev et al, 2009). 
However, this has yet to be further investigated and confirmed by multiple laboratories.  
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Figure 1.2 Proteolytic processing of APP  
Sequential proteolytic processing APP occurs in either an amyloidogenic pathway, which 
produces Aβ or a non-amyloidogenic pathway which precludes Aβ production.  
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The secretases 
Beta-site APP-cleaving enzyme-1 (BACE1) has been identified as the principal β-
secretase (Hussain et al, 1999; Sinha et al, 1999; Vassar et al, 1999; Yan et al, 1999). BACE1 is a 
type I single-transmembrane aspartyl protease with two active sites in the lumen/extracellular 
space. BACE1 is ubiquitously expressed with highest expression in brain. BACE1 is most active in 
acidic environments, and evidence suggests that β-secretase cleavage of APP occurs within the 
Golgi apparatus and endosomes (Vassar et al, 1999). Many preclinical studies and clinical trials 
have aimed to inhibit BACE1 to prevent Aβ production. However, the identification of a range 
of BACE1 substrates (Hemming et al, 2009) involved in many important biological pathways 
have given rise to safety concerns regarding this strategy (Wang et al, 2013).  
Several members of the ADAM (a disintegrin and metalloproteinase) family of enzymes, 
which are type I transmembrane proteins, have been implicated in α-secretase activity, 
including ADAM17 (TACE), ADAM10, and ADAM9 (Buxbaum et al, 1998; Koike et al, 1999; 
Lammich et al, 1999). APP undergoes constitutive cleavage by α-secretase, which is reported to 
release approximately 30% of cell surface APP as APPsα (Koo, 1997). However, cleavage also 
can be elevated above constitutive levels in a pathway known as ‘regulated’ cleavage.  ADAM10 
is thought to be the primary secretase involved in constitutive cleavage particularly in neurons 
(Kuhn et al, 2010). ADAM17/TACE is thought to participate only in regulated cleavage of APP 
(Buxbaum et al, 1998). The regulated α-secretase pathway involves activation of protein kinase 
C (PKC) (Zhu et al, 2001). Treatment with phorbol esters or stimulation of muscarinic 
acetylcholine receptors, which activate PKC, increases the secretion of APPsα and decreases 
secretion of APPsβ and Aβ in some cells  (Caporaso et al, 1992; Farber et al, 1995; Nitsch et al, 
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1992). Some findings suggest that PKC-regulated α-secretase activity is largely localized to 
intracellular trans- or post-Golgi compartments (Skovronsky et al, 2000), whereas, constitutive 
α-secretase activity predominantly occurs at the cell surface (Parvathy et al, 1999) .  
γ-secretase is a large complex consisting of presenilin (PS)-1 or 2, the catalytic 
component, as well as nicastrin, anterior pharynx defective (APH)-1, and PS enhancer (PEN)-2  
(reviewed in (De Strooper et al, 2012)). Presenilin is an aspartyl intramembrane protease that 
cleaves at several sites within the transmembrane domain of APP to produce Aβ peptides of 
different lengths with different propensities for aggregation (Wolfe et al, 1999). Findings by 
multiple groups support a model of sequential processivity of APP by γ-secretase in which 
cleavage occurs every 3 amino acids and begins either after amino acid 48 (of the Aβ peptide) 
and leads predominantly to Aβ42 or after amino acid 49 leading predominantly to Aβ40 ((Sastre 
et al, 2001; Weidemann et al, 2002). γ-secretase has also been the target of AD therapeutics, 
but with its many substrates (Hemming et al, 2008), more recent focus has been on γ-secretase 
modulators with APP selectivity rather than non-selective inhibitors. 
Relationship between the amyloidogenic and non-amyloidogenic pathways, and the secretases 
In non-neuronal cells, the non-amyloidgenic pathway is clearly predominant. However, 
processing by the amyloidogenic pathway is greater in neurons than in other cell lines and 
often reported to be the predominant pathway (Colombo et al, 2012; Simons et al, 1996), most 
likely due to higher expression levels of BACE1 in neurons. Reported ratios of APPsα/APPsβ 
found in cerebral spinal fluid (CSF) of healthy human controls include approximately 3.5 or 5 
12
(depending on the ELISA) (Brinkmalm et al, 2013), 2 (Rosén et al, 2012), .6 (Lewczuk et al, 2010), 
and .3 (Lewczuk et al, 2010).  
It has long been assumed that α-secretase and β-secretase compete for cleavage of APP, 
and thus an increase in α-secretase cleavage will result in a decrease in β-secretase cleavage 
and vice versa. These studies were primarily conducted using pharmacological stimulation or 
overexpression of the secretases (Hung et al, 1993; Kuhn et al, 2010; Skovronsky et al, 2000), a 
more recent well designed study compared cleavage of endogenous APP in several cell lines as 
well as primary neuronal cultures with knock-down or pharmacological inhibition of the 
endogenous secretases rather than over-expression (Colombo et al, 2012). In this study, α- and 
β- secretase did not appear to compete for cleavage of APP in several cell lines tested. 
However, there was a unidirectional inverse coupling of α- and β- secretase of APP in primary 
neuronal cultures. Knock-down of BACE1 enhanced APP cleavage by ADAM10, but knock-down 
of ADAM10 had no effect on BACE1 cleavage (Colombo et al, 2012).  
Lastly, each of the secretases have long been considered to be separated both spatially 
and temporally. However, new evidence suggests a model in which a multi-protease complex 
containing both α- and γ-secretases sequentially cleaves APP (Chen et al., unpublished). Both α- 
and β- secretase were found to co-immunoprecipitate with γ-secretase. γ-secretase was found 
to positiviely regulate ADAM10 maturation. Furthermore, pharmacological inhibition of γ-
secretase increased α-secretase activity and reduced β-secretase activity (Chen et al., 
unpublished). 
 
13
APP Trafficking 
APP is trafficked according to the constitutive secretory pathway from the endoplasmic 
reticulum (ER) through the Golgi apparatus to the plasma membrane (PM). It is estimated that 
only 10% of overexpressed APP expressed in the cell reach the PM (Haass et al, 2012). The half-
life of APP at the cell surface is estimated to be only 10 mins or less before it is either recycled 
into endocytic vesicles or undergoes ectodomain shedding (Koo et al, 1996; Koo, 1997). 
Approximately 30% of the APP at the PM undergoes ectodomain shedding  (Koo et al, 1996).  
holoAPP then is internalized into endocytic vesicles and sorted to the golgi, lysosomes, or 
recycled back to the PM. The half-life of APP within the cell is reported to be only 30 mins (Koo 
et al, 1996).  
In Madin-Darby canine kidney (MDCK) cells to model trafficking in a polarized cell, APP 
and ADAM10 are targeted to the basolateral membrane and BACE1 to the apical membrane 
(De Strooper et al, 1995; Haass et al, 1994; Wilde-Bode et al, 1997). In neurons, APP is 
transported to both axons and dendrites. The transport of APP in has been more characterized 
in axons and involves continuous unidirectional fast axonal transport by kinesin-1 (Kaether et al, 
2000) 
Parallels between APP and Notch proteolytic processing 
Soon after Presenilin was discovered as the aspartyl protease responsible for the 
intramembrane proteolytic cleavage of APP to generate Aβ, Notch was discovered as another 
substrate of presenlin mediated cleavage.  Notch, a single  type I transmembrane receptor, is 
an essential protein for early development and functions in cell fate determination (Artavanis-
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Tsakonas et al, 1999). After an initial  cleavage within the Notch ectodomain by a Furin-like 
protease in the golgi, the cleaved fragments associate together and travel to the plasma 
membrane (PM) (Blaumueller et al, 1997). At the PM, binding of its ligands, Delta or Jagged, 
stimulates α-secretase cleavage by TACE followed by presenilin mediated cleavage to release 
the cytoplasmic domain (NICD)(Brou et al, 2000; Zeng et al, 1998). NICD translocates to the 
nucleus and activates the CSL (CBR/suppressor of hairless/Lag1) family of transcription factors 
which regulates expression of specific gene targets such as the HES (Hairy/Enhancer of Split) 
family (Kopan, 2002). While there are important differences between APP and Notch 
proteolytic processing, the striking similarities bolstered the idea that APP also may be a cell 
receptor with a ligand that stimulates its ectodomain shedding by α-secretase.  
APP Function 
APP/APLP knockout animals 
The classic method to determine the function of a particular gene product is to delete 
that gene in model organisms to generate “knockouts”. In the case of APP, apparent 
compensation by its family members (and perhaps other type I transmembrane proteins) as 
well as the presence of multiple cleaved fragments of APP have made understanding its 
function difficult and led to an array of complex findings. APP does not seem to be essential for 
life, as knockout of APP results in viable and fertile mice with relatively minor defects (Li et al, 
1996; Müller et al, 1994; Zheng et al, 1995). APP knockouts have lower body and brain weight, 
the latter of which appears to be attributed to deficits in the size of forebrain commisures and 
the corpus callosum (Magara et al, 1999; Müller et al, 1994). The mice also exhibit locomotor 
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and grip strength impairment (Ring et al, 2007; Zheng et al, 1995), gliosis (Seabrook et al, 1999; 
Zheng et al, 1995), hypersensitivity to seizures (Steinbach et al, 1998), and altered exploratory 
and circadian activity (Müller et al, 1994; Ring et al, 2007). With aging, APP null mice show 
impairment in long-term potentiation and learning and spatial memory (Dawson et al, 1999; 
Ring et al, 2007; Seabrook et al, 1999). Many of these defects in APP null mice can largely be 
rescued by knock-in of APPsα, suggesting that the APP ectodomain is vital to APP function (Ring 
et al, 2007).  
The relatively mild phenotype of APP knockout mice is attributed to the proposed 
functional redundancy between APP and APLPs. While no phenotypes have been characterized 
for APLP2 knockouts and APLP1 knockouts only exhibit a reduction in body weight, combined 
APP/APLP2, APLP1/APLP2, and APP/APLP1/APLP2 knockouts are early postnatal lethal (Heber et 
al, 2000; von Koch et al, 1997). APP/APLP2 null mice display defects at neuromuscular and 
other peripheral synapses, including misalignment of pre- and postsynaptic markers, excessive 
nerve terminal sprouting, and a reduction in synaptic vesicles density and active zone size 
(Wang et al, 2005; Yang et al, 2005). These effects of APP on synaptic development at the NMJ 
have been attributed to its regulation of endocystosis of the high-affinity choline transporter 
(Wang et al, 2007; Wang et al, 2009). Conditional knockouts  with a loss of APP in either 
presynaptic motor neurons or postsynaptic muscle cells separately on a APLP2 null background 
led to similar defects at the neuromuscular synapse, indicative of a role for APP both pre- and 
post-synaptically perhaps through trans-dimerization (Wang et al, 2009). Knock-in of APPsβ was 
unable to rescue APP/APLP2 knock-out (Li et al, 2010); however, knock-in of APPsα rescues 
largely rescues postnatal lethality (Weyer et al, 2011).  However, many defects in 
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neurotransmission and cognition remain in these mice, suggesting there are some functions of 
full-length APP/APLP2 that cannot be accounted for by APPsα (Weyer et al, 2011). 
APP/APLP1/APLP2 null mice exhibit cortical dysplasias in which focal regions of neuroblasts 
migrate beyond their appropriate cortical layer, a defect resembling human type II cobblestone 
lissencephaly (Herms et al, 2004). A partial loss of the Reelin expressing Cajal Retzius cells was 
also reported(Herms et al, 2004) (Herms et al., 2004). 
Drosophila with deletion of APPL are also viable and fertile but have some behavioral 
(Luo et al, 1992) and synaptic (Ashley et al, 2005; Torroja et al, 1999)  deficits. Phenotypes at 
the synapse include a reduced numbers of synaptic boutons, reduced amplitude of evoked 
excitatory junctional potentials, and enhanced amplitude and frequency miniature excitatory 
junction potentials (Ashley et al, 2005; Torroja et al, 1999). In Caenorhabditis elegans, loss of 
apl-1 causes defects in molting and morphogenesis, leading to lethality during the larval stage 
(Hornsten et al, 2007). Similar to mice, overexpression of the apl-1 ectodomain rescues lethality 
(Hornsten et al, 2007) further emphasizing the functional importance of the APPsα fragment. 
In utero electroporation studies 
Another method, besides combined APP/APLP knockouts, utilized to circumvent the 
problem of compensation by the APP family members is in utero electroporation.  In utero 
electroporation has revealed roles for APP in cortical migration and APLP2 in neural 
differentiation within the rodent cortex (Shariati et al, 2013; Young-Pearse et al, 2007). With 
electroporation of APP shRNA, newly postmitotic cells in the ventricular zone largely failed to 
enter the cortical plate, and those in the lateral ventricle were able to migrate in the lateral 
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cortical stream but then later failed to enter the cortical plate (Young-Pearse et al, 2007).  
Electroporation of APP or the APLPs rescued this defect. However, the intracellular or 
extracellular domains of APP alone were unable to rescue (Young-Pearse et al, 2007). Taken 
together, these findings suggest that APP has a specific role in cortical plate entry, not just 
general motility of cortical neurons, and that the function of APP in cortical migration is 
redundant with the other APLP members and requires the full-length protein or perhaps its 
regulated cleavage. Further mechanistic studies demonstrated that interaction with two 
cytosolic signaling proteins, disabled 1 (DAB1) and disrupted in schizophrenia 1 (DISC1) 
mediated the effects of APP-dependent cell migration (Young-Pearse et al, 2010; Young-Pearse 
et al, 2007). In utero electroporation of APLP2 shRNA in APP/APLP1 knockout mice also resulted 
in abnormal positioning of cells in the cortical plate(Shariati et al, 2013). However, this was 
attributed to a decreased cell cycle exit and thus progenitors remaining longer within the 
ventricular zone in an undifferentiated state (Shariati et al, 2013). Further experiments should 
be performed to determine whether these represent distinct or overlapping functions of APP 
and APLP2 to produce effects on cell positioning within the cortical plate.  
In vitro and cell culture studies 
APP has been implicated as a cell adhesive factor, which is consistent with other 
demonstrated functions in neuronal cortical migration, synapse formation, and neurite 
outgrowth. APP colocalizes with markers of adhesion patches (Storey et al, 1996) and more 
specifically with Integrin β1 at these contact sites (Yamazaki et al, 1997). Integrin β1 interacts 
with APP and promotes cell adhesion through an RHDS motif located in the most C-terminal 
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portion of the APP ectodomain (Ghiso et al, 1992). The reported interactions of APP with 
extracellular matrix proteins, including heparin and collagen, further implicate APP as a cell 
adhesion factor (Beher et al, 1996; Multhaup, 1994). Lastly, multiple reports have implicating 
trans-acting dimerization of members of the APP family in promoting cell adhesion (Kaden et al, 
2008; Soba et al, 2005). 
A role in neurite outgrowth has long been attributed to holoAPP and APPs. However, 
there have been some conflicting data as to whether holoAPP and APPs enhance or inhibit 
neurite outgrowth. Studies which measured neurite outgrowth within 48 hrs reported an 
outgrowth promoting effect by holoAPP (Allinquant et al, 1995; Qiu et al, 1995), but studies 
which measured neurite outgrowth at longer time points reported a suppression in neurite 
outgrowth by holoAPP (Perez et al, 1997; Young-Pearse et al, 2008). Likewise, some studies 
suggest APPs stimulates neurite outgrowth (Araki et al, 1991; Milward et al, 1992; Ohsawa et al, 
1995; Young-Pearse et al, 2008).  
APP family members have been implicated in synapse formation and function primarily 
in peripheral synapses (i.e. the neuromuscular junction) (Wang et al, 2005; Wang et al, 2009; 
Weyer et al, 2011; Yang et al, 2005) and to a lesser extent in central synapses (Priller et al, 
2006; Tyan et al, 2012; Wang et al, 2009). In primary hippocampal cultures from APP knockout 
mice, the amplitudes of evoked EPSCs, the size of the readily releasable synaptic vesicle pool, 
and the frequency of mEPSCS were each enhanced. However, the release probability of 
synaptic vesicles and the amplitude of mEPSCs were unaltered, suggesting that lack of APP 
leads to an increase in the number of synapses per neuron (Priller et al, 2006). In an 
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HEK293/primary neuron co-culture system a transynaptic interaction of APP family members 
promoted synaptogenesis (Wang et al, 2009).  
Summary of APP function in the brain  
In summary, through both ex vivo and in vivo studies, APP and its family members have 
been implicated in a number of diverse functions in the development of the nervous system, 
including synapse formation and function, cortical cell migration, neurite outgrowth, and cell 
adhesion.  A number of studies have implicated APP at the synapse including 1) hypersensitivity 
to seizure and LTP defects  in APP null mice, 2) defects at peripheral synapses in APP/APLP2 
mice, 3) synaptic defects in hippocampal cultures from APP/APLP2 double knockout mice, and 
4) synapse promoting effects of APP in a mixed culture assay.  Evidence for a role of APP in 
neuronal cell migration includes 1) an overmigration phenotype displayed by focal cortical 
dysplasias in the combined triple knockout mice, and 2) a failure in cortical plate entry for cells 
with knockdown of APP by in utero electroporation . These seemingly opposite migratory 
effects, could be accounted for by such technical differences as chronic vs acute and global vs. 
local knockdown of APP using these two methods, but regardless  it is strong evidence towards 
a roll of APP in cortical cell migration.  A role for APP in neurite outgrowth is suggested by 1) 
deficits in the size of forebrain commisures and the corpus callosum and 2) effects of APP 
knockdown or APPsα treatment on neurite outgrowth (both promotion and inhibition) in a 
large number primary neuronal culture studies.  This array of functions described for APP in 
cortical cell migration, synapse formation, and neurite outgrowth may indicate APP is more 
generally a cell adhesive factor. 
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APP as a receptor with a putative ligand 
 Since its initial cloning over 25 years ago, APP was predicted to be a cell surface receptor 
(Kang et al, 1987). Comparison of APP processing to that of Notch which is known to be 
regulated by ligand binding, promoted the idea of APP as a receptor with a physiological ligand 
to regulate its processing and function (Figure 1.3). For many functions of APP, such as cortical 
cell migration, the intracellular and extracellular domains are both required for proper 
functioning, which has led to the hypothesis that that specific extracellular factors bind the 
ectodomain of holoAPP on the cell surface and transmit a signal to intracellular signaling 
cascades. Important downstream factors described for APP include Dab1, DISC1, Tip60, and 
Fe65(Cao & Sudhof, 2004; Kimberly et al, 2001; Young-Pearse et al, 2010; Young-Pearse et al, 
2007) (Figure 1.4). The intracellular domain of APP (AICD) has been reported to function as a 
transcription factor. However, this has been highly controversial, potential target genes 
typically have been reported by single labs and using overexpressed systems with artificial 
reporter constructs. Attempts to confirm such genes regulated by AICD has been largely 
unsuccessful (Chen & Selkoe, 2007; Hass & Yankner, 2005; Hebert et al, 2006). However, there 
is stronger evidence that  the cleaved extracellular domain of APP itself has biological activities 
(Ring et al, 2007), suggesting a functional consequence of regulated cleavage of APP. In recent 
years, several candidate protein ligands for APP, including F-spondin (Ho & Sudhof, 2004; Hoe 
et al, 2005), Reelin (Hoe et al, 2009; Hoe et al, 2006), β1 Integrin (Hoe et al, 2009; Young-Pearse 
et al, 2008),  Contactins (Bai et al, 2008; Ma et al, 2008; Osterfield et al, 2008), and Lingo-1 (Bai 
et al, 2008) have been reported to interact physically with the ectodomain of APP and  
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Figure 1.3  Hypothesis of APP as a receptor with a putative ligand 
My central hypothesis is that one or more protein ligands for APP are present in the central 
nervous system that regulate the ectodomain shedding of APP, either be promoting or reducing 
α- and/or β- secretase cleavage of APP. A ligand for APP could be either a secreted or a 
membrane-bound protein that interacts with the APP ecotodomain. 
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Figure 1.4  Schematic representation of factors involved in cortical cell migration. 
The canonical Reelin-mediated effects of APOER2 and VLDLR on cortical migration are 
shown merged with the recently described effects of APP. Recently, our group found that 
DAB1 acts downstream of APP-mediated neuronal entry into the CP and that DISC1 acts 
downstream of holoAPP-DAB1. An important next question is whether binding of 
extracellular factors (e.g., Reelin, F-spondin, Pancortin and other candidates) is required for 
this developmental function of APP. 
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Figure 1.5  Summary of published candidate APP ligands 
A number of candidate ligands for APP have been described which interact with the APP 
ectodomain, modulate processing of APP by α- or β- secretase, and in some cases modulate 
APP function.  
24
modulate APP processing and, in some cases, APP function in neurodevelopment (Figure 1.5). 
However, a cognate ligand for APP that regulates its function or processing has yet to be widely 
confirmed in multiple laboratories. 
Published candidate APP ligands 
F-spondin 
F-spondin is composed of an amino-terminal reelin domain, a central F-spondin specific 
domain, and 6 thrombospondin type-1 repeats (TSRs) in its carboxy-terminus (Burstyn-Cohen et 
al, 1999). After secretion, F-spondin is cleaved by plasmin, a serine protease, at several sites 
(Tzarfaty-Majar et al, 2001). F-spondin is expressed at high levels in the floor plate (Klar et al, 
1992), peripheral nerves (Burstyn-Cohen et al, 1998), and somatic regions avoided by migrating 
neural crest cells (Debby-Brafman et al, 1999) during embryonic development in rodents. 
Expression of F-spondin begins around E10 and diminishes by birth except after axonal injury 
(Burstyn-Cohen et al, 1998; Klar et al, 1992). F-spondin possesses dual activity by both 
promoting outgrowth of commissural axons (Burstyn-Cohen et al, 1999) and inhibiting 
outgrowth of neural crest cells (Debby-Brafman et al, 1999)and motor neurons (Tzarfati-Majar 
et al, 2001). F-spondin also has less characterized roles in neurogenesis(Schubert et al, 2006), 
angiogenesis (Terai et al, 2001), and axonal regeneration following injury (Burstyn-Cohen et al, 
1998). 
Three independent studies have demonstrated a physical interaction between F-
spondin and APP (Ho & Sudhof, 2004; Hoe et al, 2005). F-spondin was first identified as an APP 
interacting protein through an affinity chromatography screen to identify solubilized proteins 
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from the membrane fraction of rat brains that bound the CAPPD domain of APP (Ho & Sudhof, 
2004). The interaction between APP and F-spondin was validated by pull down of holoAPP by F-
spondin (Ho & Sudhof, 2004). A subsequent study confirmed that full-length APP co-
immunoprecipitates with F-spondin (Hoe et al, 2005). F-spondin was also later identified in an 
unbiased screen as one of several proteins that co-immunoprecipitated with APP from in vivo 
cross-linked mouse brains(Bai et al, 2008). Both the reelin and spondin domains of F-spondin as 
well as the CAPPD domain of APP were shown to be necessary for the binding of F-spondin to 
APP (Ho & Sudhof, 2004; Hoe et al, 2005). F-spondin also binds to ApoEr2, and full length F-
spondin increases the co-immunoprecipitation of ApoEr2 with APP, suggesting that F-spondin, 
APP, and ApoEr2 cluster at the cell surface as a complex (Hoe et al, 2005). 
Multiple groups have reported effects of F-spondin on APP processing. F-spondin was 
initially reported to decrease CTFβ levels in cells co-transfected with APP and BACE1, suggesting 
F-spondin inhibits β-secretase cleavage (Ho & Sudhof, 2004). While this study did not directly 
examine cleavage by α-secretase, F-spondin inhibited APP-dependent transactivation of Gal4-
Tip60 mediated transcription, suggesting that α-secretase cleavage would also be inhibited by 
F-spondin (Ho & Sudhof, 2004). Contrary to this prediction, a subsequent study reported F-
spondin (with co-transfection of APOER2) reduced CTFβ and enhanced both APPsα and CTFα 
levels (Hoe et al, 2005). Most recently, F-spondin gene transfer was shown to reduce Aβ levels 
in mouse brain (Hafez et al, 2012).No studies have yet to demonstrate a consequence of F-
spondin interaction with APP on APP function in neurodevelopment. 
Reelin 
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Reelin, a large secreted glycoprotein, consists of an N-terminal Reelin domain, eight Reelin 
repeats, each with an EGF-like repeat, and a C-terminal region rich in arginines. Reelin 
undergoes proteolytic cleavages at both its C-terminal and N-terminal ends to generate five 
fragments (Jossin et al, 2007; Jossin et al, 2004; Lambert de Rouvroit et al, 1999). Reelin is 
secreted from Cajal-Retzius cells in the embryonic cortex and regulates the migration of 
neuronal precursor cells (reviewed in (Honda et al, 2011)). In the adult cortex, Reelin is secreted 
by a subset of interneurons and plays a role in synaptic plasticity (reviewed in (Förster et al, 
2010)). The Reelin signaling pathway includes activation of its canonical receptors APOER2 and 
VLDLR which leads to Disabled phosphorylation and other downstream (D'Arcangelo et al, 
1999; Hiesberger et al, 1999).  
Reelin has been associated with AD in multiple studies. In these studies, AD brains have 
increased Reelin expression, as do brains from transgenic APP mice (Botella-López et al, 2010). 
Reelin associated with fibrillary Aβ species (Knuesel et al, 2009) and co-localized with 
oligomeric Aβ (Doehner & Knuesel, 2010). Reelin could reduce the Aβ-induced suppression of 
LTP  (Durakoglugil et al, 2009). In AD transgenic mice, Aβ and tau pathology is accelerated with 
reduced Reelin expression (Kocherhans et al, 2010).  Reelin knockouts (Reeler) and 
APOER2/VLDLR double knockout mice show hyperphosphorylated Tau (Hiesberger et al, 1999). 
Reelin has been shown to interact with APP in mouse brain, primary cortical neuronal 
cultures, and non-neuronal cell lines through co-immunoprecipitation studies (Hoe et al, 2009). 
The 3– 6  reelin repeats and the E1 domain of APP were essential for this interaction (Hoe et al, 
2009). In cells COS7 cells overexpressing APP, treatment with Reelin conditioned media 
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enhanced APPsα and CTFα (Hoe et al, 2009; Hoe et al, 2006) . In both COS7 cells overexpressing 
APP and neurons from APP transgenic mice, Reelin CM reduced Aβ levels (Hoe et al, 2006). 
Reelin also increased cell surface levels of APP and  enhanced to co-IP of APP with Dab1(Hoe et 
al, 2009; Hoe et al, 2006). Subsequently, another group showed that reduction of Reelin 
enhanced both CTFβ and Aβ in APP transgenic mice (Kocherhans et al, 2010).A functional 
interaction between Reelin and APP in neurite outgrowth has been described, in which Reelin 
enhanced neurite length in the presence of endogenous APP, but had no effect after APP 
knockdown (Hoe et al, 2009).  
β1 Integrin  
Integrins are type-1 transmembrane proteins that form heterodimers of α and β chains 
and link the extracellular matrix or other cells to intracellular signaling cascades. Integrins 
function in cell adhesion, cell migration, and neurite outgrowth (reviewed in (Schwartz, 2001)). 
β1 Integrin colocalizes and biochemically interact with APP (Ghiso et al, 1992; Yamazaki et al, 
1997; Young-Pearse et al, 2007). Transfection of β1 Integrin in COS7 cells overexpressing APP 
enhanced APPsα and CTFα (Hoe et al, 2009). β1 Integrin has been reported to mediate the 
neurite outgrowth effects of APP, whereby  a function-blocking antibody to β1 Integrin 
abolished the effects of APP knock-down, APP over-expression, or APPsα treatment (Hoe et al, 
2009; Young-Pearse et al, 2008). 
Contactins 
The Contactins (CNTNs) are GPI-anchored neuronal-specific cell adhesion molecules 
characterized by six aminio-terminal immunoglobulin-like domains and four carboxyl-terminal 
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fibronectin type III-like domains (Karagogeos, 2003). The CNTNs can remain bound to the 
membrane through its GPI anchor or be released as a soluble protein by GPI-specific 
phospholipase (Durbec et al, 1992; Furley et al, 1990; Lierheimer et al, 1997). The individual 
CNTNs are expressed in both overlapping and distinctive patterns within the developing and 
adult nervous system (Yoshihara et al, 1995). Expression of the CNTNs is enriched in axonal 
processes and is most robust during developmental stages (Dodd et al, 1988; Gennarini et al, 
1989; Karagogeos, 2003). The CNTNs have been primarily implicated in neurite outgrowth 
(Furley et al, 1990; Gennarini et al, 1991; Yoshihara et al, 1994). 
CNTN1 and CNTN4 were identified in separate unbiased screens as APP binding 
partners, and CNTN2 and CNTN3 were identified as APP binding partners through candidate 
approaches (Bai et al, 2008; Ma et al, 2008; Osterfield et al, 2008). CNTN1 was discovered by 
mass spectrometry as one of several proteins that co-immunoprecipitated with APP from in 
vivo cross-linked mouse brains (Bai et al, 2008). CNTN4 was identified in a screen for 
extracellular APP binding partners in embryonic chick brain (Osterfield et al, 2008). The 
fibronectin domain of CNTN4 and the E1 domain of APP were sufficient for this interaction 
(Osterfield et al, 2008). CNTN2 was investigated as an APP ligand because it was previously 
identified as a ligand for Notch and was confirmed to co-IP with APP from mouse brain (Ma et 
al, 2008). Both the immunoglobulin and the fibronectin domains of CNTN2 were reported to 
interact with APP (Ma et al, 2008). One study directly compared each of the six CNTN members 
in binding to APP and the closely related APLP1 in vitro. Only CNTN3 and CNTN4 interacted 
strongly with APPsα, only CNTNs 3, 4, and 5 interacted strongly with APLP1 (Osterfield et al, 
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2008). Noticeably, CNTNs 1, 2, and 6 either failed to or only very weakly interacted with APPs or 
APLP1 (Osterfield et al, 2008), despite other reports of physical interactions with APP. 
Both CNTN2 and CNTN4 have been implicated in APP processing. CNTN2 enhanced AICD 
release as measured by a luciferase assay and Western blot analysis in CHO cells over-
expressing APP as well as mouse embryonic fibroblasts endogenously expressing APP (Ma et al, 
2008). In addition to AICD, CTFα and CTFβ were enhanced by CNTN2, suggesting CNTN2 
stimulates α- and β- secretase cleavages.  CNTN4 modified CTFα levels as measured by Western 
blot analysis in cells over-expressing CNTN4 and APP (Osterfield et al, 2008). In the majority of 
experiments, CNTN4 mediated an increase in CTFα levels. Interestingly, CNTN4 also produced a 
decrease in CTFα levels in a smaller number of experiments. However, in these studies holoAPP 
expression increased or decreased with CTF levels (Osterfield et al, 2008).  
CNTN2 and CNTN4 have also been implicated in APP function. CNTN4 was reported to 
be involved in APP-NgCAM dependent neurite outgrowth (Osterfield et al, 2008) [11]. Both 
treatment with CNTN4 recombinant protein, which may act as a dominant negative, and 
transfection of CNTN4 shRNA inhibited the enhanced neurite outgrowth seen with 
APPs/NgCAM stimulation (Osterfield et al, 2008). In one study, CNTN2 was reported to regulate 
neurogenesis through an AICD/Fe65 signaling pathway (Ma et al, 2008).  
Lingo-1 
 Lingo-1  (leucine rich  repeat  and Ig domain-containing Nogo receptor interacting 
protein-1), is a single-transmembrane protein with 12 leucine rich repeats, an Ig domain, a 
trans-membrane domain, and a short cytoplasmic tail with an epidermal growth factor 
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receptor-like tyrosine phosphorylation site. Lingo-1 is expressed in neurons and 
oligodendrocytes with peak expression around postnatal day 1 and decreasing thereafter, 
except after injury. Lingo-1 is a member of the Nogo-66 receptor complex and negatively 
regulates axonal myelination and regeneration (reviewed in (Mi et al, 2008)). 
 Lingo-1 was among the proteins identified (along with F-spondin) in the APP 
interactome study of intact mouse brain (Bai et al, 2008). This study  further confirmed a 
physical interaction between APP and Lingo-1 and showed that knockdown of Lingo-1 in 
HEK293 cells stably overexpressing APP bearing the “Swedish” AD mutation increased CTFα and 
lowered CTFβ, whereas overexpression of Lingo-1 increased CTFβ (Bai et al, 2008). A separate 
group confirmed a physical interaction in an overexpressed cell system and determined that the 
interaction occurs via the ectodomain of Lingo-1 (Stein & Walmsley, 2012).   
Pancortin, a novel candidate ligand 
Pancortin is a secreted glycoprotein present in the extracellular matrix as four different 
isoforms specified as BMZ, BMY, AMZ, and AMY (Danielson et al, 1994). Differential promoter 
utilization generates an amino-terminus composed of either an A or B domain. Each isoform 
contains a common central M domain. Alternative splicing produces a carboxyl-terminus 
composed of either a Y or Z domain (Danielson et al, 1994). AMZ and AMY Pancortin isoforms 
are reported to be more efficiently secreted than the BMZ and BMY isoforms (Moreno & 
Bronner-Fraser, 2001).  
Pancortins are expressed in neurons of both the embryonic and mature cortex. AMZ and 
AMY are the predominant isoforms expressed in the rodent embryonic cortex (Danielson et al, 
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1994; Nagano et al, 2000). In situ hybridization of rodent embryonic cortical sections detected 
mRNA for the A and Z domains at E12.5 in the neuroepithelium and mRNA for the A, Z, and Y 
domains at E16.5 in the neuroepithelium, subplate, cortical plate but not intermediate zone 
(Nagano et al, 2000). Western blot analysis further demonstrated that AMZ is initially expressed 
at E12.5 followed by AMY at E14.5 and BMZ at E16.5 (Nagano et al, 2000). In the adult cortex, 
the protein expression is  similar for all four Pancortin isoforms (Nagano et al, 2000). While 
slightly different expression profiles are detected in chick and Xenopus, both further suggest a 
role of Pancortin in neuronal development. In chick, mRNA for the Z domain is present during 
early embryonic stages, and BMZ is expressed in a gradient within the open neural plate 
(Barembaum et al, 2000). In Xenopus, BMZ and AMZ are first detected following neural tube 
closure, and all four isoforms are robustly expressed in the adult cortex (Moreno & Bronner-
Fraser, 2001). 
While the function of Pancortin in the mammalian nervous system has not been fully 
elucidated, the BMZ and AMY isoforms of Pancortin have been reported to play a role in 
neurodevelopment in Xenopus and chick (Barembaum et al, 2000; Moreno & Bronner-Fraser, 
2001). Over-expression of BMZ in chick embryos revealed a role for BMZ in neural crest 
formation (Barembaum et al, 2000). Studies in Xenopus suggest that BMZ and AMY cooperate 
in regulating the timing of neuronal differentiation (Moreno & Bronner-Fraser, 2001). In 
addition to these functions in neuronal development, one study reported a role for Pancortin in 
the adult rodent brain. Through studies in mice that lacked Pancortin expression in the adult 
cortex, BMY was proposed to function in a complex that sequesters an anti-apoptotic factor 
and promotes cell death following ischemic injury (Cheng et al, 2007). However, it remains 
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unclear what the normal function of Pancortin may be during development, as the loss of 
Pancortin only protected adult but not embryonic neurons against ischemic death, and other 
putative developmental phenotypes were not presented.  
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Abstract 
Neuronal precursor cell migration in the developing mammalian brain is a complex process 
requiring the coordinated interaction of numerous proteins. We have recently shown that 
Amyloid Precursor Protein (APP) plays a role in migration into the cortical plate through its 
interaction with two cytosolic signaling proteins, Disabled-1 (DAB1) and Disrupted in 
Schizophrenia-1 (DISC1). In order to identify extracellular factors that may signal through APP to 
regulate migration, we performed an unbiased mass spectrometry-based screen for factors that 
bind to the extracellular domain of APP in the rodent brain. Through this screen, we identified 
an interaction between APP and Pancortins, proteins expressed throughout the developing and 
mature cerebral cortex. Via co-immunoprecipitation, we show that APP interacts with all four of 
the mammalian Pancortin isoforms (AMY, AMZ, BMY, BMZ). We demonstrate that the BMZ and 
BMY isoforms of Pancortin can specifically reduce β-secretase but not α-secretase cleavage of 
endogenous APP in cell culture, suggesting a biochemical consequence of the association 
between Pancortins and APP.  Using in utero electroporation to overexpress and knock down 
specific Pancortin isoforms, we reveal a novel role for Pancortins in migration into the cortical 
plate. Interestingly, we observe opposing roles for alternate Pancortin isoforms, with AMY 
overexpression and BMZ knock down both preventing proper migration of neuronal precursor 
cells. Finally, we show that BMZ can partially rescue a loss of APP expression and that APP can 
rescue effects of AMY overexpression, suggesting that Pancortins act in conjunction with APP to 
regulate entry into the cortical plate. Taken together, these results suggest a biochemical and 
functional interaction between APP and Pancortins and reveal a previously unidentified role for 
Pancortins in mammalian cortical development.  
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Introduction 
 Migration of neuronal precursor cells in the developing cerebral cortex is a complex 
process that requires the coordinated interaction of many factors. Extracellular cues are relayed 
to intracellular signaling pathways via transmembrane receptors to mediate migration of 
formative neurons from the ventricular  and subventricular zones through the intermediate 
zone and to the proper layer of the cortical plate. While dozens of genes have been identified 
that play important roles in this process, large gaps remain in our understanding of the 
molecular mechanisms involved.  
 We have recently shown that Amyloid Precursor Protein (APP) plays a role in migration 
of neuronal precursor cells into the cortical plate.  APP is a type I single transmembrane 
glycoprotein centrally involved in the pathogenesis of Alzheimer’s disease (AD) [reviewed in 
(Hardy & Selkoe, 2002)]. APP undergoes sequential proteolytic processing by β- and γ-secretase 
to generate the amyloid β-peptide (Aβ) [reviewed in (De Strooper & Annaert, 2000)].  Several 
therapeutic strategies for AD, some of which have already entered clinical trials, aim to 
chronically inhibit β- or γ-secretase to prevent Aβ generation [reviewed in (Selkoe, 2011)].  To 
understand the potential effects of chronically reducing APP processing to treat AD, it is 
important to decipher the normal functions of APP and understand the molecular pathways 
through which APP executes these functions. 
 Recent studies from several labs have begun to clarify an essential role for APP in the 
development of the nervous system.  APP is now believed to function in neurite outgrowth 
(Araki et al, 1991; Perez et al, 1997; Young-Pearse et al, 2008), cell adhesion (Ghiso et al, 1992; 
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Soba et al, 2005), synapse formation (Priller et al, 2006; Wang et al, 2009) and migration of 
neuronal precursors (Pramatarova et al, 2006; Young-Pearse et al, 2007).  The precise 
mechanisms regulating the proteolytic processing and function of APP are only partially 
understood. While the cleaved extracellular domain of APP itself has biological activities in vivo 
(Ring et al, 2007), we found that both the ectodomain and intracellular domain of APP are 
required to be expressed as a holoprotein in order to mediate proper neuronal precursor cell 
migration during cortical development (Young-Pearse et al, 2007), and that the cytoplasmic 
factors Disabled-1 (DAB1) and Disrupted in Schizophrenia-1 (DISC1) biochemically and 
functionally interact with APP in this function (Pramatarova et al, 2008; Pramatarova et al, 
2006; Young-Pearse et al, 2010). On the basis of these findings, we hypothesize that certain 
extracellular factors bind the ectodomain of holoAPP on the cell surface and transmit a signal to 
intracellular signaling cascades during development. Accordingly, identifying extracellular 
binding partners for APP will help reveal the molecular pathways that regulate APP processing 
and function.   
 Several candidate ligands for APP, including F-Spondin (Ho & Sudhof, 2004; Hoe et al, 
2005), Contactins (Ma et al, 2008; Osterfield et al, 2008), and Reelin (Hoe et al, 2009; Hoe et al, 
2006),  have been reported to interact with the ectodomain of APP and modulate APP 
processing and/or APP function in neurodevelopment. However, despite these initial reports, 
an endogenous functional ligand for APP has yet to be widely confirmed in multiple 
laboratories. We initiated a search for additional factors that could interact with the APP 
ectodomain and modulate APP processing and/or function in vivo.  Here, we identified 
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Pancortin in an unbiased screen for proteins that interact with the ectodomain of APP in the 
mouse cerebral cortex. 
Pancortin, also known as Noelin (chicken and Xenopus), Olfactomedin-related 
glycoprotein (rats), and hOlfA (humans), is a secreted glycoprotein highly expressed in the 
developing and mature cortex (Danielson et al, 1994; Nagano et al, 2000). In the rodent, four 
isoforms of Pancortin are expressed; these variants are named based upon the domains 
incorporated and are designated BMZ, BMY, AMZ, and AMY (Danielson et al, 1994). Each 
isoform contains the common central M domain.  Differential promoter utilization generates an 
amino-terminus composed of either the A or B domain, and alternative splicing produces a 
carboxyl-terminus composed of either the Y or Z domain (Danielson et al, 1994) (Fig. 2.1A). 
While the function of Pancortin in the developing mammalian nervous system has not been 
elucidated, the BMZ and AMY isoforms have reported functions in neurodevelopment in 
Xenopus and chick. The BMZ isoform functions in the migration of neural crest cells in chick 
embryos (Barembaum et al, 2000), and BMZ and AMY isoforms have opposing roles in 
regulating the timing of neuronal differentiation in Xenopus (Moreno & Bronner-Fraser, 2001; 
Moreno & Bronner-Fraser, 2005).  
Here, we report the biochemical and functional interaction of APP and Pancortins and 
identify a novel function of Pancortins in mammalian cortical development.  We identify 
Pancortin as an APP binding partner and show that specific Pancortin isoforms inhibit β-
secretase cleavage of APP. We reveal that, similar to APP, Pancortins play a role in migration of 
neuronal precursor cells into the cortical plate, with different variants of Pancortin having 
opposing roles in this process. Together, our studies identify a novel function of Pancortins in  
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Figure 2.1. Identification of Pancortin as an APP binding partner. (A) Schematic of Pancortin 
isoforms and their domains. (B) Pancortin peptides identified by mass spectrometry in an 
unbiased screen for extracellular factors within murine cortical slices that interact with the 
APP ectodomain. (C) Western blot (WB) for Pancortin (anti-FLAG) of the lysate and 
conditioned media (CM) from HEK293 cells transiently transfected with each of the Pancortins 
or control vector both with and without PNGase F treatment. Red arrowheads highlight 
specific bands. (D) WB for Pancortin isoforms (“BMZ/AMZ”, Abcam; “BMY/AMY”, Neuromab), 
APP, and GAPDH in E16 and adult brain homogenates from WT or APP KO mice.  
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cortical cell migration and give further mechanistic insight into the physiological function of 
APP, a protein central to the pathogenesis of AD.  
Experimental Procedures 
Screen for identification of APP binding partners 
 C57/BL6 mouse brains were vibratome sectioned (350 micron) and slices were aerated 
in artificial cerebrospinal fluid (aCSF), incubated with APPsα for 1 hr, followed by incubation in 
250 uM DSS (Thermo Fisher, Rockford, IL) for 30 min. DTT (1 mM) was added to terminate the 
reaction. Slices were then homogenized in TEVP buffer (10 mM Tris-HCl, pH 7.4, 1mM EDTA, 1 
mM EGTA, protease inhibitors, 320 mM sucrose), and lysates spun at 1000 g to pellet nuclei. 
Membranes were then pelleted at 100,000 g for 1 hr and the pellet resuspended in 1% NP40 
STEN buffer (150 mM NaCl, 50 mM Tris, 2 mM EDTA, and 1.0% (v/v) NP-40). Following lysis, APP 
was immunoprecipitated with 8E5 (gift of Elan Pharmaceuticals) crosslinked to protein G 
agarose beads. Beads were washed in STEN buffer followed by 1% SDS-STEN buffer, and 
proteins eluted from the beads with ammonium hydroxide at pH 12 followed by neutralization. 
Eluted proteins were electrophoresed on a 10-20% Tricine gel, stained with colloidal blue, and 
bands excised and subjected to MALDI-TOF mass spectrometry.  
Plasmids 
 Generation of APP and control shRNA constructs were described previously (Young-
Pearse et al, 2007). Pancortin shRNA constructs were generated by cloning of oligonucleotides 
encoding the shRNA sequence into the pENTR-U6 plasmid (Invitrogen, Carlsbad, CA). Pancortin 
shRNAs target the following sequences: shRNA 3 (targeting AMY) 
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GGAGAAGATGGAGAACCAAAT; shRNA 4 (targeting BMZ) GCAACATTGTCATCAGCAAGC. Murine 
Pancortin cDNAs were cloned by PCR into the pCAGGs expression vector for mammalian 
expression, and the cDNAs confirmed to have the sequences corresponding to the following 
Genbank entries: NM_019498 (BMZ or transcript variant 1), NM_001038612 (BMY or transcript 
variant 2), NM_001038613 (AMZ or transcript variant 3), and NM_001038614 (AMY or 
transcript variant 4).   In order to rescue shRNA 4 with a non-targetable BMZ construct 
(“BMZ4m”), four synonymous mutations (bold, underlined) were introduced at the shRNA 4 
target site: GCAATATCGTGATAAGCAAGC.  
Protein expression, immunoprecipitation, and Western blotting 
HEK293 cells were transiently transfected using Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA) or Fugene HD (Promega, Madison, WI). 48 hrs after transfection, conditioned 
media (CM) was collected and cells lysed in 1% NP40 STEN buffer. E18 rat cortical neurons were 
nucleofected with the Amaxa 4D-Nucleofector Device using the P3 primary cell kit according to 
manufacturer’s protocol (Lonza, Basel, Switzerland).  For deglycosylation of Pancortin, lysates 
and CM from transfected HEK293 cells were treated with PNGase F (New England Bioloabs, 
Ipswich, MA) according to manufacturer’s protocol. For IP, HEK293 cells were transfected with 
each of the FLAG-tagged Pancortin isoforms or domains plus either empty vector alone, human 
APP (695 residue splice variant), the C-terminal 99 amino acid fragment of APP (C99), or the 
APP ectodomain E1 or E2 deletion constructs, APPΔ1 and APPΔ2, respectively (kindly provided 
by T. Sudhof, Stanford University). Lysates were immunoprecipitated with M2-agarose (Sigma, 
St. Louis, MO) or the APP antiserum C9 with protein A and G agarose resin (Sigma, St. Louis, 
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MO) overnight and washed 3X with 1% NP40 STEN buffer. Lysates, CM, and 
immunoprecipitations were  electrophoresed on 10–20% Tricine or 4-12% Bis-Tris gels 
(Invitrogen, Carlsbad, CA) and transferred to nitrocellulose. Western blotting was performed 
with primary antibodies anti-APP (C9, 1:1,000; Selkoe Lab), anti-APPsα (1736, 1:2,000; Selkoe 
Lab), anti-rodent APP/APPsα (597,1:200; Immuno-biological Laboratories, Minneapolis, MN), 
mouse anti-Pancortin (K96/7, 1:1000, UC Davis/NIH NeuroMab Facility, Davis, CA), rabbit anti-
Pancortin (ab3512, 1:1000, abcam, Cambridge, MA) anti-GAPDH (1:2,000; Millipore, Billerica, 
MA), anti-FLAG (M2; 1:1,000; Sigma, St. Louis, MO), anti-BACE1 (1:500, Millipore, Billerica, MA), 
anti-ADAM 10 (1:1,000, Millipore, Billerica, MA), anti-ADAM17 (1:500, abcam, Cambridge, MA), 
anti-Nicastrin (1:1,000, BD Biosciences, San Jose, California), and anti-Presenilin-1 (1:1,000, 
Millipore, Billerica, MA) followed by IRDye800- or IRDye680-conjugated secondary antibodies 
(1:10,000; Rockland Immunochemicals, Gilbertsville, PA) and detection with the LICOR Odyssey 
detection system. 
APP processing assay 
 HEK293 cells were plated in 6 well plates at 1x10^6 cells/well and transiently 
transfected with Pancortin isoforms or domains or empty vector (as control) using Fugene HD 
(Promega, Madison, WI).  24 hrs post-transfection, media (DMEM + 10% FBS) was replaced, and 
at 48 hrs post-transfection media were collected and centrifuged at 200 g for 5 min and cells 
were lysed in 1% NP-40 STEN buffer. APPsα, APPsβ, and Aβ levels in the CM was quantified by 
ELISA (Meso Scale Discovery, Gaithersburg, Maryland) and normalized to total intracellular 
protein. For each isoform, 2-4 independent experiments performed in triplicate were analyzed. 
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For the individual domains, a representative experiment performed in triplicate is shown. One-
way ANOVA tests were performed with the Bonferroni correction for multiple comparisons.  
In utero electroporation   
 Sprague Dawley rats (Charles River Laboratories, Wilmington, MA) were housed and 
cared for under the guidelines established by Harvard University’s Institutional Animal Care and 
Use Committees in compliance with federal standards. Timed pregnant rats embryonic day 15.5 
(E15.5) were anesthetized with ketamine/xylazine (100/10 mixture, 0.1 mg/g body weight, i.p.). 
The uterine horns were exposed, and a lateral ventricle of each embryo injected with DNA 
constructs and Fast Green (2 mg/ml; Sigma, St. Louis, MO) via a microinjector (Picospritzer III; 
General Valve, Fairfield, NJ) and pulled glass capillaries. For characterization of shRNA 
phenotypes, 1.0 –1.5 mg/ml of shRNA was co-electroporated with 0.5 mg/ml pCAG-green 
fluorescent protein (GFP). For cDNA expression, 0.5 mg/ml pCAG-GFP was co-electroporated 
with 3.0 mg/ml cDNA constructs. For rescue experiments, 0.5 mg/ml shRNA was co-
electroporated with 0.5 mg/ml pCAG-GFP and 3.0 mg/ml rescue constructs. All rescue 
constructs were expressed in the pCAGGs vector. Electroporation was accomplished by 
discharging a 500 mF capacitor charged to 50–100 V with a sequencing power supply or with a 
BTX square wave electroporator, at 50–75 V, for 50 ms on followed my 950 ms off for 5 pulses. 
The voltage was discharged across copper alloy oval plates placed on the uterine wall across the 
head of the embryo. Brains from rat embryos were harvested 3 or 6 days following 
electroporation in 4% paraformaldehyde by immersion.  For each plasmid combination, at least 
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three independent brains were analyzed. Ex vivo culture of electroporated cells were 
performed as described previously (Rice et al, 2010).  
Quantitative analyses of cortical plate entry 
  For quantitative analyses of migration, all electroporations were performed targeting 
the same region of the developing rat cortex. This resulted in a reliable electroporation of the 
dorsal-lateral region of the neocortex adjacent to the lateral ventricle. After harvest, brains 
were vibratome-sectioned (150 μm) in the coronal plane and immunostained for microtubule-
associated protein 2 (MAP2) to delineate the cortical plate. For each electroporation condition 
(i.e., each set of electroporated DNAs), greater than a total of 500 cells were counted and 
assessed for their location in either the MAP2+ cortical plate or the intermediate zone. To 
determine significant changes relative to control electroporations, at least three independent 
brains were electroporated and analyzed for each DNA condition. For each brain, the 
percentage of GFP-positive cells in the intermediate zone (IZ) and cortical plate (CP) were 
calculated. These values were then compared between electroporation conditions using 
GraphPad InStat (San Diego, CA). Using this program, one-way ANOVA tests were performed 
with the Bonferroni multiple comparisons test. This analysis was used to determine whether 
the percentage of cells in the CP in the specified electroporation condition was significantly 
different from the percentage cells in the CP of control electroporations, or in the case of 
rescue experiments, of shRNA-receiving electroporations (similarly, these same conditions were 
assessed for statistical significance when comparing the percentage cells in the IZ for each 
condition). Data presented in Figures 2.4 and 2.5 were generated in concomitant experiments 
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and are presented separately for clarity. Therefore, the combined data from the control 
electroporation condition with GFP alone for 3 and 6 days post-electroporation are presented 
twice in both figures for comparison to other conditions. 
Immunofluorescent staining and confocal microscopy 
 Coronal sections of electroporated brains were incubated in blocking buffer (2% donkey 
or goat serum; 0.1% Triton X-100 in PBS) for >1 h. Sections were then incubated in primary 
antibody (anti-MAP2, 1:10,000 (Abcam, Cambridge, MA), anti-Tbr1, 1:200 (Abcam, Cambridge, 
MA) between 6 h and overnight at 4°C, followed by three washes in PBS. Sections were then 
incubated with Cy3 - and Cy5-conjugated secondary antibodies (1:500 –1:1000; Jackson 
Immunoresearch, West Grove, PA) for >2 h followed by four PBS washes. Sections were 
mounted on glass slides using GelMount (Biomeda, Foster City, CA). Images were acquired 
using a Zeiss (Oberkochen, Germany) LSM 510 confocal microscope with Axiovert 100M system.  
Results  
Identification of Pancortin as an APP binding partner 
In an unbiased screen for extracellular proteins that interact with the APP ectodomain, 
murine cortical slices were treated with human APPs-α, cross-linked and homogenized.  APP 
was immunoprecipitated (IPed) with a monoclonal antibody to the APP ectodomain and eluted. 
The eluted proteins were run on SDS-PAGE, and mass spectrometry was performed on 
horizontal slices excised from the gel that contained any co-immunoprecipitated (co-IPed) 
proteins. This method identified three dozen proteins, including APP. Of the published APP 
binding partners, only NCAM1 (Bai et al, 2008) was identified. Among the novel putative APP 
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interacting proteins identified, one of the top hits was Pancortin, with recovery of 2 peptides 
within the Z domain and 1 within the B domain (Fig. 2.1B).  
To examine the potential biochemical interactions between APP and Pancortin, HEK293 
cells were transiently transfected with empty vector (as control) or the four individually FLAG-
tagged Pancortin isoforms (Fig. 2.1C). Each of the Pancortin isoforms was present in the HEK293 
lysate with BMY and AMY detected as multiple specific bands. In the conditioned media (CM), 
all of the isoforms with the exception of AMY (which often was not secreted at detectable 
levels) were detected as a band migrating at a slightly higher molecular weight than in the 
lysate. The immunoreactive bands in the lysate and the higher migration of Pancortins in the 
CM appear to be due to N-linked glycosylation, as digestion of the respective lysates with 
Peptide: N-Glycosidase F (PNGase F) resulted in a single lower band now running at the same 
size in both the CM and lysate for each of the four isoforms. 
 
Developmental expression of Pancortin isoforms  
Previous studies have shown that multiple Pancortin isoforms are expressed in both the 
embryonic and mature cortex (Danielson et al, 1994; Nagano et al, 2000). Here, multiple 
antibodies for Pancortins were tested by Western blot analysis of purified, baculovirus-
expressed Pancortin isoforms. We found that a rabbit polyclonal antibody (Abcam) 
preferentially recognizes the Z-domain-containing isoforms AMZ and BMZ and a monoclonal 
antibody (NeuroMab) that preferentially recognizes the Y-domain-containing isoforms AMY and 
BMY (Fig. 2.2A).  Using these antibodies, AMY/BMY and AMZ/BMZ expression were observed in  
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Figure 2.2. Pancortins are expressed in the developing and adult rodent cerebral cortex 
(A) Western blots of lysates from mouse cerebral cortices at different developmental 
time points and of baculovirus produced Pancortin isoforms. Lysates were blotted with two 
different Pancortin antibodies. Rabbit anti-Pancortin (Abcam) appears to preferentially 
recognize AMZ and BMZ while a monoclonal antibody (NeuroMab) preferentially recognizes 
AMY and BMY. (B-I) Coronal sections of E16 and Adult wild type mouse brains immunostained 
with both Pancortin antibodies and counterstained with TOPRO3.  
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rodent cortex at both E16 (during active cortical migration) and adult ages (Fig. 2.1, 2.2). Levels 
of expression of the Pancortins were not affected by genomic disruption (knock out) of APP 
(Fig. 2.1D). Immunostaining of wild type E16 and adult mouse brain sections showed significant 
signal throughout the cerebral cortex with the Pancortin polyclonal antibody (favoring the Z-
domain) (Fig. 2.2D,E,H,I). Immunostaining with the Pancortin monoclonal antibody (favoring the 
Y-domain) also showed extensive signal in the E16 brain, but signal was strongly diminished in 
the cortical plate (Fig. 2.2B,C). 
 
Biochemical characterization of the interaction between APP and Pancortins  
 In order to confirm a biochemical interaction between APP and Pancortin, stable 
HEK293-APP695 cells were transiently transfected with the four individual FLAG-tagged 
Pancortin isoforms or vector alone. Cell lysates were IPed with M2 (anti-FLAG)-agarose beads 
and probed for both Pancortin (M2) and APP (C-terminal APP antiserum, C9). APP was able to 
co-IP with each of the Pancortin isoforms (Fig. 2.3A). Because each of the Pancortin isoforms 
co-IPs with APP, we predicted that the M domain common to each isoform was sufficient for an 
interaction with APP. FLAG-tagged B, M, and Z domains of Pancortin were expressed in stable 
HEK293-APP695 cells, and lysates were IPed with C9 (APP). The Y and A domains were not 
examined as they are only 1 and 22 amino acids in length, respectively. As predicted, the M 
domain was sufficient to co-IP with APP while the B domain was not (Fig 2.3B).  Surprisingly, the 
Z domain also was capable of interacting with APP, however, this interaction was inconsistent 
between replicates (Fig. 2.3B).  
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Figure 2.3. APP and Pancortins biochemically interact. 
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Figure 2.3. APP and Pancortins biochemically interact (continued). Western blots (WBs) for 
APP (anti-APP, C9) and FLAG-tagged Pancortin (anti-FLAG, M2) are shown for both the input 
(lysates) and the immunoprecipitated (IPed) products. Immunoprecipitations (IPs) of lysates 
for FLAG (M2) shown in A and for APP (C9) in B-F. Asterisks represent non-specific or cross-
reactive IgG bands.  (A) WBs of lysates of HEK293-APP695 cells transiently transfected with 
FLAG-tagged Pancortin isoforms or vector alone (ctrl). (B) WBs of lysates of HEK293-APP695 
cells transiently transfected with FLAG-tagged Pancortin domains, B, M, and Z. (C) WBs of 
lysates of HEK293-APP695 cells transiently transfected with BMZ and AMY isoforms alone or 
together. (D) Quantification of the percent of BMZ and AMY co-IPed with APP relative to the 
total amount of each isoform in the lysate for BMZ and both the unglycosylated (lower band, 
“ungly”) and glycosylated (upper band, “gly”) forms of AMY when BMZ and AMY were 
expressed separately (-) or together (+). (E) WBs of lysates of HEK293 cells transiently 
transfected with each of the Pancortins and either full-length APP (APPfl) or a C-terminal 
fragment of APP (C99). (F) WBs of lysates of HEK293 cells transiently transfected with the AMY 
isoform of Pancortin and either full-length APP, APPΔ1 (lacking residues 36-289), APPΔ2 
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To investigate whether APP shows preferential interaction with specific isoforms of Pancortin, 
BMZ and AMY were expressed alone or together in HEK293 cells and the percentage of BMZ 
and AMY that co-IPed with APP relative to the total amount of each isoform in the lysate was 
quantified. AMY (both glycosylated and unglycosylated forms) had a higher co-IP efficiency than 
BMZ when each were expressed alone, but when expressed together the co-IP efficiency of 
AMY decreased and BMZ increased to reach a similar IP efficiency for each (Figs. 2.3C,D). 
Interestingly, the unglycosylated form of AMY (lower band) had a much greater binding 
efficiency than the glycosylated form (upper band) when expressed alone but not when co-
expressed with BMZ (Figs 2.3C,D). Further, expression of BMZ stabilized the glycosylated form 
of AMY in the lysate of HEK293 cells (Fig. 2.3C).  
To determine whether Pancortin interacts with the intracellular or extracellular region 
of APP, each of the Pancortins plus either full-length APP or the -secretase cleaved, 
membrane-tethered C-terminal fragment of APP (C99) were expressed in HEK293 cells.  Each of 
the Pancortins co-IPed strongly with full-length APP but weakly or not at all with C99, 
suggesting a requirement of the APP ectodomain for interaction with Pancortin (Fig. 2.3E). In 
order to narrow down this region of interaction, the AMY isoform of Pancortin and either full-
length APP, APPΔ1 (lacking residues 36-289), APPΔ2 (lacking residues 288-493) or C99 were 
expressed in HEK293 cells. Deletion of the E1 domain of APP led to failure to co-IP AMY, 
whereas deletion of the E2 domain did not disrupt the interaction with AMY (Fig. 2.3F). Taken 
together, these studies demonstrate that APP interacts with each of the Pancortin isoforms and 
that the E1 domain of APP and both the M and Z domains of Pancortin are important for the 
interaction.  
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Effects of Pancortin isoforms on APP proteolytic processing  
Pancortin may interact functionally with APP by altering the proteolytic processing of 
holoAPP, thus regulating potential downstream signaling activities of APP. Furthermore, 
cleavage of APP to generate Aβ is a process central to Alzheimer’s disease pathogenesis, and 
understanding what factors trigger or inhibit this process may provide valuable insights into 
disease progression. The APP ectodomain is first shed by either α-secretase or β-secretase to 
release APPsα or APPsβ, respectively. When APP is cleaved by β-secretase followed by γ-
secretase, Aβ is generated.  To determine if Pancortins can modulate the processing of 
endogenous APP, HEK293 cells were transiently transfected with the Pancortin isoforms or 
empty vector (as control). Endogenous APPsα, APPsβ, and Aβ levels were measured in the 
conditioned media by ELISA.   
Expression of the B domain containing isoforms resulted in a dramatic reduction in the 
generation of β-secretase cleavage products (APPsβ and Aβ), but had no significant effect on 
the α-secretase cleavage product (APPsα). BMZ and BMY reduced APPsβ levels by 51.8% ± 2.0% 
and 51.4% ± .8%, respectively (Fig. 2.4A) and reduced Aβ levels by 57.5% ± 3.4% and 65.6% ± 
6.1%, respectively (Fig. 2.4B). The inhibition of β-secretase cleavage of APP by BMZ and BMY 
was a robust effect seen consistently in each individual experiment. While in these experiments 
slight changes in APPsα levels were seen in some experiments, overall there was no statistically 
significant effect of Pancortins on APPsα levels (Fig. 2.4A). Expression of AMZ did not 
significantly modulate α-secretase or β-secretase cleavage of APP, and expression of AMY 
resulted in smaller reductions in β-secretase cleavage of APP as compared to BMZ and BMY 
(Figs. 2.4A,B).  
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Figure 2.4. Specific Pancortin isoforms reduce β-secretase but not α-secretase cleavage of 
APP 
HEK293 cells were transiently transfected with Pancortin isoforms and individual domains or 
empty vector (ctrl). 24 hours post-transfection, media was replaced, and after 24 additional 
hours media was collected and cells lysed. (A,D) Quantification of endogenous APPsα and 
APPsβ in the conditioned media (CM) via a multiplex ELISA, which allows for the simultaneous 
detection of each. (B) Quantification of Aβ40 in the CM by a separate ELISA.  (C,E) Western 
blots of lysates (and conditioned media where noted by “CM”) showing expression of 
endogenous full length APP, transfected Pancortins, and each of the secretases. Asterisk 
denotes a non-specific band. Each bar represents data from 2-4 independent experiments 
performed in triplicate for (A) and (B) and a single representative experiment performed in 
triplicate for (D).  Error bars represent s.e.m. ***p<0.001. 
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We next investigated the mechanism by which Pancortin isoforms regulate β-secretase 
cleavage of APP. The effects of the Pancortins on APP processing were not due to alterations in 
the expression of APP or its secretases, as transfection of the Pancortins did not alter 
endogenous holoAPP or the principal secretases responsible for cleavage at the β-site, BACE-1 
(β-site APP cleaving enzyme-1), or α-site, ADAM17 and ADAM 10 (members of the disintegrin 
and metalloproteinase domain-containing family of proteins) (Fig 2.4C). Expression levels of 
Nicastrin and Presenilin-1, members of the γ-secretase complex, also were unchanged (Fig 
2.4C). Because B domain-containing isoforms of Pancortin showed the most robust effects on 
APP processing but the B domain alone was not sufficient for binding APP, we tested whether a 
physical interaction with APP was necessary for the effects of BMZ and BMY on APP processing. 
As predicted, expression of the M and Z domains alone had no effect on APPsα or APPsβ (Figs. 
2.4D,E) despite their ability to physically interact with APP (Fig 2.3D). However, the B domain 
alone also was not sufficient to reduce β-secretase cleavage of APP (Figs. 2.4D,E), suggesting 
that BMZ and BMY require a physical interaction with APP via the M and/or Z domains to 
modulate APP processing.   
 
Role of Pancortin and APP in cortical cell migration 
Since APP was previously shown to play an important role in cortical precursor cell 
migration (Young-Pearse et al, 2007; Young-Pearse et al, 2010), we asked whether Pancortins 
also function in this capacity. To address this question, E15.5 rat embryos were electroporated 
with a cDNA construct encoding GFP alone or co-electroporated with constructs encoding GFP 
and each of the Pancortin splice variants. Three days following electroporation, brains were 
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harvested, sectioned coronally, and immunostained for MAP2, which is expressed in 
differentiated neurons in the cortical plate, and for Tbr1, which is strongly expressed in cortical 
layer VI and in remnant subplate cells (and at lower levels in upper layers) at this 
developmental stage (Bulfone et al, 1995). At this time point (E18.5), electroporated cells are 
actively migrating from the ventricular zone through the intermediate zone and into the cortical 
plate.  Using this experimental paradigm, cells electroporated with GFP alone were observed in 
both the cortical plate and below the cortical plate in the intermediate zone (Figs. 2.5A,B), as 
expected for day E18.5. Expression of each of the Pancortin isoforms had differential effects on 
location of the respective electroporated cells. While expression of BMZ resulted in a 
distribution of GFP-positive (i.e., BMZ-expressing) cells qualitatively similar to that observed 
with the control GFP-only electroporation, expression of AMY had a consistent effect of 
preventing electroporated cells from entering the cortical plate (Figs. 2.5A,B).  Expression of 
AMZ and BMY had intermediate effects on cell location (Figs. 2.5A, B).  
 Given the consistent qualitative effects of AMY overexpression on cell location, we 
aimed to evaluate these effects by quantifying migration into the cortical plate of the 
electroporated cells at two time points: three days after electroporation, when control (GFP-
only) electroporated cells are actively migrating, and six days after electroporation when the 
control cells have completed migration. At least three brains per condition were analyzed, and 
the summary results of these analyses are shown in Fig. 2.5A,D.  AMY expression had a 
significant retarding effect on cell migration into the cortical plate at both 3 and 6 days post 
electroporation. At 6 days, almost all of the cells of control- and BMZ-electroporated brains 
entered the cortical plate, whereas AMY expressing brains show a major and significant  
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Figure 2.5. Expression of different Pancortin isoforms has opposing effects in migration of 
neural precursor cells into the cortical plate. 
E15.5 rat embryos were co-electroporated with GFP and constructs encoding Pancortin 
cDNAs. Quantification of the percent of GFP-positive cells that migrated into the cortical plate 
after 3 (A) and 6 (D) days post electroporation. Each bar represents the average of data 
acquired from at least three independent embryos electroporated with constructs listed. Error 
bars represent s.e.m. *p<0.05, ***p<0.005. (B) Representative images from control brains or 
those expressing the listed Pancortin isoforms at 3 days post electroporation. MAP2 
immunostaining is shown in red and TBR1 in blue. CP=cortical plate, IZ=intermediate zone (C) 
Representative images showing the 6 days post electroporation time point following 
electroporation of AMY with and without BMZ or APP co-electroporation. White lines mark 
boundaries of the cortical plate.  (E) Two panels of a representative image showing GFP, 
Pancortin immunostaining (red) and TOPRO-3 staining (blue), or else Pancortin 
immunostaining alone of sections electroporated with AMY and BMZ.  
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impairment of cell movement past the IZ/CP boundary (Figs. 2.5C,D). Interestingly, co-
expression of either BMZ or APP rescued this effect of AMY expression (Figs. 2.5C,D). To 
address whether expression of BMZ or APP prevented the overexpression of AMY, 
immunostaining for AMY was performed, and strong immunostaining for AMY was observed in 
sections from brains co-electroporated with AMY plus either BMZ or APP, at a level qualitatively 
similar to expression of AMY alone (Fig 2.5and data not shown).   
To address whether a physical interaction between APP and Pancortin is necessary for 
proper rescue of the AMY defect by APP, we examined whether deletion of the AMY binding 
site within APP (APPΔ1) affected its ability to rescue. Indeed, co-expression of APPΔ1 with AMY 
failed to rescue the migration defect of AMY, while no effect was observed upon deletion of a 
neighboring domain in the APP ectodomain (APPΔ2) that does not affect binding to AMY (Figs. 
2.5C,D). These data support the hypothesis that a biochemical interaction between APP and 
AMY is required for APP to rescue the failure of neuronal precursor to enter the cortical plate 
with AMY overexpression.  
 It has been reported that the AMZ and AMY Pancortin isoforms are more efficiently 
secreted than the BMZ and BMY isoforms (Barembaum et al, 2000; Moreno & Bronner-Fraser, 
2005; Nagano et al, 2000).  However, it also has been reported in multiple studies that the BMZ 
isoform is robustly secreted (Barembaum et al, 2000; Moreno & Bronner-Fraser, 2001). In order 
to examine whether Pancortin splice variants are secreted and/or retained intracellularly when 
expressed in cells of the developing cerebral cortex, brains electroporated with each of the 
FLAG-tagged splice variants were sectioned coronally and immunostained with an anti-FLAG 
antibody. With AMY or AMZ electroporation, immunostaining for FLAG showed a primarily 
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diffuse staining pattern in the cortical plate (Fig. 2.6A). In contrast, electroporation of BMY or 
BMZ resulted in an immunostaining pattern that was more strongly cell-associated and co-
localized with cellular GFP fluorescence in the cortical plate, suggesting that these proteins are 
either primarily present intracellularly, or they are associated with the cell membrane of the 
cells in which they are expressed (Fig. 2.6B). In order to confirm and extend these observations, 
we performed ex-vivo cultures of the cells electroporated with the individual Pancortin 
isoforms (Appendix 1). Total Pancortin in the lysate and CM was determined by IP with M2 
(anti-Flag)-agarose beads. Both BMZ and AMY were strongly detected in the CM, suggesting 
that both BMZ and AMY are secreted from electroporated neural cells. However, the level of 
secreted AMY was greater than BMZ relative to total expression in both the CM and the lysate 
(Fig. 2.6C). The levels of AMY in the lysate were below detection levels; therefore, to obtain 
higher expression levels and more accurately quantify the relative secretion of BMZ and AMY in 
neurons, we transfected E18 rat primary cortical neurons ex vivo using the Amaxa Nucleofector 
system. While both BMZ and AMY were again highly secreted, the percentage of AMY in the CM 
relative to total AMY in both the lysate and CM was greater than that of BMZ (Figs 2.6D,E). Co-
expression of both BMZ and AMY had no effect on the secretion of either isoform (Figs 2.6D,E). 
Thus, we conclude that all isoforms are secreted, but the A-domain isoforms are secreted more 
robustly than the B-domain isoforms in developing neurons.   
 Next, we asked whether endogenous Pancortin expression is necessary for proper 
cortical migration. shRNA constructs were generated to target different Pancortin isoforms. The 
Pancortin shRNAs were first tested via transient transfection of HEK cells with each FLAG-
tagged Pancortin isoform. Two days following this co-transfection, cells were lysed and Western  
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Figure 2.6. Differential secretion of the Pancortin isoforms from neuronal cells  
(A-B) E15.5 rat embryos were co-electroporated in utero with GFP and constructs listed, and 
harvested 3 days later. Brains were sectioned and immunostained for FLAG and MAP2. Shown 
are representative images of GFP (green), anti-FLAG (red) and anti-MAP2 (blue). (C-E)  Lysates 
and CM from ex-vivo cultures of cortical neurons electroporated in utero (C) or transfected in 
vitro (D) BMZ or AMY were IPed with M2 (anti-Flag)-agarose and WBs performed to detect 
FLAG-tagged Pancortin (anti-FLAG) (C-D). (E) Quantification of the percent of BMZ and AMY 
detected in the CM relative to total (CM + lysate) following in vitro transfection of BMZ and 
AMY both together and separately.  
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blots performed. Pancortin shRNA 3 targets the “M” domain and was expected to target each 
of the Pancortin isoforms. Interestingly, although all splice variants contain the target site for 
shRNA 3, it was only effective in knocking down expression of AMY (Fig. 2.7A). Pancortin shRNA 
4 targets domain “Z”, and it effectively knocked down BMZ but not other Pancortin isoforms 
(Fig. 2.7A).  
 With harvesting at 3 days post-electroporation, Pancortin shRNA 3 (targeting AMY) had 
no qualitative effect on cell location, whereas Pancortin shRNA 4 (targeting BMZ) resulted in a 
failure of electroporated cells to enter the cortical plate (Fig. 2.7B). The effects of knock down 
of BMZ with shRNA 4 persisted at 6 days post-electroporation, producing a phenotype strikingly 
similar to that observed with APP knock down or AMY overexpression (Fig. 2.7C & (Young-
Pearse et al, 2007)). Quantification of these effects was performed at both 3 and 6 days, with 
analysis of at least three brains per condition (Figs. 2.7D,E). Knock down of AMY (by shRNA 3) 
only modestly decreased migration into the cortical plate at 3 days, and by 6 days, no 
significant effect on entry into the cortical plate was observed. However, those cells that 
entered the cortical plate were not localized to a single layer but rather were found in a “wavy” 
pattern throughout the cortical plate, which could be rescued by either APP or BMZ 
overexpression (Fig. 2.7F). 
 As expected, electroporation of shRNA 3, which knocks down AMY, rescued the AMY 
overexpression phenotype (Fig. 2.7D,E). In contrast, knock down of BMZ (with shRNA 4) did not 
rescue the AMY overexpression phenotype at 3 or 6 days (Fig. 2.7D,E). Similarly, knock down of 
APP had no additional effect on AMY overexpression. Overexpression of a mutated BMZ cDNA 
construct, which contains 4 synonymous mutations in the shRNA target site (“BMZ4m”), 
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rescued the knock down phenotype of Pancortin shRNA 4 (BMZ) at 3 and 6 days, suggesting 
that the effects observed with this shRNA are specifically due to a loss of Pancortin expression 
(Fig. 2.7E). Interestingly, overexpression of BMZ partially rescued the APP knock down 
phenotype at 6 days (Fig. 2.7E). Taken together, these data demonstrate a role of the 
Pancortins in proper migration of neuronal precursor cells into the cortical plate. Furthermore, 
our data suggest that APP and Pancortin may act in concert to regulate cortical precursor cell 
migration, as APP overexpression rescues both the defect in cortical plate entry of AMY 
overexpression and the “wavy” phenotype of AMY knock down.  
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Figure 2.7. Pancortins are required for proper migration in the developing cerebral cortex. 
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Figure 2.7. Pancortins are required for proper migration in the developing cerebral cortex 
(continued). 
(A) ShRNA constructs targeting Pancortin isoforms were generated and tested for their ability 
to knock down each of the FLAG-tagged Pancortin isoforms. HEK293 cells were transfected 
with construct combinations as labeled. GFP was co-transfected in all cases to monitor 
transfection efficiency. 48 hours following transfection, cells were lysed and Western blots 
performed to examine GFP and Pancortin levels, using M2 (α-FLAG). (B-F) E15.5 rat embryos 
were electroporated in utero with GFP and constructs listed, and harvested 3 or 6 days later. 
Brains were dissected, fixed, sectioned coronally, and immunostained for MAP2 and TBR1.  (B) 
Representative images of a 3 day harvest following introduction of shRNA 3 (which knocks 
down AMY) and shRNA 4 (which knocks down BMZ). MAP2 immunostaining is shown in red 
and TBR1 in blue. (C) Representative images of brains electroporated with constructs listed 
and harvested 6 days later. White lines delineate the boundaries of the cortical plate as 
determined by MAP2 and TBR1 immunostaining. (D,E) Quantification of the percent of GFP 
positive cells present in the cortical plate after 3 (D) and 6 (E) days post electroporation. Each 
bar presents data from the average of at least three independent embryos electroporated 
with constructs listed. Error bars represent s.e.m. * p<0.05, **p<0.01, ***p<0.005. Black 
asterisks represent significance relative to GFP vector control, red asterisks to AMY, green 
asterisk to Pancortin shRNA 4 (BMZ), and blue asterisk to APP shRNA. Quantifications from Fig. 
3A,D for GFP, AMY, BMZ, AMY+BMZ, and AMY+APP are re-shown here for direct comparison 
to knock down data. (F) Representative images of brains electroporated with shRNA targeting 
AMY with and without co-electroporation of AMY, APP, or BMZ and harvested at 6 days post 
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Discussion   
A Role for Pancortins in Mammalian Cortical Development 
Pancortin, originally named for its high expression in the cerebral cortex (Nagano et al, 
1998), has been implicated in migration of neural crest cells and neuronal differentiation in 
chick embryos and Xenopus, respectively (Barembaum et al, 2000; Moreno & Bronner-Fraser, 
2001; Moreno & Bronner-Fraser, 2005). However, no studies have yet identified a role for 
Pancortin in the development of the mammalian brain. In a single report of a Pancortin 
knockout mouse, it was proposed that Pancortins are mediators of ischemia-induced neuronal 
cell death in the adult brain (Cheng et al, 2007). However, it remains unclear what the normal 
function of Pancortin may be during development, as the loss of Pancortin only protected adult 
but not embryonic neurons against ischemic death, and other putative developmental 
phenotypes were not presented. Here, utilizing the technique of in utero electroporation to 
both overexpress Pancortin and knock down endogenous Pancortin in a subset of neural cells, 
we reveal a novel function of Pancortin in the migration of neuronal precursors into the cortical 
plate of the rat cortex. AMY knock down produces a phenotype in which neuronal precursors 
enter the cortical plate but exhibit abnormal positioning, a unique phenotype that we have not 
observed with in utero electroporation of over a dozen different genes thought to have roles in 
neuronal development. Overexpression of the AMY isoform or knock down of the BMZ isoform 
results in failure of neuronal precursors to enter the cortical plate. Phenotypes of abnormal cell 
positioning can result from a number of different types of primary insult including a decline in 
cell survival, defects in the cytoskeletal network critical for the mechanics of cell movement, 
and disruptions of signaling pathways that instruct cells when to migrate and when to stop and 
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differentiate.  Here, we believe that the primary defect is not in cell survival, as there is no 
dramatic loss in electroporated cells between 3 and 6 days post electroporation. Further, 
electroporated cells are able to migrate away out of the ventricular zone and through the 
intermediate zone with AMY overexpression and BMZ knock down, suggesting that these cells 
have the necessary machinery for cell movement. Rather, cells stop just below the cortical plate 
boundary, similar to the defect observed with knock down of APP. We hypothesize that this is 
due to a defect in signaling within the cells that either fails to direct the cells to continue 
migrating or else directs the cells to prematurely halt migration.  
Our data support an opposing role for BMZ and AMY in regulating developmental 
processes. While BMZ promotes migration into the cortical plate, AMY appears to inhibit 
normal cortical plate entry.  Further, overexpression of BMZ rescues the phenotype observed 
with AMY overexpression. Interestingly, the observation of functional antagonism between the 
BMZ and AMY isoforms in neurodevelopment is consistent with previous studies in Xenopus in 
which BMZ promoted neuronal differentiation and AMY rescued this effect (Moreno & 
Bronner-Fraser, 2001; Moreno & Bronner-Fraser, 2005), perhaps through direct interaction of 
the BMZ and AMY isoforms (Moreno & Bronner-Fraser, 2005). In addition, our observation that 
both isoforms are able to bind to APP but differ in their co-IP efficiency with APP when each are 
expressed separately but reach similar co-IP efficiencies with APP when expressed together 
lend support to an additional model of competition between these isoforms for binding to 
putative receptors.   
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Biochemical and Functional Interaction of Pancortin and APP 
Here, we report a novel biochemical and functional interaction between Pancortins and 
APP.  In an unbiased screen, we identified Pancortins as extracellular binding partners for APP, 
and confirmed that each of the Pancortin isoforms binds either directly or indirectly to the APP 
ectodomain. The E1 region of the APP ectodomain and the M and Z domains of Pancortin were 
critical for a physical interaction.  Further, expression of the B domain containing isoforms 
strongly inhibits β-secretase cleavage of APP, suggesting a biochemical consequence of the 
association between Pancortins and APP. However, the B domain, which confers activity but 
cannot physically interact with APP, has no effect on β-secretase processing when expressed 
alone, suggesting that a physical interaction between APP and Pancortin is required to 
modulate APP processing.  
Knock down of BMZ or overexpression of AMY phenocopies a loss of APP expression in 
the developing rodent brain, each showing a specific defect in migration of neural precursor 
cells into the cortical plate. We hypothesize that for this function in cortical development, 
Pancortins act in part through binding to APP, but also though APP-independent mechanisms. 
Based upon the data presented herein (summarized in Fig. 2.8), we propose that BMZ binding 
to the extracellular domain of APP promotes proper migration into the cortical plate while 
binding of AMY to APP inhibits proper migration. Thus, loss of APP or BMZ, or else 
overexpression of AMY inhibits cortical plate entry (Fig. 2.5, 2.7). We posited that if AMY 
overexpression inhibits the functions of BMZ and APP in normal migration, then overexpression 
of either BMZ or APP should rescue the AMY defect, which was the effect that was observed 
(Fig. 2.5). Further, we found that APP rescues the AMY defect through a physical interaction, as 
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blockade of the interaction through deletion of the E1 domain of APP prevents rescue of the 
AMY defect (Fig. 2.5D). In HEK293 cells, co-expression of BMZ and AMY reduces binding of AMY 
to APP, suggesting that BMZ may rescue the AMY defect by preventing AMY from binding APP 
(Figs. 2.3C,D). Interestingly, overexpression of APP does not rescue the loss of BMZ (Fig. 2.5D,E), 
indicating that the migration-promoting effect of APP is dependent upon expression of BMZ.  
Taken together, the data presented suggest that Pancortins functionally and 
biochemically interact with APP in cortical development. However, our data showing that BMZ 
overexpression can partially rescue the phenotype observed with knock down of APP suggest 
that Pancortins also may act through APP-independent mechanisms, perhaps through 
interaction with the highly homologous APP family members (APLP1 and 2) or possibly through 
other type I-transmembrane domain proteins. Future studies are warranted to examine how 
Pancortins interact with other known signaling pathways to regulate proper migration and 
differentiation of neuronal precursor cells in the mammalian cerebral cortex.  
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 Figure 2.8. Summary of the effects observed of Pancortins and APP on migration in the 
developing cerebral cortex. 
 
84
Figure 2.8. Summary of the effects observed of Pancortins and APP on migration in the 
developing cerebral cortex (continued).    
In utero electroporation of Pancortin constructs in the developing rat brain revealed novel and 
opposing roles of the AMY and BMZ isoforms in cortical cell migration. (a) Cells overexpressing 
AMY fail to enter the cortical plate suggesting that AMY inhibits cortical plate entry. (b) Knock 
down of BMZ results in failure to enter the cortical plate, suggesting that endogenous BMZ 
promotes cortical plate entry. (c) BMZ overexpression rescues the defect observed with AMY 
overexpression. Taken together with previous studies of neuronal differentiation in Xenopus 
(Moreno and Bronner-Fraser, 2005), the data support a model where AMY and BMZ mutually 
inhibit the activity of the other. In support of an APP-dependent mechanism , d) peptides to 
the B and Z domain of Pancortin were identified in an unbiased mass spectrometry screen for 
APP interacting proteins and both BMZ and AMY co-IP with APP, an interaction disrupted by 
deletion of the E1 region of the APP ectodomain. e) Overexpression of APP rescues AMY 
overexpression,  but  f)  blockade of the interaction through deletion of the AMY binding site 
within APP (the E1 domain) prevents rescue of the AMY defect by APP, supporting a model 
whereby AMY inhibits the function of APP in cortical cell migration through a physical 
interaction. g) Expression of BMZ can decrease the co-IP efficiency of AMY with APP, which 
suggest that BMZ may rescue the AMY defect by preventing AMY from binding to APP.  h) 
BMZ inhibits β-secretase cleavage of APP; however, whether this activity is mechanistically 
involved in regulating migration has yet to be determined.  
 
85
References 
Araki W, Kitaguchi N, Tokushima Y, Ishii K, Aratake H, Shimohama S, Nakamura S, Kimura J (1991) 
Trophic effect of β-amyloid precursor ptotein on cerebral cortical neurons in culture. Biochem Biophys 
Res Commun 181: 265-271 
 
Bai Y, Markham K, Chen F, Weerasekera R, Watts J, Horne P, Wakutani Y, Bagshaw R, Mathews PM, 
Fraser PE, Westaway D, St George-Hyslop P, Schmitt-Ulms G (2008) The in vivo brain interactome of the 
amyloid precursor protein. Mol Cell Proteomics 7: 15-34 
 
Barembaum M, Moreno TA, LaBonne C, Sechrist J, Bronner-Fraser M (2000) Noelin-1 is a secreted 
glycoprotein involved in generation of the neural crest. Nat Cell Biol 2: 219-225 
 
Bulfone A, Smiga SM, Shimamura K, Peterson A, Puelles L, Rubenstein JL (1995) T-brain-1: a homolog of 
Brachyury whose expression defines molecularly distinct domains within the cerebral cortex. Neuron 15: 
63-78 
 
Cheng A, Arumugam TV, Liu D, Khatri RG, Mustafa K, Kwak S, Ling HP, Gonzales C, Xin O, Jo DG, Guo Z, 
Mark RJ, Mattson MP (2007) Pancortin-2 interacts with WAVE1 and Bcl-xL in a mitochondria-associated 
protein complex that mediates ischemic neuronal death. J Neurosci 27: 1519-1528 
 
Danielson PE, Forss-Petter S, Battenberg EL, deLecea L, Bloom FE, Sutcliffe JG (1994) Four structurally 
distinct neuron-specific olfactomedin-related glycoproteins produced by differential promoter utilization 
and alternative mRNA splicing from a single gene. J Neurosci Res 38: 468-478 
 
De Strooper B, Annaert W (2000) Proteolytic processing and cell biological functions of the amyloid 
precursor protein. J Cell Sci 113: 1857-1870 
 
Ghiso J, Rostagno A, Gardella JE, Liem L, Gorevic PD, Frangione B (1992) A 109-amino-acid C-terminal 
fragment of Alzheimer's-disease amyloid precursor protein contains a sequence, -RHDS-, that promotes 
cell adhesion. Biochem J 288: 1053-1059 
 
Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the 
road to therapeutics. Science 297: 353-356 
 
Ho A, Sudhof TC (2004) Binding of F-spondin to amyloid-beta precursor protein: a candidate amyloid-
beta precursor protein ligand that modulates amyloid-beta precursor protein cleavage. Proc Natl Acad 
Sci 101: 2548-2553 
 
86
Hoe HS, Lee KJ, Carney RS, Lee J, Markova A, Lee JY, Howell BW, Hyman BT, Pak DT, Bu G, Rebeck GW 
(2009) Interaction of reelin with amyloid precursor protein promotes neurite outgrowth. J Neurosci 29: 
7459-7473 
 
Hoe HS, Tran TS, Matsuoka Y, Howell BW, Rebeck GW (2006) DAB1 and Reelin effects on amyloid 
precursor protein and ApoE receptor 2 trafficking and processing. J Biol Chem 281: 35176-35185 
 
Hoe HS, Wessner D, Beffert U, Becker AG, Matsuoka Y, Rebeck GW (2005) F-spondin interaction with the 
apolipoprotein E receptor ApoEr2 affects processing of amyloid precursor protein. Mol Cell Biol 25: 
9259-9268 
 
Ma QH, Futagawa T, Yang WL, Jiang XD, Zeng L, Takeda Y, Xu RX, Bagnard D, Schachner M, Furley AJ, 
Karagogeos D, Watanabe K, Dawe GS, Xiao ZC (2008) A TAG1-APP signalling pathway through Fe65 
negatively modulates neurogenesis. Nat Cell Biol 10: 283-294 
 
Moreno T, Bronner-Fraser M (2001) The secreted glycoprotein Noelin-1 promotes neurogenesis in 
Xenopus. Developmental biology 240: 340-400 
 
Moreno TA, Bronner-Fraser M (2005) Noelins modulate the timing of neuronal differentiation during 
development. Dev Biol 288: 434-447 
 
Nagano T, Nakamura A, Konno D, Kurata M, Yagi H, Sato M (2000) A2-Pancortins (Pancortin-3 and -4) are 
the dominant pancortins during neocortical development. J Neurochem 75: 1-9 
 
Nagano T, Nakamura A, Mori Y, Maeda M, Takami T, Shiosaka S, Takagi H, Sato M (1998) Differentially 
expressed olfactomedin-related glycoproteins (Pancortins) in the brain. Brain Res Mol Brain Res 53: 13-
23 
 
Osterfield M, Egelund R, Young LM, Flanagan JG (2008) Interaction of amyloid precursor protein with 
contactins and NgCAM in the retinotectal system. Development 135: 1189-1199 
 
Perez RG, Zheng H, Van der Ploeg LH, Koo EH (1997) The beta-amyloid precursor protein of Alzheimer's 
disease enhances neuron viability and modulates neuronal polarity. J Neurosci 17: 9407-9414 
 
Pramatarova A, Chen K, Howell BW (2008) A genetic interaction between the APP and Dab1 genes 
influences brain development. Mol Cell Neurosci 37: 178-186 
 
Pramatarova A, Ochalski PG, Lee CH, Howell BW (2006) Mouse disabled 1 regulates the nuclear position 
of neurons in a Drosophila eye model. Mol Cell Biol 26: 1510-1517 
87
 
Priller C, Bauer T, Mitteregger G, Krebs B, Kretzschmar HA, Herms J (2006) Synapse formation and 
function is modulated by the amyloid precursor protein. J Neurosci 26: 7212-7221 
 
Rice H, Suth S, Cavanaugh W, Bai J, Young-Pearse T (2010) In utero electroporation followed by primary 
neuronal culture for studying gene function in subset of cortical neurons. J Vis Exp 44 
 
Ring S, Weyer SW, Kilian SB, Waldron E, Pietrzik CU, Filippov MA, Herms J, Buchholz C, Eckman CB, Korte 
M, Wolfer DP, Muller UC (2007) The secreted beta-amyloid precursor protein ectodomain APPs alpha is 
sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP-deficient 
mice. J Neurosci 27: 7817-7826 
 
Selkoe D (2011) Resolving controversies on the path to Alzheimer's therapeutics. Nature medicine 17: 
1060-1065 
 
Soba P, Eggert S, Wagner K, Zentgraf H, Siehl K, Kreger S, Lower A, Langer A, Merdes G, Paro R, Masters 
CL, Muller U, Kins S, Beyreuther K (2005) Homo- and heterodimerization of APP family members 
promotes intercellular adhesion. EMBO J 24: 3624-3634 
 
Wang Z, Wang B, Yang L, Guo Q, Aithmitti N, Songyang Z, Zheng H (2009) Presynaptic and postsynaptic 
interaction of the amyloid precursor protein promotes peripheral and central synaptogenesis. J Neurosci 
29: 10788-10801 
 
Young-Pearse TL, Bai J, Chang R, Zheng JB, Loturco JJ, Selkoe DJ (2007) A Critical Function for beta-
Amyloid Precursor Protein in Neuronal Migration Revealed by In Utero RNA Interference. J Neurosci 27: 
14459-14469 
 
Young-Pearse TL, Chen A, Chang R, Marquez C, Selkoe DJ (2008) Secreted APP regulates the function of 
full-length APP in neurite outgrowth through interaction with integrin beta1. Neural Development 3 
 
Young-Pearse TL, Suth S, Luth ES, Sawa A, Selkoe DJ (2010) Biochemical and functional interaction of 
disrupted-in-schizophrenia 1 and amyloid precursor protein regulates neuronal migration during 
mammalian cortical development. J Neurosci 30: 10431-10440 
 
 
 
88
  
 
 
 
Chapter 3:  
 
 
 
 
 
Systematic evaluation of candidate ligands regulating ectodomain shedding  
of Amyloid Precursor Protein 
 
 
 
Heather C. Rice, Tracy L. Young-Pearse, and Dennis J. Selkoe 
 
 
 
Experimental contributions to this chapter:HCR performed all experiments 
This chapter was modified from a manuscript published in Biochemistry 2013 May 2. [Epub 
ahead of print]. 
89
  
Abstract 
Despite intense interest in the proteolysis of the ß-Amyloid Precursor Protein (APP) in 
Alzheimer’s disease (AD), how the normal processing of this type I receptor-like glycoprotein is 
physiologically regulated remains ill-defined.  In recent years, several candidate protein ligands 
for APP, including F-spondin, Reelin, β1 Integrin, Contactins, Lingo-1 and Pancortin, have been 
reported. However, a cognate ligand for APP that regulates its processing by α- or β-secretase 
has yet to be widely confirmed in multiple laboratories. Here, we developed new assays in an 
effort to confirm a role for one or more of these candidate ligands in regulating APP 
ectodomain shedding in a biologically relevant context.   A comprehensive quantification of 
APPsα and APPsβ, the immediate products of secretase processing, in both non-neuronal cell 
lines and primary neuronal cultures expressing endogenous APP yielded no evidence that any 
of these published candidate ligands stimulate ectodomain shedding.  Rather, Reelin, Lingo-1 
and Pancortin-1 emerged as the most consistent ligands for significantly inhibiting ectodomain 
shedding. These findings led us to conduct further detailed analyses of the interactions of 
Reelin and Lingo-1 with APP. 
90
  
Introduction  
Although the stepwise proteolysis of the ß-Amyloid Precursor Protein (APP) to release 
amyloid ß-protein (Aß) has been central to the study of Alzheimer’s disease (AD), how the 
normal processing of this conserved type I membrane glycoprotein is physiologically regulated 
remains poorly defined.  In AD, amyloid (neuritic) plaques are principally composed of the 
potentially neurotoxic Aβ peptides, which are generated by the sequential proteolytic 
processing of APP (reviewed in (Haass et al, 2012)). Cleavage of APP by either α- or β- secretase 
results in the shedding of large extracellular portions of APP termed APPsα or APPsβ, 
respectively.  The remaining C-terminal fragments (CTFα and CTFβ) are then cleaved 
intramembranously by γ-secretase. Cleavage of CTFβ by γ-secretase releases Aβ into the 
luminal/extracellular space and AICD into the cytoplasm. Cleavage of CTFα by γ-secretase 
releases the smaller p3 fragment into the lumen/extracellular space and AICD into the 
cytoplasm.  The latter pathway, which begins with APP ectodomain shedding by α-secretase, 
predominates in almost all cell types and precludes Aβ production.   
 Experimental studies suggest several roles for APP in brain development, including 
migration of neuronal precursor cells (Pramatarova et al, 2008; Young-Pearse et al, 2007), 
neurite outgrowth (Araki et al, 1991; Perez et al, 1997; Rama et al, 2012; Young-Pearse et al, 
2008), cell adhesion (Ghiso et al, 1992; Soba et al, 2005) and synapse formation (Priller et al, 
2006; Wang et al, 2009).  Since its initial discovery, APP has been hypothesized to be a cell 
surface receptor (Kang et al, 1987). In recent years, several candidate protein ligands for APP, 
including F-spondin (Ho & Sudhof, 2004; Hoe et al, 2005), Reelin (Hoe et al, 2009; Hoe et al, 
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2006), β1 Integrin (Hoe et al, 2009; Young-Pearse et al, 2008),  Contactins (Bai et al, 2008; Ma et 
al, 2008; Osterfield et al, 2008), Lingo-1 (Bai et al, 2008) and Pancortin (Rice et al, 2012), have 
been reported to interact physically with the ectodomain of APP and modulate APP processing 
and, in some cases, APP function in neurodevelopment.  
F-spondin, a secreted extracellular matrix glycoprotein, was identified in unbiased 
screens for APP interactors (Bai et al, 2008; Ho & Sudhof, 2004).  Transfection of F-spondin was 
initially found to inhibit β-secretase cleavage of APP as measured by CTFβ levels in human 
embryonic kidney (HEK) 293 cells also over-expressing APP and BACE1 (Ho & Sudhof, 2004). F-
spondin inhibited AICD-dependent gene transactivation, suggesting that α-secretase cleavage 
was also inhibited by F-spondin (Ho & Sudhof, 2004). However, a subsequent study reported 
that F-spondin enhanced APPsα and CTFα in addition to reducing APPsβ in COS7 cells 
overexpressing APP (Hoe et al, 2005).   
β1 Integrin is a type I single transmembrane protein important for cell adhesion. We 
have found β1 Integrin to physically interact with APP and to be involved in APP-dependent 
neurite outgrowth (Young-Pearse et al, 2008). These findings were confirmed in a study by 
another group in which they also reported that β1 Integrin enhanced APPsα and CTFα levels in 
COS7 cells overexpressing APP (Hoe et al, 2009).  
The Contactins (CNTNs) are GPI-anchored neuronal-specific cell adhesion molecules 
(reviewed in (Shimoda, 2009)). CNTN4 was identified in a screen for extracellular APP binding 
partners in embryonic chick brain, and only CNTN3 and CNTN4 but not the remaining CNTN 
family members were found to directly bind APP in vitro (Osterfield et al, 2008). However, other 
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groups reported evidence of a physical interaction of  CNTN2 (Ma et al, 2008) and CNTN1(Bai et 
al, 2008) with APP. Expression of CNTN4 in HEK cells overexpressing APP led to an increase of 
CTFα levels in some experiments and a decrease in others (Osterfield et al, 2008). CNTN2 was 
reported to enhance AICD, CTFα and CTFβ in both overexpressed and endogenous assays (Ma 
et al, 2008).  Functional interactions between CNTN4 and APP in neurite outgrowth (Osterfield 
et al, 2008) and CNTN2 and APP in neurogenesis (Ma et al, 2008) have been reported. 
Lingo-1  (leucine rich  repeat  and Ig domain-containing Nogo receptor interacting 
protein-1), a single-transmembrane protein, is a member of the Nogo-66 receptor complex and 
negatively regulates axonal myelination and regeneration (reviewed in (Mi et al, 2008)). Lingo-1 
was among the proteins identified (along with F-spondin) in the APP interactome study of intact 
mouse brain (Bai et al, 2008). This study reported a physical interaction between APP and 
Lingo-1 and showed that knockdown of Lingo-1 in HEK293 cells stably overexpressing APP 
bearing the “Swedish” AD mutation increased CTFα and lowered CTFβ, whereas overexpression 
of Lingo-1 increased CTFβ (Bai et al, 2008). A separate group confirmed a physical interaction in 
an overexpressed cell system and determined that the interaction occurs via the ectodomain of 
Lingo-1 (Stein & Walmsley, 2012).   
Reelin, a large glycoprotein, is secreted from Cajal-Retzius cells in the embryonic cortex 
and regulates the migration of neuronal precursor cells (reviewed in (Honda et al, 2011)). In the 
adult cortex, Reelin is secreted by a subset of interneurons and plays a role in synaptic plasticity 
(reviewed in (Förster et al, 2010)).  In two studies, Reelin was shown to physically interact with 
APP and enhance APPsα and CTFα levels in COS7 cells overexpressing APP (Hoe et al, 2009; Hoe 
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et al, 2006) . Subsequently, another group showed that reduction of Reelin enhanced both CTFβ 
and Aβ in APP transgenic mice (Kocherhans et al, 2010). A functional interaction between 
Reelin and APP in neurite outgrowth has been described (Hoe et al, 2009).  
We recently reported Pancortin, a secreted glycoprotein with multiple isoforms, as a 
candidate ligand for APP (Rice et al, 2012).  Pancortin was identified in an unbiased screen of 
endogenous proteins from murine cortical slices that interacted with the APP ectodomain (Rice 
et al, 2012). Pancortin-1 and Pancortin-2 were found to specifically reduce β-secretase but not 
α-secretase cleavage of endogenous APP in HEK293 cells, while Pancortin-3 had no effect (Rice 
et al, 2012).  We also uncovered a functional interaction of Pancortin isoforms with APP in 
regulating the entry of neuronal precursor cells into the cortical plate (Rice et al, 2012). 
In the context of these numerous reports of candidate ligands with often variable 
individual results, a cognate ligand for APP that regulates its processing by α- or β- secretase 
has yet to be widely confirmed by multiple laboratories in biologically relevant systems. Here, in 
an effort to confirm a role for one or more reported candidate ligands in regulating α- or β- 
secretase cleavage of APP, we describe a systematic comparison of candidate ligands by directly 
quantifying APPsα and APPsβ, the immediate products of secretase processing, across multiple 
assays. First, we compare candidate APP ligands in a non-neuronal mammalian cell line with 
overexpression of APP, in keeping with virtually all of the above initial reports on these 
candidate ligands. Then, we compare the candidates in novel assays we have developed to 
measure proteolytic processing of endogenous APP in both non-neuronal and neuronal cell 
lines. From these studies, we do not confirm any candidates as triggering ectodomain shedding 
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of APP. However, Reelin, Lingo-1 and Pancortin-1 emerge as the most consistent ligands that 
reduce α- and/or β- secretase cleavage of APP.  Accordingly, we report further detailed analyses 
of the interactions of Reelin and Lingo-1 with APP. 
Experimental Procedures 
Plasmids  
Plasmids utilized for transient and stable transfections include, pCAX-APP751(human)  as 
described (Young-Pearse et al, 2007), pcDNA-APP695-swedish (human), as described (Citron et 
al, 1992), pCAX-β1 Integrin (mouse)  as described (Young-Pearse et al, 2008), PCAX –Pancortin-1 
and -4 (mouse) as described (Rice et al, 2012). pcDNA4-His/Myc-F-spondin(human) was kindly 
provided by T. Südhof  (Ho & Sudhof, 2004).  Lingo-1 (human) was obtained from DF/HCC DNA 
Resource Core deposited by the Mammalian Gene Collection consortium and cloned into the 
pCDH vector. CNTN2-Fc(human) was kindly provided by J. Flanagan (Osterfield et al, 2008) and 
cloned into the pcDNA vector. pcDNA-Reelin (mouse) was kindly  provided by T. Curran 
(D'Arcangelo et al, 1997). Constructs for the Reelin fragments (N-R6, R3-8, 3-6, N-R2, and R7-8) 
(mouse) were provided by A. Goffinet (Jossin et al, 2004). pcDNA-APOER2 were kindly provided 
by J. Herz. VLDLR-myc (mouse) was kindly provided by H-S Hoe (Hoe et al, 2005). HEK293 cell 
lines stably expressing Reelin or vector control, CER or CEP4 respectively, were kindly provided 
by T. Curran (Benhayon et al, 2003).  
Immunoprecipitation (IP) and Western blotting (WB) 
For IP studies, HEK293 cells were transfected with the specified combinations of Reelin, 
APOER2, VLDLR, and APP. Cells were lysed in 1% NP40 STEN buffer (150 mM NaCl, 50 mM Tris, 
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2 mM EDTA, and 1.0% (v/v) NP-40).  Lysates were IPed with either anti-Reelin (G10, Millipore), 
anti-APOER2 (Abcam, Cambridge, MA) anti-VLDLR (R&D Systems, Minneapolis, MN ), or anti-
APP (C9) and protein A and G agarose resin (Sigma, St. Louis, MO) overnight and washed 3X 
with 1% NP40 STEN buffer. Lysates, CM, and immunoprecipitations were electrophoresed on 
10–20% Tricine or 4-12% Bis-Tris gels (Invitrogen, Carlsbad, CA) and transferred to 
nitrocellulose. Western blotting (WB) was performed with primary antibodies anti-APP (C9, 
1:1,000; Selkoe lab), anti-APPsα (1736, 1:2,000; Selkoe lab), anti-rodent APP/APPsα (597,1:200; 
Immuno-biological Laboratories, Minneapolis, MN), anti-GAPDH (1:2,000; Millipore, Billerica, 
MA), anti-FLAG (M2; 1:1,000; Sigma, St. Louis, MO), anti-Lingo-1(1:1,000; Millipore, Billerica, 
MA),  anti-β1 Integrin (1:1,000; Abcam, Cambrdige, MA), anti-F-spondin (1:1,000 ; Abcam, 
Cambrdige, MA), anti-Reelin (N-terminal, G10) (1:500, Millipore, Billerica, MA), anti-Reelin (mid-
region, R4B) (1:1000,  Developmental Studies Hybridoma Bank, Iowa City, IA) anti-Reelin (C-
terminal) ( 1:1000, E5, Santa Cruz Biotechnology, Santa Cruz, CA), anti-Tau (1:2,000, Dako, 
Carpinteria, CA), anti-BACE1 (1:500, Millipore, Billerica, MA), anti-ADAM17 (1:500, Abcam, 
Cambridge, MA), each followed by IRDye800- or IRDye680-conjugated secondary antibodies 
(1:10,000; Rockland Immunochemicals, Gilbertsville, PA) and detection with the LICOR Odyssey 
detection system. For quantitative Western blots, Pancortin-3 (Rice et al., 2012), Reelin and F-
spondin (R&D systems, Minneapolis, MN) recombinant proteins were utilized as standards.  
APP processing assays in HEK293 cells  
HEK293 cells were plated in 6 well plates at 1x10^6 cells/well and transiently 
transfected with cDNA of each candidate ligand or empty vector (as control) using Fugene HD 
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(Promega, Madison, WI). In the assay to examine effects on overexpressed APP, APP751 was 
co-transfected with the candidate ligand or empty vector.  At 24 hr post-transfection, media 
(DMEM + 10% FBS) were replaced, and at 48 hr post-transfection, media were collected and 
centrifuged at 200 g for 5 min, and cells were lysed in 1% NP-40 STEN buffer. Human APPsα, 
APPsβ, Aβ40, and Aβ42  levels in the CM was quantified by multiplex ELISA kits (Meso Scale 
Discovery, Gaithersburg, MD) and normalized to holoAPP  in the lysate (for the overexpressed 
APP assay) or normalized to total intracellular protein (for the endogenous APP assay) . For 
DAPT treatment of Lingo-1 transfected HEK293 cells, cells were treated for 24 hrs with 5 μM 
DAPT in DMSO. One-way ANOVA tests were performed with the Bonferroni correction for 
multiple comparisons.  
APP processing assays in rat primary cortical cultures 
Cortical neurons from E18 Sprague Dawley rats were plated in 6-well poly-D-lysine 
coated plates at 7.5 x 10^5 cells/well typically for 4 DIV (but but some experiments ranged for 
2-12 DIV with similar effects). In our co-culture assay, The HEK293 stable cell lines expressing 
the ligand of interest were pelleted by centrifugation and then resuspended in neuronal 
medium. The HEK293 cells are then plated at 7.5 x 10^5 cells/well overlying the neurons for 18-
24 hr.  Medium is then changed 4 hrs later to remove any unattached HEK293 cells. In our CM 
assay, neurons were treated for 18-24 hr with CM from the HEK293 cell lines stably expressing 
the ligand of interest.  CM was obtained from stable cell lines conditioned for 24 hr in serum-
free optiMEM concentrated 10x with Amicon Ultra 10K MWCO centrifugal filters (Millipore) and 
diluted to a 1X solution in Neurobasal media. After the 18-24 hr period of CM treatment or co-
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culture, CM was collected and centrifuged at 2000 rpm for 5 min. Cells were lysed in 1% NP-40 
STEN. Endogenous rat neuronal APPsα was quantified by a rodent-specific ELISA kit (Immuno-
biological Laboratories). APPsα was normalized to a neuronal-specific protein, Tau, by WB 
analysis in the co-culture assay and to total intracellular protein by BCA assay (Fisher) in the CM 
assay. One-way ANOVA tests were performed with the Bonferroni correction for multiple 
comparisons. 
Results  
Effects of candidate ligands on APPsα and APPsβ levels in HEK293 cells 
 Candidate APP ligands were first examined in a non-neuronal mammalian cell line 
overexpressing APP, because this had been done in nearly all of the initial reports of these 
particular candidate ligands (reviewed in Introduction). In this assay, HEK 293 cells were 
transiently co-transfected with one of the putative ligands and human APP751, and the 
medium (DMEM with 10% FBS) was changed 24 hr after transfection. At 48 hr, the conditioned 
media (CM) were collected, and cells were lysed. APPsα and APPsβ levels in the CM were 
measured by a sensitive and highly reproducible MSD multiplex ELISA. APPsα and APPsβ levels 
were normalized to holoAPP, which was measured by WB of the respective cell lysates. Using 
this assay, F-spondin and CNTN2-Fc did not significantly modulate APPsα or APPsβ levels (Fig 
3.1A-C). Expression of Reelin resulted in the greatest change of APPsα and APPsβ levels, with a 
decrease of 54.9 ± 3.5% (p<0.001) and 25.4 ± 4.2% (p<0.001), respectively (Fig 3.1A-C). 
Expression of Lingo-1 also significantly reduced levels of APPsα by 34.1 ± 4.2% (p<0.001) and  
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Figure 3.1: Effects of candidate ligands on APPsα and APPsβ levels in HEK293 cells  
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Figure 3.1: Effects of candidate ligands on APPsα and APPsβ levels in HEK293 cells 
(continued)  
(A-C) HEK293 cells were co-transfected with APP751 (human, wild-type) and candidate ligands 
or empty vector (as control) . APPsα and APPsβ levels were quantified by ELISA and 
normalized to holoAPP by Western blot and shown as a percentage of control.  (D-F) HEK293 
cells (expressing only endogenous human APP) were transfected with candidate ligands or 
empty vector (as control) and APPsα and APPsβ levels were quantified by ELISA and 
normalized to total intracellular protein and shown as a percentage of control.   (A,D) Bar 
graph showing average APPsα and APPsβ levels of all experiments. Scatter plots showing 
APPsα (B,E) and APPsβ (C,F) levels for each replicate of each experiment.  Error bars represent 
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APPsβ by 16.1 ± 5.3% (p<0.05) (Fig 3.1A-C). β1 Integrin increased APPsβ levels by 28.6% ± 7.5 
(p<0.001) and did not significantly modulate APPsα levels (Fig 3.1A-C).   
Of note, these mean changes in soluble APP shedding were all determined by ELISAs on 
numerous individual samples performed over multiple experimental days (Fig. 3.1B, C).  Reelin 
produced the most robust and consistent effect in this assay (see scatterplots in Fig. 3.1B-C). 
Across all replicates, Reelin overexpression resulted in a 25% or greater decrease in APPsα (Fig 
3.1B). Transfection of β1 Integrin resulted in the highest variability across experiments, as 
APPsα and APPsβ levels were enhanced in some experiments but reduced in others (Figs 3.1B-
C). These variable effects of β1 Integrin on APPsα and APPsβ shedding appeared to be due to 
differences in holoAPP expression levels. In this overexpression assay system, co-transfection of 
β1 Integrin with APP751 led to much greater percent changes in holoAPP levels than did co-
transfection of the other 4 candidates (Fig 3.2). Even after normalization of the APPsα and 
APPsβ levels to holoAPP levels in each experiment, the effects of β1 Integrin on APPsα secretion 
were significantly correlated (R
2
 = .44, p<0.01) with differences in holoAPP expression (Fig 3.2). 
For example, when holoAPP levels were relatively high in the β1 Integrin co-transfectants 
compared to vector transfected controls, then relative APPsα/holoAPP levels were also high. In 
contrast, we observed no significant correlations between APPsα/holoAPP and changes in 
holoAPP expression levels for F-spondin, Reelin and Lingo-1 (Fig. 3.2).  
Proteolytic processing of overexpressed APP can be quite different than that of 
endogenous APP. For example, we observed that the APPsα/APPsβ ratio in CM was 6.6 ± 0.7 in 
HEK293 cells expressing just endogenous human APP but was a remarkable 78.4 ± 8.8 in  
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Figure 3.2: Only β1 Integrin shows a correlation between holoAPP and APPsα/holoAPP 
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Figure 3.2: Only β1 Integrin shows a correlation between holoAPP and APPsα/holoAPP 
(continued) 
For co-transfection of candidate ligands with APP751 (human, wild-type) with HEK293 
cells,the levels of percent change in APPsα/holoAPP was graphed as a function of holoAPP for 
each replicate. A regression correlation was performed, and p values represent statistical 
significanceof the slope deviating from 0. 
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HEK293 cells overexpressing human APP (Fig 3.3). This striking many-fold difference highlights 
the non-physiological nature of the procesing of overexpressed APP, and we therefore 
developed assays to investigate the effects of candidate ligands on proteolytic processing of 
endogenous APP, something that has not typically been reported for potential APP ligands. 
These experiments were initially performed in HEK293 cells using the same methods as in the 
above assay with the exception that no co-transfection of APP occurred. WBs of cellular lysates 
confirmed that the transfection of the candidate ligands did not alter endogenous holoAPP 
levels (Fig 3.4); therefore, endogenous APPsα and APPsβ levels in the CM were normalized to 
the more quantitative measure of total intracellular protein concentration in the lysate. Using 
this assay, we found that the expression of each candidate ligand resulted in a small but 
significant change in APPs level. APPsα and APPsβ levels were significantly reduced by the 
expression of F-spondin (APPsα: 11.7 ± 3.1%; p<0.001; APPsβ: 16.7 ± 4.3%; p<0.001), Reelin 
(APPsα: 18.0 ± 1.6%; p<0.001; APPsβ: 20.2 ± 2.0%; p<0.001), and Lingo-1 (APPsα: 13.1 ± 2.7%; 
p<0.001; APPsβ: 26.2 ± 2.8%; p<0.001) (Fig 3.1D-F).  Expression of β1 Integrin significantly 
increased APPsα by 20.4 ± 2.9% (p<0.001) but did not significantly change APPsβ levels (Fig 
3.1D). CNTN2 did not significantly affect APPsα or APPsβ levels.  Thus, while Reelin and Lingo-1 
strongly inhibited α- and β- secretase cleavage of overexpressed APP in HEK293 cells (Fig. 3.1A), 
cleavage of endogenous APP was more weakly – but still significantly -- inhibited by Reelin and 
Lingo-1 (Fig. 3.1D).  As a comparative control in this same assay, we repeated experiments on 
the proteins Pancortin-1 and Pancortin-3 that we recently described as APP ectodomain ligands 
(Rice et al, 2012). In agreement with our previous report, Pancortin-1 significantly reduced β-
secretase cleavage (47.9 ± 3.6%; p<0.001) without affecting α-secretase cleavage of  
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Figure 3.3 APPsα/APPsβ is dramatically higher and more variable with overexpressed 
relative to endogenous APP. 
The ratio of APPsα to APPsβ is shown for HEK293 cells with endogenous APP (human) or 
HEK293 cells transiently transfected with APP751 (human, wild-type). 
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endogenous APP, whereas the isoform Pancortin-3 had no significant effects on either α- or β- 
secretase cleavage. The effect of Pancortin-1 on APPsβ was more robust and less variable than 
any of the other candidate ligands we tested in this endogenous APP cleavage assay in 293 cells 
(Fig 3.1E-F). 
 Western blots (WB) from representative experiments are shown for the HEK293 cell 
assays in which APP was either overexpressed (Fig 3.4A) or endogenous (Fig 3.4B), 
demonstrating the expression levels of both holoAPP and the candidate ligands. Expression 
levels were similar among the various candidate ligands, with an estimate of 5-10 μg/mg of cell 
lysate or 5-10 mg/mL secreted into the CM for those tested by quantitative Western blot (Fig  
3.5).  In the initial experiments where APP was overexpressed, CTFs and APPsα could be readily 
detected by WB, and these paralleled the changes in APPs by ELISA (Fig 3.4A, see e.g., Reelin 
and Lingo-1). Levels of ADAM17 (an α-secretase for APP) and BACE-1 (β-site APP cleaving 
enzyme-1, or β-secretase) were not changed by the expression of the candidate ligands (Fig 
3.4B), suggesting that any effects on APP processing we observed were not due to changes in 
the levels of the secretases that cleave APP.  
 In both of these HEK293 cell assays (Fig. 3.1), we utilized DMEM media with 10% fetal 
bovine serum (FBS). Previous reports of these and other candidate APP ligands have used a 
variety of medium conditions, including medium with serum, serum-free (SF) medium, and SF 
medium supplemented with bovine serum albumin (BSA) as a carrier protein. This technical 
variability could help explain some of the different results obtained by different labs. We found 
that medium supplemented with either FBS or BSA enhanced the recovery and subsequent  
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Figure 3.4  Representative Western blots of APP shedding assays with HEK293 cells  
(A)  Western blot of lysates (and CM where noted) showing expression levels of holoAPP, APP 
CTF, candidate ligands,  and APPsα in a representative experiment with co-transfection of 
candidate ligands and APP751 into HEK293 cells. (B)  Western blot of lysates (and CM where 
noted) showing expression levels of holoAPP, secretases, and candidate ligands from a 
representative experiment with transfection of candidate ligands into HEK293 cells with 
endogenous APP.  
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Figure 3.5 Quantitative Western blot analysis of candidate ligand expression levels 
Relative levels of (A) F-spondin and (B) Pancortins expressed in the lysates and (C) Reelin 
secreted in the CM of HEK293 cells were determined by quantitative Western blot with 
recombinant proteins for each used as standards. 20 μg of cell lysates (A,B) or 10 uL of CM 
(C)were loaded for quantification. 
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detection of APPsα in the CM by over 3-fold (Fig 3.6A). Moreover, transfected cells conditioned 
in media with serum were healthier than those with only BSA. Therefore, we chose to condition 
our cells in DMEM+10% FBS for all of the studies reported above, as this allows the best health 
of the transfected cells and the best recovery of APPsα. Importantly, we showed that the effect 
of Reelin on endogenous APPsα levels was similar across these three media conditions (Fig 
3.6B). 
Figure 3.6 FBS and BSA increase the detection of APPsα 
(A) HEK293-APP695 stable cell lines were cultured in serum-free media (SF), media 
supplemented with 1%, 5%, or 10% fetal bovine serum (FBS) or 0.25,0 .5 or 1.0 mg/mL bovine 
serum albumin (BSA). (B) HEK293 cells with endogenous APP were transfected with Reelin 
and cultured in SF media, media with 10% FBS, or SF media supplemented with 1mg/mL BSA. 
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Effects of candidate APP ligands on APPsα levels in primary cortical neuronal cultures 
The most physiologically relevant culture system for analyzing putative ligands that 
regulate processing of APP in the central nervous system would assay the effects on 
endogenous APP in primary neurons with the ligands presented in trans. To this end, we 
developed both co-culture and conditioned medium (CM) assays in untransfected primary 
neuronal cultures (Fig. 3.7A). In both assays, E18 rat primary cortical neurons were utilized as 
the reporter cell. In our co-culture assay, stable HEK293 cells expressing the ligands of interest 
were co-cultured overlying the neurons for 18-24 hr (Fig. 3.7A). Alternatively, in our CM assay, 
neurons were treated with the CM of stably transfected HEK293 cells expressing the ligand of 
interest (Fig 3.7A). Endogenous APPsα produced from the neurons (but not from the human 
HEK293 cells) was detected by a rodent-specific APPsα ELISA. APPsα was  normalized to a 
neuron-specific marker (Tau) in the lysate of our co-culture assay (in order to normalize to only 
the neuronal reporter cells but not the HEK293 ligand source) or to total intracellular protein in 
our CM assay. As an important negative control, we observed no significant difference in APPsα 
levels secreted from neurons cultured alone compared to those co-cultured with control 
(untransfected) HEK293 cells at the optimized densities of both cell types employed here (Fig 
3.7B, first two bars). In both assays, an expected increase in neuronal APPsα could be detected 
in the CM upon treatment with PMA (phorbol-12-myristate-13-acetate) as a positive control 
(Fig 3.7B-C) (Buxbaum et al, 1998; Lammich et al, 1999). Further, human APPsα from the 
HEK293 cells represents a negligible percentage of the total APPsα detected in both the co-
culture and CM assays, confirming the specificity of our rodent-specific ELISA (Figs 3.7B-C).  
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Figure 3.7 Effects of candidate ligands on APPsα levels in primary cortical cultures  
(A) Schematic of methods used for co-culture and CM assays. (B-C) Positive controls (PMA 
treatment) and negative controls (neurons and HEK293 cells alone) for the co-culture (B) and 
CM (C) assays.  (D) ELISA quantification of APPsα (endogenous, rodent) secreted from cortical 
neurons co-cultured with HEK293 cells stably expressing ligand of interest. (E) ELISA 
quantification of APPsα (endogenous, rodent) secreted from cortical neurons treated with CM 
from HEK293 cells expressing ligand of interest. Error bars represent s.e.m.; * p<.05 
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Reelin and Lingo-1 (which showed the most consistent effects in reducing APPsα in the HEK293 
cell assays) significantly reduced neuronal APPsα in the co-culture assay (Fig 3.7D-E).  Reelin 
reduced APPsα by 14.3 ± 2.4% (p<0.001), and Lingo-1 reduced APPsα by 14.7 ± 3.6% (p<0.001). 
F-spondin, β1 Integrin, and CNTN2-Fc did not significantly modulate APPsα levels in the 
neuronal co-culture assay (Fig 3.7D). Only those proteins that are secreted could be tested in 
the CM assay. As in the co-culture assay, treatment of neurons with F-spondin and CNTN2-Fc 
CM had no effect on APPsα levels (Fig 3.7E). In contrast to the neuronal co-culture assay and 
the two HEK293 assays, Reelin CM had no effect on neuronal APPsα levels (Fig 3.7E). For 
comparison, we performed experiments with Pancortin-1 and Pancortin-3 in both of these 
assays. We had previously reported a decrease in endogenous APPsβ but not APPsα levels by 
expressing Pancortin-1 in HEK293 cells. Here, we were only able to perform a rodent-specific 
ELISA for APPsα, since rodent-specific antibodies for APPsβ are not available, and we confirmed 
that there was no significant effect of either Pancortin isoform on APPsα secretion in neurons 
(Fig 3.7D,E).  
Western blots from representative experiments are shown for both the co-culture (Fig 
3.8A) and CM (Fig 3.8B) assays in rodent cortical neuronal cultures, demonstrating the 
expression levels of the candidate ligands and endogenous rat APP. Expression of endogenous 
holoAPP in the neuronal lysates was not affected by the candidate ligands in either assay (Fig 
3.8A,B). Expression of Tau, which we used as a neuronal-specific protein for normalization, was 
relatively consistent across conditions (Fig 3.8A).   
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Figure 3.8  Representative Western blots of APP shedding assays with rat primary cortical 
cultures  
(A)  Western blot of lysates (and CM where noted) showing expression levels of holoAPP, Tau, 
and candidate ligands in a representative experiment with co-culture of neurons with HEK293 
cells expressing putative ligands. (B)  Western blot of lysates (and CM where noted) showing 
expression levels of holoAPP and candidate ligands from a representative experiment with 
neurons treated with CM from HEK293 cells expressing putative ligands.  
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Figure 3.9  Summary of candidate ligands tested in multiple APP shedding assays. 
(continued)  
The magnitude of statistically significant changes (p< .05) in APPsα or APPsβ are 
represented by arrows.  ↑ or ↓ < 25% change relative to control; ↑↑ or ↓↓ = 25-50% 
change; ↑↑↑ or ↓↓↓ > 50% change. An equals sign (=) represents no significance 
difference. Gray boxes represent conditions not determined. 
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Addressing discrepancies in the effects of Reelin and Lingo-1 on APP cleavage  
After testing these candidate ligands in assays on both overexpressed and endogenous 
APP and in both neuronal and non-neuronal cells, Reelin, Lingo-1 and Pancortin-1 emerged as 
the candidate APP ligands with the most consistent and quantitatively significant effects on the 
α- and/or β-secretase cleavages of APP (Fig. 3.9). However, the effects of Lingo-1 and Reelin in 
our assays were not identical to previous reports. We have already characterized in detail the 
interaction of the Pancortins with APP in a recent publication (Rice et al, 2012). Here, we 
attempt to reconcile experimentally the discrepancy between our data and previous reports for 
Reelin and Lingo-1.  
For Lingo-1 in our HEK293 assay with overexpressed APP, the variability in the 
magnitude of reduction of APPsα and APPsβ (normalized to holoAPP) across experiments 
appears to be due to the expression levels of Lingo-1. The degree of reduction in APPsα and 
APPsβ was directly and significantly correlated with protein levels of Lingo-1 (APPsα: R
2
 = .69, 
p<.001; APPsβ: R
2
 = .76, p<.001 ) (Fig. 3.10A-B). The reduction of APPsβ by Lingo-1 was in 
contrast to a previous study (Bai et al, 2008) in which Lingo-1 enhanced β-secretase cleavage of 
APP.  This discrepancy could be due to differences in the processing of wild-type APP, which we 
studied, and APP with the Swedish AD mutation that Bai et al (Bai et al, 2008) studied. 
Therefore, we tested the effects of Lingo-1 in HEK293 cells transfected with APP695 bearing the 
Swedish mutation (APPswe). Co-transfection of Lingo-1 with APPswe significantly reduced 
APPsα but, unlike with wild-type APP, had variable effects on APPsβ. Lingo-1 caused enhanced 
APPsβ in some experiments and reduced APPsβ levels in others and overall had no significant  
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Figure 3.10 Biochemical analysis of the interaction of Lingo-1 with APP.  
117
  
Figure 3.10 Biochemical analysis of the interaction of Lingo-1 with APP. (continued) 
 (A-B) For co-transfection of Lingo-1 and APP751 (human, wild-type) into HEK293 cells, the 
percent change in  APPsα/holoAPP (A) or APPsβ/holoAPP (B) was graphed as a function of  
Lingo-1 expression. A regression correlation was performed, and p values represent statistical 
significance of the slope deviating from 0. (C-E) HEK293 cells were transfected with APP695-
swedish (human) and either vector only (control) or Lingo-1 ( with both 1.0 μg and 0 .1 μg of 
DNA). (C) Western blot of lysates showing expression levels of holoAPP and Lingo-1. 
Quantification of APPsα (D) APPsβ (E) for each replicate of each experiment shown with 
scatterplots.   (F-G) HEK293were transfected with Lingo-1 or Lingo-1 plus APP751 (human, wild-
type) and treated for 24 hrs with DAPT or DMSO (as control). (F) Western blot of lysates 
showing expression levels of holoAPP, APP CTF, Lingo-1 (apparent full-length and CTF). (G) 
Quantification of  Lingo-1 CTF/full-length Lingo-1 with and without expression of APP. **p<.01, 
***p<.001 
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effect on APPsβ (Fig 3.10C-D).  However, we noticed that co-transfection of the standard 1 μg 
of Lingo-1 cDNA with APPswe cDNA reduced APPswe expression. Therefore, we tested 0.1 μg of 
Lingo-1 cDNA in which APPswe expression was less affected, but Lingo-1 still had variable 
effects on APPsα and APPsβ, with no overall significant effect on either (Fig 3.10C, E).  In our 
studies of Lingo-1, we also uncovered evidence of the γ-secretase-dependent intramembrane 
cleavage of Lingo-1. Upon transfection of Lingo-1 into HEK293 cells, we detected a ~10 kDa 
fragment of Lingo-1 with a C-terminal Lingo-1 antibody, and the cellular levels of this CTF were 
enhanced 2-fold when the cells were treated with a γ-secretase inhibitor (DAPT) (Fig 3.10F-G). 
These data strongly suggest that Lingo-1 is processed by γ-secretase via the regulated 
intramembranous proteolysis mechanism, something which was not previously known. 
Overexpression of APP did not alter the production of the Lingo-1 CTF (Fig 3.10F-G).  
Reelin was previously reported to enhance APPsα and CTF and reduce Aβ levels (Hoe et 
al, 2009; Hoe et al, 2006), whereas we found a reduction of APPsα and APPsβ levels by Reelin. 
First, we examined CTF and Aβ levels. Upon co-transfection of APP with Reelin in HEK293 cells, 
APP CTFs and Aβ40 and Aβ42 could be readily detected. Expression of Reelin not only 
decreased APPsα and APPsβ as documented above, but it also substantially reduced levels of 
the APP CTF, Aβ40, and Aβ42 (Figs. 3.4 and 3.11A). Next, we investigated whether the 
reduction in APPsα and APPsβ by Reelin expression was dose-dependent, or if differences in 
expression levels of Reelin might explain the conflicting results. Increasing concentrations of 
Reelin cDNA were transfected, leading to rising expression of Reelin secreted into the CM (Fig 
3.11B) accompanied by a dose-dependent decrease in both APPsα and APPsβ (Fig 3.11C), 
consistent with our earlier Reelin results (Fig. 3.1A and B). Finally, the effect of Reelin on APPsα  
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Figure 3.11  Biochemical analysis of the interaction of Reelin with APP.  
(A) Quantification of Aβ40, and Aβ42 (by ELISA) and CTF (by WB) in HEK293 assay with over-
expression of APP751 (human, wild-type). (B) Reelin expression in CM of HEK293 cells co-
transfected with APP751 (human, wild-type) and increased concentrations of Reelin cDNA. (C) 
Quantification of APPsα and APPsβ levels in response to increasing Reelin expression.  (D) 
HEK293 cells were transfected with listed combinations of Reelin, APP, APOER2, and VLDLR, 
and co-IPs were performed for Reelin or else APP, APOER2, or VLDLR. Error bars represent 
s.e.m.; * p<.05, **p<.01, ***p<.001 
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was investigated according to the methods in which Reelin was previously reported to enhance 
APPsα levels (Hoe et al, 2009; Hoe et al, 2006). Here, Reelin CM was applied to COS7 cells 
transfected with APP751. In contrast to this prior study, we found no effect of Reelin when 
utilizing this method (Fig 3.12).  
Biochemical analysis of the interaction of Reelin with APP 
Next, we sought to confirm whether Reelin and APP could physically interact. Reelin and 
APP were co-transfected into HEK293 cells, and lysates were immunoprecipitated (IP) for either 
Reelin or APP. Indeed, Reelin co-IPed with APP, and in the reverse direction, APP co-IPed with 
Reelin (Fig. 3.11D, right panel). As a negative control, IP with the APP antibody (C9) failed to co-
IP Reelin in the absence of APP overexpression.  IP with the Reelin antibody (G10) did IP 
detectable levels of APP in the absence of Reelin overexpression; however, overexpressing 
Reelin greatly enhanced the co-IP of APP with Reelin above this background endogenous level 
(Fig 3.11D). Importantly, we found that the co-IP of Reelin and APP was quantitatively 
comparable to the co-IP of Reelin with its canonical receptors, APOER2 and VLDLR (D'Arcangelo 
et al, 1999; Hiesberger et al, 1999; Trommsdorff et al, 1999) (Fig 3.11D).  
Reelin undergoes proteolytic cleavages in primary neurons at both its C-terminal and N-
terminal ends to generate five fragments (Fig 3.13A) (Jossin et al, 2007; Jossin et al, 2004; 
Lambert de Rouvroit et al, 1999). To determine which physiological fragments of Reelin may be 
sufficient for the inhibition of α-secretase cleavage of APP, HEK293 cells were co-transfected 
with APP751 and cDNAs for full-length Reelin or else each of the 5 known Reelin fragments. 
Reelin antibodies with epitopes towards the different regions of Reelin (G10, R4B, E5) (Fig 
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3.13A) were used to detect all of the Reelin fragments by Western blot (Fig 3.13B). Each 
fragment of Reelin significantly reduced α-secretase cleavage of APP compared to control (Fig 
3.13C). However, expression of the fragments containing the N-terminal region of Reelin (N-R6 
and N-R2) resulted in the greatest reduction in APPsα, and this lowering was not significantly 
different than that seen from full-length Reelin (Fig 3.13C). Conversely, expression of Reelin 
fragments containing the C-terminal region but lacking the N-terminal region (R3-8 and R7-8) 
led to relatively higher levels of APPsα, compared to the effect of full-length Reelin (Fig 3.13C). 
These differential effects due not appear to be due to differential expression levels. When the 
levels of each transfected Reelin fragment detected with single antibodies were compared to 
full-length Reelin, their expression levels were relatively similar to one another, with only R7-8 
having higher expression levels but still less effect on APP shedding (Fig 3.13B). Thus, while each 
physiological proteolytic fragment of Reelin can inhibit α-secretase cleavage of APP to some 
extent, the N-terminal region of Reelin is the most active.  
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Figure 3.12  Effect of Reelin CM treatment on COS7 cells overexpressing APP751 
COS7 cells transfected with APP were treated with CM from either control or Reelin stable cell 
lines, and APPsα levels were quantified by ELISA.  
123
  
Figure 3.13 Effects of Reelin fragments on APPsα in HEK293 cells. 
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Figure 3.13 Effects of Reelin fragments on APPsα in HEK293 cells. (continued) 
(A) Schematic of Reelin fragments generated from proteolytic processing. Reelin repeat 
domains are numbered in blue. Red arrows represent cleavage sites. Black arrowheads 
represent antibody epitopes. (B) Western blots of cell lysates showing expression of Reelin 
fragments transfected into HEK293 cells. (C) ELISA quantification of APPsα levels in HEK293 
cells co-transfected with APP751 (human, wild-type) and either full-length Reelin or individual 
Reelin fragments. Error bars represent s.e.m.; ***p<.001, relative to full-length Reelin (FL) 
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Discussion   
Novel and systematic approaches to analyze the effects of candidate ligands on APP 
processing 
Several extracellular and membrane-bound proteins have been proposed as candidate 
ligands that may modulate proteolytic processing of the ubiquitously expressed APP 
polypeptide. However, these candidates have not been validated by multiple laboratories and 
have often been examined solely with overexpressed APP and with one or two assay systems. 
In an effort to clarify a role for one or more of the reported ligands in regulating the processing 
of APP, we systematically and rigorously investigated the ability of these candidates to 
modulate α- and β- secretase cleavage of APP. In contrast to virtually all prior studies, we used 
multiplex ELISA-based assays to obtain quantitative measures of both APPsα and APPsβ, as 
opposed to solely relying on Western blotting.  Further, many of the previous studies show data 
from a single “representative” experiment. We chose to show our data by scatter-plot analysis 
of all experiments, and we found that for most putative ligands, a single experiment could not 
adequately represent the complete data set of the range of effects on APP cleavage and would 
thus be misleading. Instead, we report a comprehensive quantification of data points across all 
experiments to capture the inherent biological variability of the effects of each ligand, as well as 
the technical variability for different assay types. Furthermore, the quantification of secreted 
APPsα/β we used provides a direct measure of the α- and β-secretase cleavages, as opposed to 
measuring only CTFα/β, the levels of which can be further complicated by the degree of γ-
secretase activity.  
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Another important aspect to consider when performing assays to accurately measure 
APPsα/β generation in the CM is the appropriate normalization. Changes in cellular holoAPP 
levels can change APPsα and APPsβ levels independent of any effects of a ligand on α- and β-
secretase cleavage per se. Because co-transfection of APP concurrent with the candidate 
ligands could lead to differences in APP levels due to technical rather than biological reasons, 
we normalized data in which APP is overexpressed to holoAPP levels in the lysates of the same 
cultures.  However, because normalizing to holoAPP, which as an end-point measurement in 
lysates may not fully correct for variations in the levels of APPs that accumulate in the media, 
we also checked for correlations between the holoAPP cellular level and the APPsα/holoAPP 
ratio (Fig 3.2). For assays measuring cleavage of endogenous APP, we observed no detectable 
differences in holoAPP in the lysates by Western blot and therefore normalized to the more 
quantitative measure of total intracellular protein concentration in the lysate. For the co-
cultures of neurons with HEK293 cells, we normalized to a neuron-specific marker (Tau) in the 
lysate, in order to normalize only to the neuronal reporter cells but not the HEK293 ligand 
source.  
As a result of attention to these various technical factors and controls, a side-by-side 
comparison of candidate ligands across multiple assays is presented here for the first time. We 
initially used an assay similar to the original reports for each of these ligands, i.e., with non-
neuronal immortalized mammalian cells overexpressing APP, to enable direct comparisons to 
those previous reports. We found that co-transfection of APP with certain candidate ligands can 
lead to the most dramatic effects on APPsα/β levels, perhaps due to a wider dynamic range 
inherent to the overexpression assay or to artifacts from supraphysiological levels of APP or 
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non-biologically relevant changes in APP levels. For example, we found evidence that despite 
normalization to holoAPP, the effects of β1 Integrin in the overexpression assay were due to 
variations in APP expression levels (Fig 3.2). Furthermore, we found that APPsα/APPsβ ratios 
were more than 10-fold higher with overexpressed APP (~75) than with endogenous APP (~6), 
suggesting a fundamental alteration in the processing of overexpressed APP (Fig 3.3). A likely 
explanation is that β-secreatse (BACE1) is not highly expressed endogenously in these non-
neuronal cells, and overexpressing APP leads to much greater processing in the α-secretase 
pathway. For these reasons and because the goal is to determine the in vivo neurobiological 
relevance of these ligands, it is critical to confirm any findings from APP-overexpressing systems 
in endogenous and, preferably, neuronal systems. In this context, we proceeded to develop 
novel assays to compare the candidate ligands in non-neuronal and neuronal cell lines relying 
on endogenous APP. In particular, we believe the co-culture assay using primary rat cortical 
neurons has advantages over other systems: 1) APP is endogenously expressed by the neuronal 
reporters; 2) necessary but unknown co-receptors/co-ligands also should be endogenously 
expressed in the neuronal reporters; 3) ligands are continuously produced by the co-cultured 
HEK cells (rather than requiring artificial pulse administration); 4) ligands that require 
expression on the plasma membrane for activity will be expressed in their natural state; and 5) 
effects on APP processing that could be relevant to AD are best studied in neurons. 
F-spondin 
While F-spondin was the first reported candidate APP ligand with perhaps the most 
evidence across laboratories for effects on APP cleavage (Hafez et al, 2012; Ho & Sudhof, 2004; 
128
  
Hoe et al, 2005), we observed little evidence of these effects in our assays. We found no 
significant changes in APPsα or APPsβ levels in HEK293 cells co-transfected with APP and F-
spondin (Fig 3.1A) or in primary neurons co-cultured with F-spondin stable cells lines (Fig 3.7D) 
or treated with F-spondin-containing CM (Fig 3.7F). However, we did observe a subtle decrease 
of endogenous APPsα and APPsβ in plain HEK293 cells transfected with F-Spondin (Fig 3.1D). A 
potential underlying difference between our results and previous results is that in order to 
maintain a less artificial system, we did not overexpress BACE1 (as in (Ho & Sudhof, 2004)) or 
APOER2 (as in (Hoe et al, 2005)). Perhaps the most direct contrast between our studies and 
previous studies was in the treatment of primary neurons with F-Spondin-containing CM. 
Previously, F-spondin CM was reported to enhance CTFα levels in primary neurons (Hoe et al, 
2005), but we failed to observe an effect on APPsα with a similar assay.   
Integrin β1 
Expression of Integrin β1 was previously reported in one study to enhance APPsα and 
APP CTF (Hoe et al, 2009). Here, we found only minor evidence for a subtle overall 
enhancement of APPsα and APPsβ in HEK293 cells. However, this effect was not confirmed in 
primary neurons.  Further, in contrast to the relative consistency of the rest of the candidate 
ligands, transfection of Integrin β1 in HEK293 cells overexpressing APP resulted in very high 
variability in APPs secretion.  The effects ranged from very dramatic increases in APPsα and 
APPsβ to only subtle or no changes in APPsα/β levels or even reductions in APPsα/β levels in 
some experiments (Fig 3.1B-C). We found that this variability in APPsα was significantly 
correlated with the expression of holoAPP upon co-transfection of APP751 with β1 Integrin, 
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even after normalization to holoAPP levels (Fig 3.2). The changes in holoAPP levels do not 
appear to represent a biologically relevant effect of β1 Integrin on APP expression, as β1 
Integrin did not change expression of endogenous APP. Thus, changes in APPsα upon co-
transfection of β1 Integrin with APP appear to be an artifact due to differences in APP co-
transfection efficiency. 
Contactin-2 
CNTN2 has been reported to modulate APP processing by increasing AICD, CTFα and 
CTFβ levels in both over expressed and endogenous assays (Ma et al, 2008). However, our data 
did not confirm these findings. We found no effects of a soluble (Fc-tagged) form of CNTN2 on 
APPsα or APPsβ both in our endogenous and overexpressed assays.  
Lingo-1 
Knockdown of Lingo-1 has been reported to enhance CTFα and reduce CTFβ levels, 
while overexpression of Lingo-1 was reported to enhance CTFβ levels in HEK293 cells 
overexpressing the APPswe mutation (Bai et al, 2008). As predicted from Bai et al. (Bai et al, 
2008), we found that Lingo-1 reduced APPsα levels in each of our assays (Figs 3.1 & 3.7), 
including primary neuronal cultures (Fig 3.7). However, instead of an enhancement in β-
secretase cleavage of APP by Lingo-1 (Bai et al, 2008), we found that Lingo-1 reduced β-
secretase cleavage. The discrepancy between these effects on β-secretase cleavage of APP may 
be due to differences in the processing of wild-type APP and APPswe. The Swedish mutation of 
APP markedly enhances β-secretase cleavage of APP (Citron et al, 1992) and modifies the 
principal subcellular loci for β-secretase cleavage (Haass et al, 1995). β-secretase cleavage of 
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wild-type APP occurs in large part upon internalization and endosomal recycling of cell-surface 
APP, whereas the Swedish mutation causes APP to be cleaved in considerable part by β-
secretase within the secretory pathway (Haass et al, 1995). In contrast to our results with wild-
type APP, we found that Lingo-1 produced quite variable effects on β-secretase cleavage of 
APPswe (Fig 3.10E). Lingo-1 enhanced APPsβ-swe in some experiments (similar to (Bai et al, 
2008)) but reduced APPsβ-swe in other experiments (similar to our data with wild-type APP, Fig 
3.1C).  Thus, the separate mechanisms of β-secretase cleavage of the two APP variants could 
explain the apparent differences in Lingo-1 effects on β-secretase cleavage of APP in these 
studies. 
Reelin 
The effects of Reelin on APP shedding was confirmed across our multiple assays, 
including with endogenous APP in neurons. However, in contrast to previous studies in which 
Reelin increased α-secretase cleavage of APP (Hoe et al, 2009; Hoe et al, 2006), we observed 
that Reelin decreased α-secretase cleavage of APP (Figs. 3.1 & 3.7). We also found that Reelin 
reduced β-secretase cleavage of APP (Fig 3.1), which corroborates a previous study in which a 
reduction of Reelin enhanced Aβ and CTFβ levels in APP transgenic mouse brain (Kocherhans et 
al, 2010). We solidified this evidence by showing that the effect of Reelin on APPsα is dose-
dependent and that Reelin also decreases CTF, Aβ40, and Aβ42. Moreover, we confirmed 
reports of a physical interaction between Reelin and APP and showed a similar level of Reelin-
APP co-IP as is seen with its canonical receptors, ApoER2 and VLDLR.  
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In an attempt to reconcile the opposing effects of Reelin on APPsα, we replicated as 
closely as we could the methods described previously that resulted in an increase in APPsα 
(Hoe et al, 2009; Hoe et al, 2006). However, using this method we found no significant effect of 
Reelin on APPsα levels (Fig 3.12). These conflicting effects on APPsα do not appear to be due to 
differences in the concentrations of Reelin, as a range of Reelin concentrations resulted in a 
decrease of APPsα in our hands (Fig 3.11C). Because Reelin is cleaved to generate several 
fragments, it is possible that different cell types secrete alternate Reelin products. However, we 
found that expression of cDNAs encoding each physiological Reelin fragment reduced APPsα to 
some extent in our assay (Fig 3.13).  
Pancortins 
Pancortin-1 produced the most robust and consistent effects on cleavage of 
endogenous APP of any of the candidate ligands tested (Fig 3.1D-F). Pancortin-1 also was the 
only candidate ligand which specifically reduced β-secretase processing while having no effects 
on α-secretase processing of APP. With Pancortins being expressed not only in embryonic but 
also adult cortex (Danielson et al, 1994; Nagano et al, 2000), regulation of β-secretase cleavage 
by Pancortin-1 could turn out to have important implications for the pathogenesis or treatment 
of Alzheimer’s disease. Recently, Pancortin was shown to interact with members of the Lingo-1 
signaling pathway and regulate axonal growth (Nakaya et al, 2012). As Pancortin and Lingo-1 
were top APP ligands in our assays, future studies to determine how the Pancortin and Lingo-1 
signaling pathways may intersect to regulate APP processing will be important.  
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A classic ligand for APP? 
Since its cloning 25 years ago, APP has been intensively studied as regards its processing 
via regulated intramembrane proteolysis and the role of its Aß fragment in AD pathogenesis, 
but studies of its physiological function and processing have received less attention and led to 
an array of complex, sometimes conflicting findings. For example, analogous to the sizeable 
number of proteins purported to be candidate ligands for APP, a number of genes had been 
reported to be transcriptionally activated by the APP intracellular domain (AICD)  (Baek et al, 
2002; Kim et al, 2003; Pardossi-Piquard et al, 2005; von Rotz et al, 2004). Like the candidate APP 
ligands, potential target genes had usually been reported by single labs, and attempts to 
confirm them had been largely unsuccessful (Hass & Yankner, 2005; Hebert et al, 2006). One 
particularly clarifying study in this field published by De Strooper and colleagues systematically 
compared these target genes in the same assay system and found that each was at best 
indirectly and weakly influenced by APP processing or not at all (Hebert et al, 2006). A central 
goal of our study was to provide similar clarity for most of the reported candidate ligands of 
APP.  
Our study raises the central question of whether a classic ligand for APP that positively 
triggers processing by α- or β- secretase exists. While we did find effects of Reelin, Lingo-1 and 
Pancortin-1 on APP processing to be consistent across the multiple assays we used, the effects 
of Reelin and Lingo-1 were subtle in endogenous systems and not identical to previous reports 
(Bai et al, 2008; Hoe et al, 2009; Hoe et al, 2006).  Further, each ligand we tested turned out to 
inhibit cleavage rather than stimulate α- or β-secretase processing. Whereas a larger portion of 
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APP processing appears to be constitutive than regulated, in contrast to the ligand-regulated 
cleavage of Notch (Mumm et al, 2000; Schroeter et al, 1998), the ability of PMA to robustly 
stimulate α-secretase cleavage of APP (Fig 2 B-C and (Buxbaum et al, 1998; Hung et al, 1993; 
Lammich et al, 1999)) suggests that there is a cellular capacity for α-secretease cleavage of APP 
to be enhanced. On the other hand, it is possible that cognate ligand(s) for APP regulate 
neuronal functions of APP without significantly modulating its proteolytic processing. It is also 
possible that instead of a single protein ligand, several proteins and non-protein factors may 
have coordinated effects to regulate APP cleavage. Thus, each ectodomain-binding ligand may 
individually result in only subtle effects, particularly in the more biologically relevant context of 
endogenous, wild-type APP in neurons that we explored. Furthermore, it may be that apparent 
ligand effects are more indirect through competition of common binding partners (Hoe & 
Rebeck, 2008; Hoe et al, 2006; Hoe et al, 2005). The cellular context of APP may affect ligand 
binding and cleavage of APP, for example homo- or hetero- dimerization of APP (Libeu et al, 
2012) or the subcellullar localization and trafficking of APP (Ehehalt et al, 2003; Haass et al, 
1995a).   Such further research is needed to better define the basic functions of this conserved 
and ubiquitously expressed protein and to better understand the consequences of chronically 
altering its proteolytic processing in older humans with AD-type cognitive syndromes. 
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Introduction 
Since its initial cloning over 25 years ago, APP has been predicted to be a cell-surface 
receptor with a cognate ligand. However, much of the current evidence implicating a receptor-
ligand interaction in the regulation of APP function and processing has been weak (i.e. 
comparison to Notch), controversial (i.e. AICD as a transcriptional regulator), or not widely 
validated (i.e. APP ligands). A number of secreted or cell-surface proteins have been reported to 
physically interact with the APP ectodomain and modulate its shedding, yet there remains to be 
a validated ligand for APP.  Nearly all initial reports of such candidate ligands utilize primarily 
APP overexpression systems, report data as a representative Western blot lacking precise 
quantification and controls, and have not been followed up by multiple groups.  Since there is 
currently not a well-established ligand for APP, I undertook both an unbiased approach in an 
attempt to identify novel potential ligands (Chapter 2) and a candidate-based approach in an 
attempt to confirm one or more of the previously reported ligands (Chapter 3). 
In the unbiased approach to reveal novel ligands (Chapter 2), Pancortin was identified 
by a mass spectrometry-based screen for factors that bind to the APP ectodomain in rodent 
brain. Each of the Pancortin isoforms was confirmed to interact with APP. However, only 
specific Pancortin isoforms reduced β-secretase but not α-secretase cleavage of endogenous 
APP. Using in utero electroporation to overexpress or knockdown Pancortin isoforms in rodent 
cortex, a previously unidentified role for Pancortin in cortical cell migration with evidence for a 
functional interaction with APP was discovered.  
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In the candidate based approach to confirm one or more published APP ligands (Chapter 
3), I developed new assays to compare each of these candidates side-by-side in biologically 
relevant culture systems. A comprehensive quantification by ELISA of APPsα and APPsβ, the 
immediate products of secretase processing, in both non-neuronal cell lines and primary 
neuronal cultures expressing endogenous APP, yielded no evidence that any of these published 
candidate ligands stimulate ectodomain shedding.  Rather, Reelin, Lingo-1 and Pancortin 
emerged as the most consistent ligands for significantly inhibiting ectodomain shedding.  
These findings prompt several key questions including 1) What are the precise 
mechanisms responsible for these effects of Reelin, Lingo-1, and Pancortin on APP processing 
and function?  2) Would  any of the candidates found to inhibit shedding in my assays be viable 
drug targets to treat AD?  3) Is there a ‘classic’ ligand for APP?   Here, I will discuss possible 
predictions based on my initial studies (reported in Chapters 2 and 3) as well as recent 
preliminary studies that are aimed at addressing these questions (reported in Appendix 2-5). 
Since these questions remain largely unanswered by current studies, I will also discuss several 
sets of experiments that could help shed further insight into these issues.  
Potential mechanisms of the APP/Pancortin interaction in cortical cell migration 
 Previously, knockdown of APP in subset of neuronal precursor cells by in utero 
electroporation resulted in an arrest of electroporated cells immediately below the cortical 
plate (Young-Pearse et al, 2007). Both the ectodomain and intracellular domain of APP were 
required to be expressed as a holoprotein in order to mediate proper neuronal precursor cell 
migration(Young-Pearse et al, 2007), and the cytoplasmic factors disabled 1 (DAB1) and 
disrupted in schizophrenia 1 (DISC1) biochemically and functionally interact with APP in this 
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function (Young-Pearse et al, 2010; Young-Pearse et al, 2007). On the basis of these findings, we 
hypothesize that specific extracellular factors bind the ectodomain of holoAPP on the cell 
surface and transmit a signal to intracellular signaling cascades during development. Data 
presented in Chapter 2 suggest Pancortin may be such an extracellular factor that regulates 
APP-dependent cell entry into the cortical plate. Our in utero electroporation studies in Chapter 
2 reveal a previously unidentified role of Pancortin in the migration of neuronal precursor cells 
into the cortical plate, with specific Pancortin isoforms having opposing roles. The AMY isoform 
inhibits cortical plate entry and BMZ promotes cortical plate entry, and rescue experiments 
suggest that BMZ can compete with AMY and act atleast in part through APP-dependent 
mechanisms (Fig 4.1A).  
Model of APP-dependent Pancortin mechanisms  
Similar to knockdown of APP, knockdown of the BMZ isoform of Pancortin resulted in a 
failure of cells to enter the cortical plate (Fig 4.1B). Interestingly, overexpression of APP does 
not rescue the loss of BMZ (Fig 4.1C), indicating that the migration-promoting effect of APP is 
dependent upon expression of BMZ. Overexpression of AMY (similar to loss of BMZ) blocked 
cortical plate entry (Fig 4.1D). Thus,  AMY and BMZ have opposing roles. Previously, BMZ has 
been shown to negatively regulate AMY in neurogenesis in lower vertebrates (Moreno & 
Bronner-Fraser, 2005), and our data supports a similar type of regulation in cortical plate entry. 
Overexpression of BMZ rescued the defect of AMY overexpression (Fig 4.1E). In HEK293 cells, 
BMZ can reduce the physical interaction between APP and AMY, suggesting a mechanism 
whereby BMZ can negatively regulate AMY through competition with AMY for binding to APP 
(Fig 4.1E).  Further supporting this hypothesis, APP overexpression can rescue the migration  
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  Figure 4.1: Model of mechanisms responsible for migration phenotypes  
Schematic diagrams illustrating predicted molecular mechanisms leading to migration 
phenotypes of in utero electroporation experiments with APP and Pancortin. OE = 
overexpression, KD = knockdown 
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defect of AMY overexpression (Fig 4.1F), but blockade of the interaction through deletion of the 
AMY/BMZ binding site within APP prevents rescue (Fig 4.1G). I propose that with APP 
overexpression there is more APP remaining that is not being inhibited by the overexpressed 
AMY, and overexpression of APP with deletion of the BMZ binding site fails to rescue since BMZ 
is required for the migration promoting effects of the additional APP (Fig 4.1G). Taken together, 
these data support a model in which Pancortin is an important extracellular regulatory factor 
for the migration-promoting function of APP at the cell surface. The BMZ isoform of Pancortin is 
required for the migration-promoting effects of APP.  BMZ also negatively regulates the AMY 
isoform of Pancortin, which would otherwise inhibit the migration-promoting effects of APP. 
Thus, the timing and localization of AMY and BMZ expression may provide an important 
mechanism for regulating APP-dependent cell migration in the cortex.   
Model of APP-independent Pancortin mechanisms 
Pancortin may also signal in part independently of APP. Overexpression of BMZ rescues 
the defect of APP knockdown indicating that BMZ functions in the absence of APP perhaps 
through other cell-surface proteins (Fig 4.1 H,I). Thus, it would be of interest to investigate the 
interaction of Pancortin with APLPs, as they are known to compensate for loss of APP. 
Interestingly, a recent study showed that knockdown of APLP2 by in utero electroporation 
produces a cell migration phenotype, which the author’s attributed to an effect of APLP2 on 
neuronal differentiation and thus timing of migration(Shariati et al, 2013). Opposing roles for 
BMZ and AMY in neuronal differentiation have been well described in Xenopus (Moreno & 
Bronner-Fraser, 2005) and would match the opposing effects on cortical migration. Thus, future 
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experiments should be aimed at determining if effects on neuronal differentiation contribute to 
the cell migration phenotype of Pancortin isoforms and also explore the biochemical 
interactions of Pancortin isoforms with the APLPs and downstream effects on APLP proteolysis 
and cortical phenotypes.  
Cell non-autonomous effects of Pancortins? 
 My model proposed here requires  cell non-autonomous effects of Pancortin. While this 
has not been directly addressed, the immunostaining patterns of overexpressed Pancortin 
isoforms is diffuse and is not localized to just the cells expressing them, thus providing the 
potential for cell non-autonomous effects. To test this directly, in utero electroporations of 
embryonic rat cortices could be performed in succession, first to overexpress Pancortin 
isoforms and then to expression GFP with or without APP shRNA on a subsequent day to target 
two separate sets of cells. The cell non-autonomous effects of the Pancortins on the GFP 
electroporated cells could then be assayed.  
Relationship between APP processing and function? 
 BMZ inhibits β-secretase cleavage of APP, however, whether this activity is 
mechanistically involved in regulating migration has yet to be determined. In fact, whether 
regulated cleavage is mechanistically involved in APP function in general is not well-established. 
Previous studies have used rescue of APP knock-down by different APP fragments to explore 
this question. For example, neither APP CTF nor APPsα can rescue the migration phenotype of 
APP knockdown, suggesting a requirement for full-length APP (Young-Pearse et al, 2007). 
However, this does not fully exclude the involvement of regulated APP cleavage, rather than 
artificial APPsα overexpression, in APP function. A more elegant experiment would be to 
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generate a non-cleavable APP construct to use for rescue of APP knockdown. This strategy has 
been utilized in at least one study in Drosophila (Luo et al, 1992)  and would give much insight 
into the relationship between APP processing and function in the mammalian brain.  
Potential mechanisms for the effects of candidate ligands on APP processing 
Coupling of α- and β- secretase cleavage? 
None of the candidate ligands examined stimulated α-secretase cleavage of APP in my 
assays, as might be predicted of a ‘classic’ ligand for APP. Instead, Reelin and Lingo-1 reduce 
both α- and β- secretase cleavage of APP and the BMZ and BMY isoforms of Pancortin reduce β-
secretase cleavage of APP while sparing α-secretase cleavage. It had long been assumed that α- 
and β- cleavage are inversely coupled, and thus it is unexpected that reducing either α- or β- 
cleavage would not result in an enhancement of the other. However, a recent study using more 
physiological assays demonstrated that the activities of α- and β- secretases are uncoupled in 
mammalian cell lines similar to the HEK293 cells utilized for my studies (Colombo et al, 2012). 
Thus, this study may help to explain the reduction of both α- and β- secretase cleavage of APP 
by Reelin and Lingo-1 in my studies. 
Direct binding? 
A ‘classic’ ligand for APP would be predicted to bind directly to the APP ectodomain in 
trans to facilitate effects on APP processing. The confirmation of Lingo-1 and Reelin in the 
neuronal co-culture assay (designed to test this specifically) is evidence that these candidates 
do act on APP in trans. The biochemical interactions of Reelin, Lingo-1 and Pancortin with APP 
in cell culture and intact brain, suggest a physical interaction of these candidates with APP. 
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However, a direct interaction cannot be assumed by these co-IP studies alone. Performing 
classic in vitro ligand-receptor binding assays will be important to confirm the impact of ligand 
binding on APP shedding in future studies. For example, the technique of surface plasmon 
resonance could be use to compare relative binding constants for each of the candidates, and 
would be a valuable analysis to perform in the future. 
Indirect interactions through common binding partners? 
Rather than through direct binding, it may be that apparent ligand effects are more 
indirect, perhaps competition of common cell-surface binding partners. For example, APP has 
been shown to interact with a number of factors within the  canonical  Reelin signaling 
pathway, including its canonical receptors APOER2 and VLDLR as well as the adapter protein, 
Dab1 (Hoe & Rebeck, 2008; Hoe et al, 2006; Hoe et al, 2005). We have intriguing preliminary 
data that APP signaling intersects with the Reelin pathway at multiple levels. Transfections of 
APOER2 and VLDLR in HEK293 cells each increased APPsα secretion but had no effect on APPsβ, 
suggesting a specific effect on α- but not β- secretase cleavage of APP. Coexpressing Reelin 
cancelled the effects of the over-expressed APOER2 and VLDLR on APPsα but did not reduce 
APPsβ (Appendix  3 ). These data encourages further analyses of the involvement of Reelin and 
its canonical receptors on APP shedding. In addition to a DAB1-APP functional interaction, 
APOER2 and VLDLR expression seems necessary for the effects of APP loss in migration: our 
recent in utero electroporation experiments suggest that APP shRNA is less active if APOER2 
and/or VLDLR are knocked down (unpublished result).  Further experiments are clearly 
warranted to see whether and how APP and the Reelin signaling pathways intersect.  
Involvement of HSPGs? 
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Heparan sulfate proteoglycans (HSPGs) often provide sites of interaction between 
ligands and their receptors, thereby serving as co-receptors in protein-mediated cell signaling 
(reviewed in (Lindahl, 2007)). Both APP and several of the candidate ligands we have assessed 
(e.g., F-spondin, Reelin) have heparin-binding domains (Small et al; Tan et al, 2008). Thus, the 
reported ability of the APP ectodomain to bind certain glycosaminoglycans and proteoglycans 
(Clarris et al, 1997; Mok et al, 1997; Narindrasorasak et al, 1991) may contribute to a 
multifactorial ligand regulation of APP secretory processing, and this should now be explored in 
the context of the ligands that most consistently affect the shedding of APP.  
 In preliminary studies, I have taken advantage of cell lines that have specific genetic 
deficiencies of proteoglycan formation. The CHO-745 line is defective in xylosyltransferase 
activity, the first sugar transfer in glycosaminoglycan (GAG) synthesis, and is thus deficient in 
GAG formation, including both heparan sulfate and chondroitin sulfate (Esko et al, 1985). The 
CHO-677 line lacks both the N-acetylglucosaminyl-transferase and glucuronyltransferase 
activities required for synthesis of heparan sulfate and thus are deficient in heparan sulfate but 
not chondroitin sulfate formation (Lidholt et al).  
First, to determine if HSPGs are required for effects of Reelin on reducing APPsα levels, 
Reelin was transfected into control and HSPG deficient cell lines (Appendix 4). However, Reelin 
reduced APPsα whether in the presence or absence of HSPGs suggesting HSPGs are not 
required for the interactions of Reelin with APP.  Next these mutant cell lines were used to 
determine if HSPGs more broadly regulate APP ectodomain shedding (Appendix 4). In initial 
experiments, HSPG deficient cell lines had reduced APPsα and CTF levels compared to wild-type 
cells. However, when additional wild-type cell lines were assayed, I noticed there were 
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significant differences between the multiple wild-type cell lines and no significant differences of 
the HSPG deficient cell lines when compared to some of the wild-type lines. Thus, effects 
potentially attributable to clonal variability were a concern. To determine the specificity of the 
apparent effects on APPsα generation, Exostosin-1 (the mutated gene in CHO-677 cells) was 
transfected into CHO-677 cell lines. However, Ext-1 failed to rescue the effect on APPsα levels 
in this experiment, despite confirmed expression of Ext-1 and partial rescue of HSPGs by 
Western blot. Thus far, these experiments are inconclusive for the effects that HSPGs may 
confer on APP processing in general but suggests HSPGs are not required for effects of Reelin. 
As an alternative or supplementary approach to using these GAG-deficient CHO-based cells, 
enzymatic heparinase treatment (which enzymatically digests heparan sulfate) antibody HS 
neutralization, or transfection of Extosin-1 shRNA in neurons could be used to compliment 
studies in mutant CHO cells.  
Common signaling pathways for Lingo-1 and Pancortin? 
Recently, a study reported that Pancortin competes with Lingo-1 for binding to Nogo A 
receptor (NgR1), and that Pancortin regulates the function of the NgR1 in growth cone 
collapse(Nakaya et al, 2012). Given that Lingo-1 and Pancortin emerged as top APP ligands in 
my assays, future studies to determine how the Pancortin and Lingo-1 signaling pathways may 
intersect to regulate APP processing will be important.  Current studies are underway to 
determine if NgR1 is necessary for the effects of Lingo-1 or Pancortin on APP processing.  Since 
APP also functions in neurite outgrowth, it will be of interest to determine potential functional 
interactions of Lingo-1, Pancortin, and APP at the growth cone.  
Ligand regulation of a large multi-secretase complex? 
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In collaboration with Christina Muratore , Tracy Young-Pearse and others, I  studied APP 
ectodomain shedding in neurons derived from induced pluripotent stem cells of control 
individuals and those carrying a familial ‘London’ AD  mutation in APP  (Appendix 1). The 
‘London’ V717I mutation resides within the transmembrane domain of APP near the γ-
secretase cleavage site and leads to increased Aβ42/40 ratio, which was confirmed in these 
neurons. Unexpectedly, I found that this mutation near the γ-secretase cleavage site of APP led 
to increased β-secretase cleavage, which was abolished by inhibiting γ-secretase. I also 
confirmed these effects in HEK293 cells with overexpression of either wild-type APP or APP 
with the London mutation.  These findings represent a novel phenotype of the London 
mutation and suggest that β-secretase and γ-secretase activities are functionally linked. This 
data supports other recent findings in the Selkoe lab in which Allen Chen et al (unpublished) 
propose a model of a large multi-protease complexes containing both α- and γ-secretases  or β- 
and γ- secretases that sequentially cleave APP. Upon identification of a cognate ligand for APP, 
studies should be directed at understanding how ligand binding might facilitate formation of 
these large complexes, trigger cleavage once complexes have formed, or direct APP towards 
one complex or the other.  
Towards more physiological systems and drug targets 
 A major goal of my studies in Chapter 3 was to develop new assays that were more 
physiolgoical than previous studies to test the effects of candidate ligands. Indeed, I developed 
assay which utilized endogenous APP rather than overexpressed  APP and examined neuronal 
cultures with the ligand presented in trans. However, one technical limitation of the neuronal 
co-culture assay was the unavailability of an APPsβ rodent-specific ELISA that was able to 
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reliably measure endogenous APPsβ from these neuronal cultures. Because Pancortin only 
affected APPsβ, but not APPsα, it was not possible to confirm these effects in the neuronal 
assays. In addition, while APP was endogenous, our assays utilized overexpression of the 
candidate ligands. To address these limitations, I have now begun to establish new assays to 
study ectodomain shedding by putative ligands in neuronal precursor cells and more mature 
neurons derived from human induced pluripotent stem cells. In these human neurons, I am 
able to measure both APPsα and APPsβ reliably.  Candidate ligands are currently being studied 
by AMAXA nucleofection and co-culture with Chinese Hamster Ovary (CHO) using cell culture 
separation chambers. Our next studies are aimed at knocking-down the endogenous expression 
of these candidates, rather than artificial overexpression. A large scale Nanostring analysis of 
mRNA levels revealed that many of our genes are interest are expressed highly in these cells, 
particularly the Pancortin isoforms. Next, we will be using a large shRNA library to conduct a 
higher throughput 96-well plate based screen of our top candidate ligands as well as other 
interesting factors potentially involved in mediating these effects (i.e. APOER2, VLDLR, Dab1, 
Extosin-1, and NgR1, as discussed above). Thus, the goal is to not only confirm previous results 
in cultured human neurons (or understand any differences from previous findings) but also 
further investigate the mechanisms and other molecular players involved in mediating these 
effects.   
Ultimately, a cognate ligand for APP should be confirmed in vivo. With this goal, I have 
begun preliminary experiments with Reelin knockout (Reeler) mice to investigate the in vivo 
effects of Reelin on APP processing. In initial preliminary experiments, I measured endogenous 
APPsα from cultures neurons of either wild-type, heterozygous, or homozygous knockout 
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embryos. However, the APPsα levels from cultured cells were too variable between embryos of 
even wild-type mice to be able to determine the effect the loss of Reelin expression might have 
in this system, particularly for small effects (Appendix 5 ). The next step will be to measure 
APPsα, Aβ, and full-length APP from brain homogenates of these mice. Another feasible 
approach is to dynamically measure Aβ in behaving wild-type and Reeler mice using the 
technique of in vivo brain microdialysis.  
Lastly, the ultimate goal of these studies would be to develop drug targets based upon a 
putative APP ligand that under normal physiological conditions is a robust regulator of the 
initial cleavage event in APP processing. Of the candidates I studied, Pancortin appears to be 
the most promising in this regards. Pancortin specifically reduced β-secretase but not α-
secretase cleavage and effects were much stronger than any of the other candidates. The first 
step would be to examine the effect of Pancortin on Aβ production and pathology in AD mouse 
models. Pancortin could be introduced to mouse brain by injection, transplantation of 
Pancortin expressing cells, or lentiviral transduction. Acute effects of Pancortin on Aβ 
production could be measured by in vivo brain microdialysis while more chronic effects could 
be determined by immunohistochemistry of brain slices.  
Conclusions: A classic ligand for APP? 
My studies raise the central question of whether a classic ligand that triggers α- 
secretase cleavage of APP exists. While I did find effects of Reelin, Lingo-1 and Pancortin on APP 
processing to be consistent across the multiple assays I used, the effects of Reelin and Lingo-1 
were subtle in endogenous systems and not identical to previous reports (Bai et al, 2008; Hoe 
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et al, 2009; Hoe et al, 2006).  Further, each ligand tested turned out to inhibit cleavage rather 
than stimulate α- or β-secretase processing. Thus, while Reelin, Lingo-1, and Pancortin may 
have important implications for APP processing and function, I do not find solid evidence that a 
‘classic’ ligand for APP has been identified by the field. While the candidates I chose to study in 
my assays were prioritized based on those with the strongest data reported by the most 
groups, there remain other published candidates to be validated. In addition, future studies 
should continue to focus on identifying novel candidate ligands with much more emphasis on 
confirming direct interactions using in vitro binding assays and confirming effects on APP 
processing and function in more physiological systems with more careful quantification and 
controls. These studies and those outlined throughout Chapter 4 are needed to better define 
the mechanisms regulating the processing and the basic functions of this conserved and 
ubiquitously expressed protein and to better understand the consequences of chronically 
altering its proteolytic processing in older humans with AD-type cognitive syndromes. 
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Abstract
In vitro study of primary neuronal cultures allows for quantitative analyses of neurite outgrowth. In order to study how genetic alterations affect
neuronal process outgrowth, shRNA or cDNA constructs can be introduced into primary neurons via chemical transfection or viral transduction.
However, with primary cortical cells, a heterogeneous pool of cell types (glutamatergic neurons from different layers, inhibitory neurons, glial cells)
are transfected using these methods. The use of in utero electroporation to introduce DNA constructs in the embryonic rodent cortex allows for
certain subsets of cells to be targeted: while electroporation of early embryonic cortex targets deep layers of the cortex, electroporation at late
embryonic timepoints targets more superficial layers. Further, differential placement of electrodes across the heads of individual embryos results
in the targeting of dorsal-medial versus ventral-lateral regions of the cortex. Following electroporation, transfected cells can be dissected out,
dissociated, and plated in vitro for quantitative analysis of neurite outgrowth. Here, we provide a step-by-step method to quantitatively measure
neuronal process outgrowth in subsets of cortical cells.
The basic protocol for in utero electroporation has been described in detail in two other JoVE articles from the Kriegstein lab 1, 2. We will provide
an overview of our protocol for in utero electroporation, focusing on the most important details, followed by a description of our protocol that
applies in utero electroporation to the study of gene function in neuronal process outgrowth.
Video Link
The video component of this article can be found at http://www.jove.com/details.php?id=2103
Protocol
The basic protocol for in utero electroporation has been described in detail in another JoVE article from the Kriegstein lab 1, 2. This technique was
originally described in the Osumi lab 3 and our protocol is based upon one developed in the LoTurco lab 4. We will provide an overview of the our
protocol for in utero electroporation of rat embryos, focusing on the most important details, followed by a description of our protocol that applies in
utero electroporation to the study of gene function in neuronal process outgrowth.
1. In utero Electroporation
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1. Preparing DNA and loading needles
The first step for in utero electroporations is to design your experiment to determine what DNA constructs you want to inject. This method is
useful for both misexpressing or knocking down genes of interest. If you are planning on misexpressing or overexpressing a gene, be sure to
use a promoter that is active in neuronal precursor cells. We recommend the CAGGS promoter, which consists of the chicken beta-actin
promoter and the CMV enhancer 5. Since only a small subset of cells are transfected using in utero electroporation, it is critical to include a
plasmid encoding a fluorescent protein such as GFP so that you can follow those cells that were successfully electroporated. For the plasmid
encoding GFP, we recommend preparing the DNA at a concentration of 0.5 μg per microliter. For shRNA constructs, we have found that
0.5-1.0 μG per μL results in efficient knock down of your gene of interest. For overexpression or misexpression, we use between 1.0 and 3.0
μG per microliter, depending upon the size of the gene and the level of expression that the experiment calls for. DNAs are prepared using a
Qiagen endotoxin-free prep kit, and diluted in 1 x PBS. We inject approximately 0.5-1.0 μL per embryonic brain, so, for a litter of animals we
prepare 10 μL of DNA mixture for injection. We add 1 μL of Fast Green to the DNA so that we can follow the injected DNA.
Pulling needles to the correct shape is a critical step. Walantus et al. uses a different system for delivering the DNA and so their needle prep
is also slighly different then ours1,2. The settings that you use to pull your needles will depend upon the brand of needle puller that you have.
We use Model 750 from David Kopf. The settings we use are : Heat 1: 9.0, Heat 2: 0, Soleniod: 0, Filament size 3.0 mm, Heater Proximity: 3
mm, Time: 10 sec. Once pulled, we cut our needles with a razor blade at a ~45 degree angle such that the distance from the largest part of
the opening to the tip is 11 mm. We then load the DNA from the back end of the needle. We then fill the remaining space in the needle with
corn oil. For DNA injection, we use a Picospritzer III. Depending upon the exact bevel that is cut for each needle, we set the Picospritzer from
4.0 to 6.0. We use a foot pedal to deliver the pressurized air that expels the DNA from the needle.
2. Preparing animals for surgery
We use pathogen-free Sprague Dawley rats exclusively for these surgeries. Several other labs use mice of varying genotypes as well. Here,
we describe show our protocol for electroporation of E15 rat embryos, but in utero electroporation is routinely performed in rats between the
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2. Culturing Electroporated Cortical Neurons
3. Analyzing Neuronal Process Outgrowth
4. Representative Results
We have found that Sprague Dawley litter size ranges between 6 and 14 embryos. We usually electroporate all of the embryos. Each embryo can
be electroporated with a different combination of DNAs. However, we usually electroporate at least four brains with the same condition and pool
these brains before dissociating and plating.
We have found that with this technique approximately 75% of electroporated brains are targeted to the desired region of the cortex, whether that
be dorsal medial or ventral lateral cortex (Figure 1). In addition, we have found early electroporations at E13-14 target deep layer neurons such
as Tbr1 positive layer VI neurons, while later electroporations target CTIP2 positive, TBR1 negative layer V cells, and still later electroporations
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ages of E13 and E18. While early stage electroporation targets deep layers of the cortex, later stage electroporations target more superficial
layers.
Animals are given a pre-operative dose of buprenorphine (0.05-0.1 mg/kg) before the surgery starts. There are multiple options for
anesthetizing the animal. Walantus et al. utilizes isofuorane inhalation, while we routinely use intraperitoneal injection of ketamine (40-80
mg/kg) and xylazine (5-10 mg/kg)1,2. A toe pinch should always be performed to ensure that animals are fully anesthetized and unresponsive.
Animals are kept on a heated pad throughout the surgical procedure.
The animal's fur is shaved in the region of incision, and washed three times with ethanol followed by three times with iodine. An incision is
made in the skin just lateral to the midline, followed by an incision in the muscle. The uterine horns are exposed very carefully. They are
gently teased out of the body cavity using your fingertips. Keep embryos hydrated with sterile PBS while they are outside of the body cavity.
3. Injecting DNA and electroporation
When you first start performing these surgeries, the hardest part is becoming familiar with where you need to inject the DNA so that you fill
the lateral ventricles, and getting used to how deep you inject your needle in order to hit the correct region. Embryos are gently manipulated
with your fingertips so that you can identify where the head is, and if you look closely you will be able to see the midline suture. This serves as
a general landmark that you can use to determine where the lateral ventricle is located. We inject the DNA through the uterine wall and into
the lateral ventricle. We use a footpedal to control the injection of the DNA - multiple pulses of DNA are performed until the lateral ventricle is
filled with the DNA/dye mixture. We then place paddle electrodes on either side of the head of the embryo and use another footpedal to
deliver the pulse across the head of the embryo. The placement of the electrodes is critical in determining which region of the cortex is
electroporated. Since DNA is negatively charged, the DNA will travel toward the positive electrode when a charge is dispelled across the
paddles. Depending on the exact placement of the electrodes, different subsets of cells will be targeted. We routinely place the positive
electrode near the dorsal-medial positions across the cerebrum. However, the LoTurco lab beautifully showed that if you place the electrodes
in more ventral lateral regions of the cerebrum you can target the cells of the cortical-striatal boundary and hit cells of the lateral cortical
stream 6. Each embryo can be electroporated, and different combinations of DNA constructs can be used in each embryo.
4. Suturing and post-operative care
Following electroporation of all embryos, the uterine horns are carefully returned to the body cavity, and both the muscle layer and the skin
are sutured. The technique for this is outlined in Walantus et al1,2. Animals are monitored continuously until they recover from anesthesia, and
the analgesic buprenorphine (0.05-0.1 mg/kg) is administered every 8-12 hours.
1. Harvesting electroporated brains and dissecting electroporated region
For in vivo analyses following in utero electroporation, animals can be harvested at any time point from 24 hours following electroporation to
early after birth to adulthood. However, when culturing primary neurons we harvest 24 hours following electroporation at E16. At this time, the
electroporated embryos are expressing detectable levels of GFP.
Animals are euthanized using carbon dioxide inhalation and rapid decapitation. Embryos are dissected out of the uterus and placed in HBSS
with divalent cations, keeping track of which embryos were electroporated with which DNA plasmids. It is critical to use filtered HBSS, sterile
tubes and plates, and autoclaved tools for dissection. The cortices are dissected out and the meninges removed using a microscope in a
hood. These cortices are then observed under a dissecting microscope with the capacity to visualize GFP. GFP positive regions of the cortex
are identified, and we ue a pair of vanna scissors to cut out the GFP positive regions from the cortex. These pieces are placed in HBSS
without divalent cations in a 15 ml conical tube.
2. Dissociating and plating neurons
Once all GFP positive regions are dissected, HBSS is replaced with 0.25% trypsin, and incubated at 37 degrees for 5 minutes. Trypsin is
removed, replaced with plating media (DMEM + 5% FBS + Penn/strep + glutamine), and triturated 5-7 times to dissociate the cells. Volumes
used depend upon the amount of tissue present. Dissociated cells are then plated on CC2 coated chamber slides. For two chamber slides,
we plate 200,000-350,000 cells per chamber in a volume of 1.5 mL of plating media. After 4 hours, plating media is aspirated and replaced
with 1.5 mL Neuronal culture media (Neurobasal media + B27 supplement + glutamax + gentamycin) per chamber.
1. Fixing and immunostaining cultures
In order to measure short term effecs of genetic manipulation of these cells, we harvest the primary neurons after three days in vitro. If
primary neurons are to be cultured longer for additional analyses, half of the media should be replaced every three days. For fixing cultures,
we aspirate the media from the chambers, and fix the neurons in 4% paraformaldhyde for 15 minutes. Following fixation, cells are washed
two times in PBS and then put in blocking solution (2% donkey serum with 0.1% Triton X-100 in PBS) for one hour. Cells are then incubated
in primary antibody for 1 hour. For analyses of neuronal process outgrowth, we use anti-beta tubululin antibody to identify neurons - beta II
tubulin immunostaining labels the neruonal cell body, dendrites and axons. Cells are then washed three times in PBS for five minutes, and
then incubated in Cy3-anti mouse for 1 hour, followed by three more PBS washes, counterstaining nuclei with DAPI and mounting.
2. Measuring neurite length
Images of GFP positive, beta-III tubulin positive neurons are acquired on a Zeiss Axioskop with a MC100 camera system. Several variables
can be examined in these GFP positive cells including length of all neurites, length of the longest neurite, branching of neurites, size of cell
soma, etc. We have used this method to analyze neuronal process outgrowth upon knock down or overexpression of genes relating to
neurodevelopment and neurodegeneration, with a focus on neuronal process length. In order to measure neuronal processes outgrowth, we
use Axiovision LE 4.4 software (from Zeiss). Within this software, there is an option to select the "outline" tool. Using this tool, you can use
your computer's mouse to trace the length of each neuronal process. It is critical to define the objective that you are using in order to get an
accurate measure of your neurites. For these analyses, we usually use a 20x objective.
159
target Brn2 positive layer II/III cells. An excellent description of different markers and explanation of neuronal subtype specification in the cortex in
found an article by Moleneaux et al 7. Figure 2 shows coronal sections of brains electroporated at either embryonic day 15.5 or 17.5 and
harvested at postnatal day 5. Shown in red is immunostaining for Oct6. You can immunostain for markers in culture to confirm what cell layer
populations you have targeted. We have found that you can expect to target the same cell layer population of cells in every embryo of the same
litter (in other words, the targeting depends upon the embryonic timepoint rather then on other technical variations).
In culture, the percent of cells that are GFP positive can range widely depending on how conservative you are when dissecting out the GFP
positive region (Figure 3). However, even when we are very conservative and dissect out only the GFP positive patch of cells, the highest
percentage that we observe is 5-10% - although you are dissecting the region of the cortex that was electroporated, cells in only one layer will be
targeted. This low transfection effciency is helpful in identifying which processes belong to the electoporated cell that you are analyzing. Plating
cells at this higher density contributes to having heathier cultures, however, it is difficult to discern which process belongs to which cell body in the
GFP negative cells (Figure 3).
If you have trouble seeing all of the fine processes of the electroporated cells, you can either increase the concentration of GFP DNA that you are
electroporating to increase expression of GFP, or you can immunostain the dissociated cells using an anti-GFP antibody (from Invitrogen) along
with a Cy2 secondary antibody.
Figure 1. E15.5 Sprague-Dawley rats were electroporated with GFP plasmid and harvested three days later. Based upon the placement of the
electrodes, different regions of the cortex will be targeted. A-F show GFP fluorescence in whole brains.
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Discussion
Figure 2. E15.5 (A) or E17.5 (B) Sprague-Dawley rats were electroporated with GFP plasmid and harvest at postnatal day 5. Brains were fixed,
sectioned coronally using a vibratome (100 micron sections), and immunostained for Oct6 (red). A and B show confocal images of
immunostained sections.
Figure 3. E15.5 Sprague-Dawley rats were electroporated with GFP plasmid. 24 hours following electroporation, brains were harvested and
GFP-positive, electroporated regions were dissected and dissociated, as described in the video. After 3 days in vitro, cells were fixed and
immunostained for bIII-tubulin (red) and staining nuclei with DAPI (blue) (A,C). The length of the longest neurite was measured using Axiovision
software (B,D).
In vitro study of primary neuronal cultures allow for quantitative analyses of neurite outgrowth. In order to study how genetic alterations affect
neuronal process outgrowth, shRNA or misexpression constructs can be introduced into primary neurons via chemical transfection or viral
transduction. However, with primary cortical cells, a heterogeneous pool of cell types (glutamatergic neurons from different layers, inhibitory
neurons, glial cells) are transfected using these methods. The use of in utero electroporation to introduce DNA constructs in the embryonic rodent
cortex allows for certain subsets of cells to be targeted: while electroporation of early embryonic cortex targets deep layers of the cortex,
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electroporation at late embryonic timepoints targets more superficial layers. Further, differential placement of electrodes across the heads of
individual embryos results in the targeting of dorsal-medial versus ventral-lateral regions of the cortex.
Targetting of specific layers:
When you inject DNA into the lateral ventricle and electroporate, only the cells immediately lining the lateral venrtricle are targeted: these cells are
the radial glial progenitor cells of the neocortex, as well as cells that have just undergone their terminal mitosis. Interestingly, when examined in
the days following electroporation, the cells targeted match the pattern of birthdated cells. In other words, cells that are born , that is to say those
that undergo their terminal mitosis on the day of electropoartion, are the cells that are targeted. Since radial glial cells also are present at the
ventricular surface, one might hypothesize that these cells would be targeted, and that all of the progeny from these cells would also be targeted.
However, this is not the case, later generations of cells do not express GFP. It may be that multiple rounds of division in the radial glial cells
dilutes out the plasmid.
Applications:
This method is an excellent way to examine the effects of gene knock down via electroporation of shRNA contructs, as well as by misexpression
of cDNA constructs. We are applying this techniqe to the study of genes involved in neurodegeneration and psychiatric disease. Through this
technique, we introduce both wild type and mutant forms of genes critical in these diseases, and examine the effects on neuronal morphology. In
addition, we can examine the effects of mutation or alternative splice variant expression in the absence of the endogenous gene product by
co-electroporating the cDNA and the shRNA contruct. Co-electorporation also can be utilized to look at genetic interactions between two gene
products: by knocking down multiple genes and by attempting to rescue effects of knock down of one gene product with other gene products 8, 9.
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Abstract 
 
Alzheimer’s disease (AD) is a complex neurodegenerative disorder characterized by 
extracellular plaques containing amyloid β-protein (Aβ) and intracellular tangles containing 
hyperphosphorylated Tau protein. Distinct brain regions are differentially susceptible to 
neurodegeneration in AD, with the cortex and hippocampus being primarily affected and the 
cerebellum and spinal cord being relatively spared. While familial AD (fAD) comprises <1% of 
cases, analyses of these patients have advanced understanding of molecular mechanisms and 
therapeutic approaches for all AD cases. Here, we describe the first generation of inducible 
pluripotent stem cells (iPSCs) from humans harboring the London fAD APP mutation (V717I), 
and examine AD-relevant phenotypes following directed differentiation of these cells to rostral 
forebrain neuronal fates vulnerable in AD, as well as more caudal fates, which are relatively 
spared in AD. In all fates examined, the APP V717I mutation led to elevated production of Aβ42 
and Aβ38. Unexpectedly, this mutation, which lies near the γ-secretase cleavage site in the 
transmembrane domain of APP, also led to increased β-secretase cleavage of APP. This 
increase was abolished by inhibiting γ-secretase, suggesting that the two protease activities are 
functionally linked. Interestingly, directing cells to different neuronal fates resulted in altered 
cleavage patterns of APP. From both control and fAD lines, Aβ generated from neurons directed 
to forebrain cortical fates showed a higher Aβ42 to Aβ40 ratio relative to neurons directed to 
more caudal fates of the hindbrain and spinal cord. Moreover, consistent with fate-specific 
biochemical effects on Aβ, the APP V717I mutation led to increased Tau expression in forebrain 
cultures but not in more caudally directed neurons. These studies identify previously 
unappreciated effects of an fAD APP mutation in human neurons and demonstrate that human 
iPSC technology provides a powerful system for analyzing the effects of both genetic alterations 
and cell types on processes directly relevant to human brain diseases.  
 
 
Introduction 
Alzheimer’s disease (AD) is a common and devastating dementia that is pathologically defined 
by the accumulation of extracellular Aβ-containing amyloid plaques and intraneuronal 
hyperphosphorylated Tau protein aggregates associated with neuronal loss in the cerebral 
cortex. Over 200 known missense mutations in APP or the Presenilin-1 and -2 genes 
(PSEN1/2) can cause dominantly inherited, early-onset forms of AD, termed familial AD (fAD) 
(reviewed in 1). The catalytic site of γ-secretase activity resides within PSEN2, and APP is 
cleaved within its transmembrane domain by the PSEN/γ-secretase complex to generate Aβ 
species primarily of 42, 40, or 38 amino acid lengths3. The fAD mutations in APP or PSEN have 
been shown to either increase Aβ production generally or to increase the ratio of Aβ42 to Aβ40 
peptides (reviewed in1,4). These genotype-to-phenotype relationships provide strong evidence 
that Aβ42 plays a causal role in at least some cases of AD.  
APP V717I was the first mutation linked to fAD5 and is the most common fAD APP mutation6. 
Residue 717 resides in the transmembrane domain of APP, near the γ-secretase cleavage site. 
Previous studies have shown that transfection of APP cDNA with the V717I mutation results in 
an increase in the ratio of Aβ42/40 generated in cell lines7 and mouse primary neurons8. Brain 
lysates from transgenic mice expressing human APP V717I also showed an increased Aβ42/40 
ratio9,10. In most studies, the increased ratio of Aβ42/40 is mainly attributable to an increase in 
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Aβ42 with no effect or a slight decrease of Aβ40. Importantly, both plasma and lysates of brains 
of patients carrying APP V717I have shown elevated Aβ42 levels relative to total Aβ, confirming 
the effect of this mutation on Aβ42 levels in the subjects of interest11,12.  
 
Rapid advancements in stem cell biology in recent years have provided neuroscientists with a 
unique opportunity to examine the effects of genetic alterations in disease-relevant human cell 
types. Previously, analyses of risk genes for neurological diseases were primarily limited to 
research on postmortem brains, mouse models, and heterologous cell lines. With the advent of 
induced pluripotent stem cell (iPSC) technology13–17 it is now possible to study genetic risk 
factors in neurons derived from primary cells of affected subjects18. Two recent studies showed 
that neurons derived from iPSCs generated from subjects with APP duplication or triplication 
(including from a Down’s syndrome line) secreted higher levels of Aβ and developed increased 
levels of Tau phosphorylated at Thr23119,20. In another study, iPSC lines were derived from two 
fAD subjects, one harboring a mutation in PSEN1 and another in PSEN213. This study showed 
that each mutation increased secretion of Aβ42 and that γ-secretase inhibitors and modulators 
effectively decreased Aβ generation13. Additionally, another study using direct conversion of 
PSEN1 and PSEN2 fibroblasts into neurons showed an increase in total Aβ as well as an 
increase in the Aβ42 to 40 ratio, with γ-secretase inhibitors decreasing production of Aβ21. 
These first studies utilizing iPSCs to study AD provided an important proof-of-principle regarding 
the utility of such cells to model biochemical processes relevant to AD.  
 
Here, we establish an independent cell model of AD using iPSCs from subjects harboring a 
dominant point mutation in APP (V717I) that causes fAD. Further, we take advantage of the 
unique property of stem cells to generate multiple neuronal types in order to address, for the 
first time, key questions regarding how developmental cell state and cell fate affects cleavage of 
APP by the α-, β-, and γ-secretases to generate APPsα, APPsβ and Aβ. In neurons of forebrain 
fate derived from human iPSCs, we confirm the previous finding that the V717I mutation leads 
to increased Aβ42 levels, and identify additional effects of this mutation on Aβ38 and APPs-β 
generation. In addition, we show that APP cleavage is altered in neurons directed to a rostral, 
cortical fate relative to neurons directed to more caudal neuronal fates of the hindbrain and 
spinal cord. APP V717I neurons express higher levels of Tau protein relative to wild type 
neurons when directed to rostral neuronal fates, but not when directed to a caudal neuronal 
fate. Interestingly, cortical and hippocampal cells are the most affected neuronal fates in 
Alzheimer’s disease, and the data presented here may provide insights into the mechanisms of 
the differential susceptibility observed in the disease.  
 
Results 
Generation and differentiation of iPS cell lines with the London (V717I) APP mutation 
 Skin biopsies were obtained from a father and daughter each harboring a mutation in APP 
(V717I) (Fig.1A). The father was 57 years old and was diagnosed with Alzheimer’s disease 
while the daughter remained asymptomatic at age 33 (Fig.1A). Fibroblasts from the biopsy were 
reprogrammed using lentiviruses encoding Oct4, SOX2, cMYC and KLF4, and three iPSC 
clones from each subject were established and characterized by the Harvard Stem Cell Institute 
(HSCI) iPSC core facility (Supp. Fig. S1). All clones maintained stem cell morphology, 
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expressed the pluripotency-associated genes OCT4, NANOG, SSEA3, SSEA4, TRA-1-60, and 
Alkaline Phosphatase, repressed retroviral transgenes, and could be differentiated into cells of 
ectodermal, mesodermal, and endodermal lineages in vitro (Supp. Fig. S1A, B, C). All clones 
from the daughter (fAD2) displayed a normal euploid karyotype (Supp. Fig. S1D), while all 
clones from the father (fAD1) displayed a normal chromosome number, but a balanced 
(t(1;12)(q42.1;q15)) translocation in all cells from four clonal lines (Supp. Fig. S1E). The 
fibroblasts obtained from this subject displayed the same abnormal karyotype, suggesting that 
this was a preexisting abnormality that did not arise during the reprogramming process. 
 Because variability exists in the differentiation efficiency among pluripotent stem cell lines, 
we first compared the capacity of each line to differentiate to neuronal fates. In order to direct 
the differentiation of these cells to forebrain neuronal fates, we utilized an embryoid body-based 
protocol22 (with modifications described in Methods). Using this method, cultures highly enriched 
in cells expressing neuronal markers were generated, with over 90% of the cells expressing 
MAP2 in each well (Fig. 1C). Initial characterizations of each clone for differentiation capacity 
informed the selection of two clones from each subject to be further analyzed. In parallel, 
differentiation experiments were performed with iPSC lines generated from healthy donors, 
which were obtained from the HSCI iPSC Core and from the UCONN Stem Cell Core (Fig. 1A). 
No significant differences were observed in differentiation capacity between the control and fAD 
cell lines, as assayed by immunostaining for the general neuronal markers MAP2, Tau and 
TUJ1, synaptic markers synapsin, PSD95 and VGLUT1, and markers of upper (Cux1) and lower 
(Tbr1) layer cortical neurons (Fig. 1C). To provide a more quantitative analysis of differentiation 
capacity over multiple clones and rounds of differentiation, NanoString analyses were performed 
with a custom designed probe set measuring 150 genes. Quantitative comparison of control and 
fAD lines showed no significant differences in expression of general neuronal markers (Fig. 1D) 
or markers of cell fate (Fig. 1E).   
 
Cleavage of APP by α-, β- and γ-secretases in fAD and control stem cell-derived neurons 
 Multiple studies in non-neuronal cell lines and transgenic mice overexpressing the APP 
V717I mutation report that this mutation alters γ-secretase cleavage of APP to generate higher 
levels of Aβ421,3,5,7,8,11,12,23 . Here, we aimed to examine the effects of this mutation expressed 
from the endogenous APP gene in human neuronal cells. Human iPSC lines were differentiated 
to neuronal phenotypes using the protocol described above. At 40-50 days of differentiation, 
conditioned media were collected 48 hours after application for analysis of secreted APP 
cleavage products, and cells remaining in the well were lysed to collect RNA for expression 
analyses. NanoString analyses showed no significant differences in RNA expression between 
control and fAD lines for APP splice variants and APP family members (APLP1 and APLP2) 
(Supp. Fig. S2A). Furthermore, no significant changes were observed in expression of genes 
encoding α-secretases, β-secretases, or components of γ-secretase (Supp. Fig. S2B). However, 
Western blot analyses suggested that APP and Tau protein levels were higher in lysates of fAD 
APP V717I neurons relative to wild type neurons (Supp. Fig. S2C, D). 
 Conditioned media from days 40-50 of differentiation from control and APP V717I lines 
were analyzed to examine Aβ38, 40 and 42 levels using a multiplex ELISA. In agreement with 
data from previous studies using other experimental paradigms, neurons derived from each 
clonal line harboring this APP fAD mutation secreted Aβ with a higher ratio of 42 to 40 than 
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neurons from control lines (control 0.25 SD+/-0.05; fAD 0.39 +/- 0.10; Fig. 2B). Notably, the 
ratios observed here appear to be physiologically relevant, as published results examining Aβ in 
TBS-extracted human brain lysates showed a highly similar range of Aβ 42/40 ratio (0.25-
0.42)24. Furthermore, the increase in ratio with the V717I mutation (1.6-fold) is highly similar to 
the previously reported ratio increase observed in the plasma of human subjects with the same 
mutation (1.7-fold)12. Here, data from each Aβ species show that this ratio change was primarily 
due to a 2-fold increase in production of Aβ42 (Fig. 2C-D, F-G, Supp. Fig. S3A-B). Interestingly, 
human neurons harboring the APP V717I mutation also secreted higher levels of Aβ38 (Fig. 
2E,H, Supp. Fig. S3C). Accordingly, the calculated Aβ38 to 40 ratio was also significantly higher 
with the fAD mutation (data not shown). Thus, the precise site of γ-secretase cleavage is altered 
with V717I mutation in neuronal cells. Of note, the intra- and inter-clonal variability in Aβ 
secretion was quite low between wells and between experiments in both fAD and control cell 
lines (Fig. 2A). The variability observed was due in part to slight technical differences between 
rounds of differentiation, with differences between ELISA plates also contributing to the modest 
variability observed (Supp. Fig. 3D,E).  
 Prior to cleavage by γ-secretase, APP must first be cleaved by α- or β-secretase to 
release the large N-terminal fragment of APP, termed APPsα or APPsβ25 (Fig. 1B). Cleavage by 
β-secretase prior to γ-secretase generates Aβ, while α-cleavage precludes Aβ generation. 
Because of the importance of these initial cleavage events in determining Aβ generation, we 
next examined whether the V717I APP fAD mutation affects α- and/or β-secretase cleavage of 
APP in a neuronal context. Surprisingly, fAD neurons secreted a lower ratio of APPsα to 
APPsβ relative to control neurons (Fig. 3A), and this decrease was due to a 1.4-fold increase in 
the production of APPsβ (Fig. 3B,C). This effect was not due to increased expression of β-
secretase, as both NanoString and Western blot analyses showed no differences in RNA or 
protein levels of the genes encoding β-secretase activity (BACE 1 and 2) (Supp. Fig. S2A-C). In 
order to test whether γ-secretase activity is necessary for the enhancement of β-secretase 
cleavage of APP by V717I, differentiated neuronal cells from control and fAD mutant lines were 
treated with a low dose (5 µM) of a potent γ-secretase inhibitor (DAPT) for 48 hours. As 
expected, this treatment efficiently inhibited the production of Aβ38, 40, and 42 in both control 
and fAD neurons (Fig. 2F-H). Interestingly, inhibition of γ-secretase potently blocked the effect of 
V717I in increasing β-secretase cleavage of APP (Fig. 3E,F). Further, γ-secretase inhibition 
increased APPsα generation relative to APPsβ generation in control neurons (Fig. 3D-F). The 
effect on this ratio was dramatically greater in neurons harboring the APP V717I mutation. 
Taken together, these results suggest that β- and γ-secretase cleavages of APP are tightly 
linked processes, and that a single point mutation of APP near the γ-secretase cleavage site 
may alter both cleavage events. Of note, the effects of the APP V717I mutation, including 
increased β-secretase cleavage of APP and elevated Aβ38 and 42 generation, were confirmed 
in HEK cells following transient transfection with cDNAs encoding wild type or V717I human 
APP (Supp. Fig. S4).  
 
  
Changes in APP processing across differentiation from stem cell to neuron 
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 We next addressed whether the effects observed on APP cleavage varied as a function of 
cell fate. RNA and conditioned media were collected from control and fAD iPSCs at multiple 
time points during differentiation from stem cell to neuron, in order to assess whether and how 
progressive differentiation alters the secretion of APPsα, APPsβ and Aβ. As expected, over 
differentiation time, cells changed morphologically and lost expression of pluripotency markers 
(OCT4) while first turning on neuronal precursor markers (CyclinD1 and Nestin, not shown) and 
then markers of mature neurons (MAP2, TAU, VGLUT1, GAD1) (Fig. 4A-B). Over differentiation 
time from d0 to d100, Aβ secretion increased markedly in both control and fAD lines, and the 
fAD-dependent increase in Aβ38 and 42, caused by the V717I mutation, was observed 
consistently and significantly after day 40 (Fig. 4C-E). Accordingly, we observed higher Aβ42/40 
ratios in fAD versus control lines, over the differentiation time-course, with statistical significance 
obtained beginning around day 24 (Fig. 4F). Furthermore, as cells became more neuronal in 
their RNA and protein expression profiles, there was a consistent and steady decrease in the 
ratio of APPsα to APPsβ secreted by these cells (Fig. 4I). While both APPsα and APPsβ 
increase over differentiation (in part due to an increase in APP expression (Fig. 4J)), there is a 
greater increase in APPsβ due to a robust increase in expression of BACE with neuronal 
differentiation (Fig. 4G, H, J).  The effect of the APP V717I mutation in significantly elevating the 
β-secretase cleavage of APP was observed at all time points examined (Fig. 4H).  
 
APP is differentially processed in human iPSCs directed to caudal versus rostral 
neuronal fates  
 Human iPSCs were directed to neuronal fates using the same general protocol described 
above. In order to direct the differentiation of these cells to caudal neuronal fates, retinoic acid 
(RA) and Sonic Hedgehog (Shh) were added to cultures at the neural progenitor stage between 
days 10-24 and 15-24 of differentiation, respectively (Fig. 5A). At day 40 of differentiation, 
conditioned media were collected and RNA or protein was harvested from the remaining cells in 
order to analyze gene expression (Fig. 5C-E, Supp. Fig. 5). Alternatively, remaining cells were 
fixed and immunostained for cell fate markers (Fig. 5B). Markers of general neuronal fate were 
unchanged when differentiation proceeded in the absence or presence of RA/Shh (Fig. 5B, C, 
Supp. Fig. S5A). However, markers of neuronal fates of the forebrain (cortical) were 
downregulated (Fig. 5B, left panel, 5D, Supp.Fig. S5B), while markers of more caudal 
(hindbrain/spinal cord) fates were upregulated (Fig. 5B middle, right panels, 5E, Supp. Fig. 
S5C,D). The gene showing the most significant upregulation with RA/Shh was HOXB4 (Fig. 
5B,E). In the nervous system, HOXB4 is expressed in the spinal cord and hindbrain with no 
expression in the mid- and forebrain reported26. HB9, EN-1, and Irx3 also were upregulated, 
consistent with the presence of spinal cord interneurons and motor neurons in caudally directed 
cultures27,28. 
 Neurons directed to caudal neuronal fates secreted more Aβ40 (Fig. 5F) relative to 
forebrain neuronal fates, which led to a decrease in the Aβ42/40 ratio in both control and fAD 
lines (Fig. 5G). Further, neurons with caudal fates secreted more APPsα and APPsβ relative to 
those of more rostral fates (Fig. 5I,J). However, in fAD lines this increase is more pronounced 
for APPsβ, resulting in a net decrease in the ratio of α- to β-cleavage of APP (Fig. 5H).  
 To determine whether iPSC-derived human neurons can reflect putative downstream 
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effects of the APP V717I mutation observed in AD patients, we quantified the levels and 
phosphorylation state of Tau. Neurons directed to forebrain neuronal fates and expressing the 
APP V717I mutation exhibited higher levels of Tau mRNA (Fig. 6A) and a 1.7 fold increase in 
protein levels (Fig. 6B, D, Supp. Fig. S2C,D) at both d40 and d100 of differentiation. At d100, 
APP V717I neurons exhibited higher levels of phospho-Tau at two different amino acids (S202 
and S262). In the case of pS202, this increase was proportional to an increase in total Tau (Fig. 
6B). However, when normalized to total Tau, pS262 was significantly elevated beyond the 
increase of total Tau expression observed (Fig. 6B, D, E). Importantly, the increases in total and 
phospho-Tau levels caused by the fAD mutation in forebrain neurons were no longer observed 
when neurons were directed to more caudal fates (Fig. 6D,E). Consistent with the data 
observed at day 40 (Supp.Fig. 2C, D), APP protein levels also were elevated in d100 cultures 
directed to a cortical fate (Fig. 6B, C). Similar to effects on Tau expression, neurons directed to 
a caudal fate did not show a significant increase in APP expression (Fig 6B-E).  
  
Discussion 
 
 Aβ homeostasis plays a central role in the pathogenesis of AD29. Aβ is generated 
physiologically by sequential cleavages of APP by β- and γ-secretase. Cleavage by γ-secretase 
is imprecise and results in the generation of a variety of Aβ species varying in length between 
36 and 43 residues. Aβ40 is the most abundant, followed by Aβ42 and 3825,29. Although Aβ42 is 
a minor form, the two extra amino acids (isoleucine and alanine) make this peptide more 
hydrophobic and prone to self-aggregation. It has been previously shown that fAD mutations in 
APP, PSEN1 or PSEN2 each act to either increase total Aβ levels or (more commonly) to 
increase the amount of Aβ42 relative to Aβ40 generated (reviewed in 3). Here, we demonstrate 
that human neurons derived from iPSC lines established from subjects harboring one such 
mutation (V717I) generate significantly more Aβ42. The fold-increase in Aβ42/40 ratio reported 
here (1.6-fold) is highly similar to that observed in plasma from subjects with the V717I mutation 
(1.7-fold)12. We extend these findings to show that Aβ38 also is elevated, in accordance with the 
helical model of γ-secretase processivity within the transmembrane domain30. This model of 
APP cleavage describes stepwise cleavages of APP by γ-secretase, beginning with epsilon 
cleavage near the transmembrane-cytoplasmic interface to release Aβ of 48 or 49 residues31. 
These longer Aβ-like species are then cleaved every 3-4 amino acids along the transmembrane 
domain to generate smaller species, such that Aβ49 is cleaved to generate Aβ peptides of 46, 
43 and 40 amino acids, whereas Aβ48 is similarly cleaved to generate Aβ peptides of 45, 42, 
and 38 amino acids25,32. In agreement with this processivity model, we observed an increase in 
both Aβ42 and 38 caused by the APP V717I mutation, suggesting that this mutation may 
primarily act to alter the initial epsilon site of cleavage within APP.  
 In addition to effects on the sites of γ-secretase cleavage within APP, we also describe an 
unexpected effect of this fAD mutation on β-secretase cleavage of APP. β-secretase activity is 
encoded by the genes BACE1 and BACE233–35,and expression of these genes is high in the 
CNS35–37. Human pluripotent cells provide a model system to examine the activity of these 
enzymes during simulated, in vivo human neuronal development. Here, we show a dramatic 
increase in β-secretase cleavage of APP as cells differentiate to neuronal fates. Moreover, 
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although the V717I mutation occurs at the site of the γ-secretase cleavages in the 
transmembrane domain of APP, a significant effect of this mutation on β-secretase cleavage of 
APP was observed at all differentiation time points examined. The increase was not due to 
indirect effects on BACE expression, as both RNA and protein levels of BACE were unchanged 
in the fAD neurons. One possible explanation is that the V717I mutation affects the position of 
APP within the membrane, which in turn affects both the site of epsilon cleavage of APP and the 
position of APP relative to the active site of BACE, which is a membrane-anchored protease 
that cleaves its substrates just outside of their transmembrane domains. α- or β-cleavage must 
occur prior to γ-secretase cleavage, as APP holoprotein cannot access the active site of γ-
secretase. To examine whether γ-secretase activity was necessary for the effect of V717I 
mutation on β-secretase activity, we asked whether γ-secretase inhibition could rescue the 
effect of the APP V717I mutation on β-cleavage. Indeed, γ-secretase inhibition by DAPT 
prevented the effect of the V717I mutation in elevating β-secretase processing of APP. This was 
observed in both iPSC-derived human neurons and HEK cells confirming the novel observation 
and suggesting that these enzymatic activities are functionally interdependent. This result is in 
agreement with very recent evidence that these proteases may exist in a previously 
unrecognized complex and affect the activities of each other (Chen, Shepardson, Patel, Guo, 
Lehm, Rice, LaVoie and DJS, in preparation). Further studies are therefore warranted to 
examine whether other fAD mutations affect β-secretase cleavage of APP, in addition to their 
known effects on γ-secretase processivity. 
 The accumulation of Aβ in all AD brains, as well as the dominant effects of APP, PSEN1 
and PSEN2 mutations in causing an accelerated but otherwise typical AD phenotype, point to 
Aβ being critical to pathogenesis. Accumulation of intraneuronal hyperphosphorylated Tau is a 
key feature observed in the AD brain. Multiple lines of evidence suggest that this pathological 
hallmark of AD can arise as a downstream result of accumulation of extracellular Aβ 20,38–40. 
Here, we observed a significant increase in Tau protein levels in neurons of forebrain fate 
derived from APP V717I iPSCs. This indicates that increased Tau levels can result from the 
effects of an APP fAD mutation in a relatively simple neuronal cell culture system, thus 
connecting the two major abnormalities of AD pathogenesis. Notably, cultures of both wild type 
and fAD neurons of rostral or caudal fates remain healthy at d100 of differentiation, with no 
obvious cell death observed (data not shown). However, in contrast to other studies, which have 
shown an increase in death of primary rodent neurons in response to exogenously added Aβ, in 
this study the extracellular Aβ is cleared from the cultures every 2-3 days with full media 
changes. The use of this system provides the opportunity to further probe the initiating events in 
AD pathogenesis, namely, the generation of pathological Aβ and the accumulation of 
phosphorylated Tau, in the absence of frank cell loss, which is not observed until late stages of 
Alzheimer’s disease. 
 The effects of the APP V717I mutation on the β- and γ-secretase processing of APP were 
observed in human iPSC-derived neurons from both fAD subjects as well as in HEK cells 
transfected with APP V717I cDNA, supporting the validity of using each of these models to 
study mechanisms relevant to AD. A powerful advantage of using human iPSCs, however, is 
the potential to direct the fates of these cells to any cell type. Therefore, iPSCs provide a unique 
opportunity to compare functional effects of endogenous genetic alterations between multiple 
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neural cell types derived from the same human donor. Importantly, distinct brain regions are 
differentially susceptible to neurodegeneration in AD, but the mechanistic basis for this is poorly 
understood. AD progression varies somewhat among subjects but often begins stereotypically 
with gradual loss of episodic declarative memory that correlates with synapse loss and 
neuritic/neuronal degeneration in the hippocampus and certain connected regions of the 
association neocortex (reviewed in 3). Although APP, β-secretase and γ-secretase are each 
expressed in all neurons, some regions of the CNS outside of the limbic and cerebral cortices, 
such as cerebellum, thalamus, midbrain and spinal cord are relatively spared of amyloid plaque 
accumulation and local synapse/neuron loss41. Here, we exploited the pluripotent nature of stem 
cells to show that APP processing differs significantly in neurons having distinct cell fates both 
in wild-type and APP V717I lines. Our data suggest that neurons of a forebrain (cortical) fate, 
which are more affected in AD, secrete Aβ that has a higher level of the pathogenically critical 
Aβ42/40 ratio, than neurons with more caudal fates of the hindbrain and spinal cord. 
Interestingly, the increase in total Tau levels observed with the fAD mutation in cortically-
directed cultures is not observed in neurons directed to a caudal fate. The observed ratio 
changes in our cell cultures and differences in cleavage products support the hypothesis that 
alterations in cleavage of APP in different neuronal subtypes may, in part, underlie the 
differential susceptibility observed in AD. 
 Taken together, the findings presented here provide several unexpected insights into the 
effects of APP fAD mutations on processing by the β- and γ-secretases. Furthermore, we 
provide evidence that APP is differentially cleaved in neurons of alternate fates and that 
different neuronal subtypes may respond differentially to an APP fAD mutation. Our work 
demonstrates the utility of iPSCs from human donors to model the differential neuronal 
susceptibility and downstream biochemical effects observed in AD, with related therapeutic 
implications. 	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Figure Legends 
 
Figure 1. Characterization of the neuronal differentiation capacity of familial AD iPSC 
lines harboring the APP V717I mutation. 
Human iPSC lines were derived from a father and daughter with an fAD mutation (APP V717I). 
A) Table summarizing human iPS lines used in this study. B) Schematic outlining α-, β-, and γ-
secretase cleavage sites in APP. Residue in red is V717, those in blue encode wild type Aβ. C) 
Control and fAD lines were differentiated to neuronal fates using an embryoid aggregate 
protocol. After 40 days of differentiation, cells were fixed and immunostained for general 
neuronal markers such as MAP2, Tau and TUJ1, a marker of lower layer cortical neurons 
(TBR1), a marker of upper layer cortical neurons (CUX1), and/or synaptic markers (PSD95, 
synapsin, VGLUT1). Data shown are representative images from control and fAD lines. Scale 
bars = 50 µm. Magnified views of dotted boxes are shown as insets or adjacent to each image. 
D, E) After 40 days, cells were lysed, RNA extracted, and expression of 150 genes analyzed 
using the NanoString platform. Expression of general neuronal markers are shown in D, cell fate 
specific markers are shown in E. Error bars = SEM. 
 
Figure 2. FAD mutation (APP V717I) in forebrain neuronal cells leads to increased Aβ42 
and Aβ38 production.  
Control and fAD iPSC lines were differentiated for 40-60 days to neuronal fates. Media 
conditioned on the cells for the final 48 hr were collected, and Aβ 38, 40, and 42 were detected 
in a single well using a multiplex ELISA (MesoScale Discoveries). Following collection of media, 
cells were lysed and RNA collected for parallel analyses of markers of differentiation. A, B) Aβ 
42/40 ratio. Data are shown for individual clones (A) or pooled as control and APP V717I (fAD) 
(B-H). For B-H, Aβ data were generated from the two control and four fAD lines shown in A and 
averaged over 13 rounds of differentiation (YZ1 n=45, YK26 n=24, 1a n=33, 1b n=16, 2a n=29, 
2b n=41). One way ANOVA performed with Tukey’s multiple comparisons test, ** p<0.01, *** 
p<0.001. In A, black asterisks show significance vs. YZ1 and green asterisks show significance 
vs. YK26. In F-H, day 40 cells were treated with vehicle or DAPT (5 µM) for the final 48 hr of 
differentiation (n = 4-5 for each condition). Two-tailed t-tests were performed, ** p<0.01, *** 
p<0.001. Error bars = SEM. 
 
Figure 3. APP V717I mutation in forebrain neuronal cells leads to increased cleavage of 
APP at the β-secretase site. 
Control and fAD iPSC lines were differentiated for 40-60 days to neuronal fates. Media 
conditioned for the final 48 hr were collected, and APPsα  and APPsβ detected in a single well 
using a multiplex ELISA (MesoScale Discovery). Following collection of media, cells were lysed 
and RNA collected for parallel analyses of markers of differentiation. A) Ratio of APPs α/β in 
each line analyzed. Green asterisks represent significance relative to YZ1, red asterisks relative 
to YK26. (B) APPsα or (C) APPsβ levels normalized to total RNA from control and fAD neurons 
are shown, summary data. Data in A is combined from 6 differentiation rounds, for YZ1 n=19, 
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YK26 n=11, 1A n=8, 1B n=, 2a n=26, and 2b n=28; for B and C n=20 for controls and n=38 for 
fAD. One way ANOVA performed with Tukey’s multiple comparisons test, * p<0.05; ** p<0.01, 
*** p<0.001. (D-F) Cells differentiated to neuronal fates for 50 days were treated with 5 µM 
DAPT or vehicle (DMSO) for the last 48 hr of culture prior to lysis. Media were collected and 
APPsα and APPsβ measured using multiplex ELISA. In D, “pre” conditions show data from the 
media collected from the same wells 48 hr prior to treatments. Green asterisks in (D) show 
significance relative to control cells treated with DMSO, and the purple asterisk in (F) shows 
significance relative to fAD DMSO. Representative data from a single round of differentiation are 
shown, n=3-5. Error bars represent SEM, ** p<0.01, *** p<0.001.   	  
 
Figure 4. Examination of APP cleavage products generated during differentiation to 
mature neuronal fates.  
Control and APP V717I (fAD) iPSC lines were differentiated over 100 days to neuronal fates. (A) 
At multiple time points, cells were fixed and immunostained for a pluripotency marker (OCT4) 
and a neuronal marker (MAP2). (B) Alternatively, cells were lysed following collection of media 
and RNA purified for qPCR analysis. Media were analyzed by ELISA to measure levels of Aβ 
(C-F) and/or APPsα and APPsβ (G-I). (J) qPCR analysis of APP and BACE mRNAs across the 
differentiation time course. For data in B-J, error bars = SEM. For each comparison, a two-tailed 
t-test was performed, * p<0.05; ** p<0.01, *** p<0.001. For d9, d17, d24, n=2-4, for d40 n=70-
100, for d60, d80, d100 n = 5-10.	  
 
Figure 5. Directed differentiation to alternate neuronal fates significantly affects β- and γ-
secretase processing of APP.  
A) Schematic of differentiation to neuronal fates showing window of morphogen treatment. B) 
Immunostaining of day 40 iPSCs differentiated to neuronal fates with and without retinoic acid 
(RA) and Sonic hedgehog (Shh) treatment. Scale bars = 100 µm. C-E) NanoString analysis of 
expression of a subset of 150 genes analyzed in control lines differentiated for 40 days with (+) 
and without (-) RA and Shh treatment. With RA/Shh treatment, general markers of neuronal fate 
were unchanged (C), markers of more rostral fates were downregulated (D), and markers of 
more caudal fates were upregulated (E). Data in (C-E) are derived from two lines over six 
rounds of differentiation. -RA/Shh n=25, +RA/Shh n=8. Error bars represent SEM. For each 
gene, a two-tailed t-test was done, * p<0.05; ** p<0.01, *** p<0.001. F-G) Conditioned media 
from day 40 differentiations with and without RA/Shh in control and APP V717I (fAD) lines were 
analyzed by Aβ triplex ELISA to measure 38, 40, and 42 levels. Aβ levels normalized to total 
RNA (F) and the Aβ 42/40 ratio (G) are shown separately for each line. APPsα and APPsβ were 
measured in the same samples using a duplex ELISA (MesoScale Discovery), and ratios of α/β 
are shown (H), as well as APPsα normalized to total RNA (I) and APPs-β normalized to total 
RNA (J). Data in H-J are combined from five differentiation rounds, two control lines, two fAD #1 
lines and two fAD #2 lines. n=35, 19, 32, 22 for ctl (-), ctl (+), fAD (-), and fAD (+), respectively. 
For each comparison in H-L, a two-tailed t-test was performed, * p<0.05; ** p<0.01, *** p<0.001. 
Error bars = SEM.  
 
Figure 6. Tau proteins levels are increased in fAD neurons directed to a forebrain fate. 
A) NanoString analysis of Tau mRNA expression (normalized to the geometric mean of 7 
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housekeeping genes) in control and fAD lines at days 40 and 100 (n = 25, 9, 3, 3 for ctl d40, 
fAD d40, ctl d100, fAD d100). B-E) Western blot for total and phospho-Tau of lysates from 
control and fAD iPSCs differentiated to day 100 with and without RA/Shh (B), and quantification 
by densitometry (D,E). C) Quantification by densitometry of APP normalized to GAPDH. * 
p<0.05; ** p<0.01, *** p<0.001. Error bars = SEM. 
 
Supplementary Figure S1. Characterization of human iPSC lines generated in this 
manuscript.  
A) Representative images showing fAD 2 iPSCs stained for Alkaline Phosphatase or else 
immunostained for OCT4, NANOG, SSEA3, SSEA4, or TRA-1-60. B) RNA templates purified 
from iPSC lines were first reversed-transcribed to cDNA (+) or without reverse transcription (-), 
followed by PCR for markers listed. A representative example for fAD line 2 is shown. C) To test 
for pluripotency, each line was differentiated using an embryoid body protocol, and RT-PCR 
was utilized to test for the ability to generate all three germ layers. A representative example for 
fAD line 2 is shown. Karyotyping results from fAD 2 clone b (D) and fAD 1 clone a (E) performed 
by Cell Line Genetics. 
 
Supplementary Figure S2. Human neurons derived from APP V717I carriers do not have 
altered gene expression profiles of cell fate markers or secretase components.  
Control and fAD APP V717I lines were differentiated to neuronal fates. A,B) After 40 days, cells 
were lysed, RNA extracted, and expression of 150 genes analyzed using the NanoString 
platform. Expression of APP family members are shown in A and components of α-, β- and γ-
secretases in B. Each bar represents data from 9 independent wells collected from three rounds 
of differentiation. Data from four different iPSC lines are represented. Error bars represent SD. 
C) Representative Western blot analysis of selected genes following 40 days of differentiation. 
For the final 48 hours of differentiation, wells were treated with vehicle or DAPT (a γ-secretase 
inhibitor, 5uM). D) Quantification by densitometry of APP and Tau normalized to GAPDH. 
Individual samples are shown. Two-tailed t-tests for each comparison were performed  
***p<0.001. 
 
 
Supplementary Figure S3. FAD mutation (APP V717I) in forebrain neuronal cells leads to 
increased Aβ42 and Aβ38 production, shown relative to total protein and shown by 
differentiation round. 
Control and fAD iPSC lines were differentiated for 40-60 days to neuronal fates. Media 
conditioned on the cells for the final 48 hours was collected, and Aβ40 (A), Aβ42 (B), and Aβ38 
(C) were detected in a single well using a multiplex ELISA (MesoScale Discoveries) and 
normalized to total protein. Error bars represent SEM, control n=4, APP V717I (fAD) n=19 
*p<0.05. Aβ ELISA data shown in Figure 3 is broken down by round of differentiation (D) and by 
ELISA plate (E). Each point represents data form a single well. 
 
Supplementary Figure S4. APP V717I mutation increases Aβ42 and Aβ38 generation as 
well as increases APPsβ generation in HEK cells. 
HEK cells were transiently transfected with APP V717I or wild type APP. 24 hours later, cells 
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were treated with DAPT (5 µM) or vehicle for 24 hours, followed by collection of media and lysis 
of cells. A-G) In the media, Aβ40 (A,C), Aβ42 (A,B), and Aβ38 (D) were detected using a 
multiplex ELISA, and APPsα (E,F) and APPsβ (E,G) were detected using a duplex ELISA. H) 
Western blots were performed on the lysates and conditioned media to confirm equal levels of 
expression of APP. Error bars represent SEM, Two-tailed t-tests for each comparison were 
performed  * p<0.05; ** p<0.01, *** p<0.001. ND=not detectable. 
 
Supplementary Figure S5. Control and APP V717I mutation lines differentiate similarly in 
the presence of RA and Shh. 
Control and APP V717I iPS lines were differentiated with and without RA/Shh as in Figure 5. 
Quantitative RT-PCR was performed for a general neuronal marker (A, MAP2), a marker of 
rostral forebrain fate (B, Tbr1), a marker of more caudal hindbrain (C, HoxB6) and a lower motor 
neuron (D, HB9) marker. Data shown are from four differentiation rounds, two control lines and 
three fAD lines. n=10-20 for each condition. For each comparison, a two-tailed t-test was 
performed, * p<0.05; ** p<0.01, *** p<0.001. Error bars = SEM. 
 
 
Methods 
Patients and fibroblast derivation and iPSC generation 
iPSCs were generated in collaboration with the Harvard Stem Cell Institute. Skin punch biopsies 
were taken from a father and daughter pair, each with the APP (V717I) mutation, after informed 
consent and in accordance with Institutional Review Board approval. iPSCS were 
reprogrammed as described18. cDNAs for Oct4, Sox2, Klf4 and Myc were cloned into pMIG 
vectors and packaged into VSVG-pseudotyped retroviruses. Fibroblasts (~1  ×  105) were 
transduced with retroviruses. Valproic acid (50uM) was added for 7 days, beginning on day 2 
after transfection. iPSC colonies appeared after ~3 weeks and were picked based on 
morphology and GFP silencing. Colonies were transferred to 6-well plates containing irradiated 
mouse embryonic fibroblasts (MEFs). ROCK inhibitor (Y27632) (Millipore) was used at 10uM to 
increase cell survival. Each picked colony was one line. For passaging, cells were dissociated 
with collagenase (Stemcell Technologies). For a 10cm culture plate, between 5-50 colonies 
emerged.  
Karyotype Analysis and Characterization 
iPS clones were karyotyped by Cell Line Genetics. For pluripotency assays, iPSCs were 
dissociated from the plate with collagenase and then resuspended in ultra low-attachment 
plates and fed with iPSC media. Cells were re-plated onto gelatin after 1 week with DMEM 10% 
FBS. Cells were harvested for RNA extraction after 1 week of plating. Karyotyping was routinely 
performed using the NanoString nCounter CNV CodeSets, in order to ensure a normal 
chromosome number across passages. 
iPS Cell Culture:  iPSCs were cultured in medium consisting of 400 mL Dulbecco’s Modified 
Eagle’s Medium: Nutrient Mixture F12 (DMEM/F12, Gibco), 100 mL  Knockout Serum 
Replacement (Gibco), 5 mL MEM-NEAA (Invitrogen), 5 mL of Penicillin/Streptomycin/Glutamine 
(Invitrogen) and 500 µL 2-Mercaptoethanol (100x) (Invitrogen). bFGF (Millipore) was added 
fresh daily at 10 µg/ml (1000x). Cells were maintained at 37°C/5% CO2 and were split as 
necessary based on colony growth (5-6 days). Differentiating colonies were removed from the 
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plate prior to splitting. iPSCs were maintained on a mouse embryonic fibroblast (MEF) feeder 
layer at 1.7-2.0 x105 cells/well (Globalstem). For passaging, cells were dissociated with 
collagenase (Stemcell Technologies). 
Neuronal Differentiation: For the induction of forebrain neurons, iPSCs were differentiated 
using an embryoid body-based protocol22 that was further optimized (Muratore and Young-
Pearse, unpub.). iPSC colonies were dissociated from MEFs at day 1 and cultured as 
aggregates 4 days in suspension with iPSC media. Aggregates were plated on matrigel-coated 
(BD Biosciences) culture dishes at day 7, forming primitive neuroepithelial (NE) structures over 
10 days with Neural Induction media (N2). By day 17 definitive NE structures were present, and 
cells were dissociated and further cultured in suspension using Neural Induction media (N2/B27 
with cAMP (Sigma) and IGF-1 (Peprotech). Neural rosettes were either selected manually or 
with STEMDiff Neural Rosette Selection reagent (Stemcell Technologies). The second culture in 
suspension aimed to purify neuronal progenitors, by clearing improperly differentiating cells. 
Cells were dissociated to single cells with accutase (Innovative Cell Technologies) and plated 
on matrigel for final differentiation at day 24 in Neural Differentiation media (N2/B27, Invitrogen) 
with ROCK inhibitor (Millipore, 10uM). Matrigel was used per the manufacturer’s instructions. 
Neural Induction Medium consisted of 490 mL DMEM/F12, 5 mL N2 supplement (Invitrogen), 10 
mL B27 supplement (Invitrogen), 5 mL MEM-NEAA and 2 µg/ml Heparin (Sigma-Aldrich). 
Neural Differentiation Medium consisted of 490 mL of Neurobasal medium (Gibco), 5 mL of N2 
supplement, 5 mL of MEM-NEAA, and 10 mL of B27 supplement (Invitrogen) with the addition 
of fresh cAMP (1 µM) (Sigma), BDNF, GDNF, and IGF1 (PeproTech, 10 ng/mL) to the medium. 
A full media change was performed every 2-3 days for the duration of the experiment. For the 
induction of more caudal neurons, iPSCs were differentiated using the protocol described 
above. The aforementioned differentiation medias were used, with the addition of retinoic acid 
(100mM) (Sigma) and Sonic Hedgehog (100µg/mL) (R+D) from days 10-24 and 15-24 (as per 
22).  
Primers 
Actin: Forward, ggacttcgagcaagagatgg; Reverse, agcactgtgttggcgtacag  
Dnmt3b: Forward, ataagtcgaaggtgcgtcgt; Reverse, ggcaacatctgaagccattt 
hTERT: Forward, tgtgcaccaacatctacaag; Reverse, gcgttcttggctttcaggat 
Nanog: Forward, tccaacatcctgaacctcag; Reverse, gactggatgttctgggtctg 
Oct4: Forward (transgene), gtggaggaagctgacaacaa; Reverse (endogenous), caggttttctttccctagct 
RexI: Forward, tggacacgtctgtgctcttc; Reverse, gtcttggcgtcttctcgaac  
Sox2: Forward, ttgtcggagacggagaagcg; Reverse, tgaccaccgaacccatggag  
β-Tubulin: Forward, cagatgttcgatgccaagaa; Reverse, tgctgttcttgctctggatg  
NCAM: Forward, atggaaactctattaaagtgaacctg; Reverse, tagacctcatactcagcattccagt  
Pax6: Forward, tctaatcgaagggccaaatg; Reverse, tgtgagggctgtgtctgttc  
AFP: Forward, agcttggtggtggatgaaac; Reverse, ccctcttcagcaaagcagac  
GATA4: Forward, ctagaccgtgggttttgcat; Reverse, tgggttaagtgcccctgtag  
Flk1: Forward, agtgatcggaaatgacactgga; Reverse, gcacaaagtgacacgttgagat  
GATA2: Forward, gcaacccctactatgccaacc; Reverse, cagtggcgtcttggagaag  
PECAM: Forward, cccagcccaggatttcttat; Reverse, accgcaggatcatttgagtt  
VECAD: Forward, cagcccaaagtgtgtgagaa; Reverse, tgtgatgttggccgtgttat 
 
qPCR 
qpcr was performed using Fast SYBR Green Master Mix (Applied Biosystems) and run on a 
ViiA 7 System (Applied Biosystems). Samples were assayed in 2 technical replicates. Data was 
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analyzed using the ΔΔCT method and expression was normalized to GAPDH expression42. RNA 
was purified from individual samples and processed through a PureLink RNA Mini Kit (Ambion), 
followed by reverse transcription using SuperScript II (Invitrogen). Primer efficiency was 
calculated for each pair of primers and the slope of the dilution line was found to be within the 
appropriate range. Dissociation curves also showed single peak traces, indicating template-
specific products. 
Immunocytochemistry and microscopy 
Cultures were fixed with 4% paraformaldehyde, followed by membrane permeabilization with 
0.1% TritonX-100 and then staining with primary and secondary antibodies (see Antibodies). 
Imaging was performed using a Zeiss LSM710 confocal microscope and images were acquired 
using ZEN black software. Software was used to pseudo-color images and add scale bars.  
Western Blots and antibodies 
Lysates and conditioned media were electrophoresed on 4-12% Bis-Tris gels (Invitrogen) and 
transferred to nitrocellulose. Lysates were prepared with standard buffer containing 1% NP40, 
0.5M EDTA, 5M NaCl, 1M Tris and cOmplete protease inhibitors and phosSTOP (Roche). 
Western blotting and immunostaining were performed with the following antibodies: MAP2 
(1:5000), Oct4 (1:1000), Tbr1 (1:200), Cux1 (1:100), SYP (1:250), PSD95 (1:250) VGLUT1 
(1:500), Nanog (1:50), abcam; SSEA3 (1:200), SSEA4 (1:200), TRA-1-60 (1:200), GAPDH 
(1:2000), BACE (1:500), Millipore; Tau (1:200, Dako), TuJ1 (1:1000, Sigma), Hoxb4 (1:50, 
Developmental Studies Hybridoma Bank), APP (C9) (1:1000, Selkoe Lab, Brigham and 
Women’s Hospital), APPs (4F2) (1:1000, Selkoe Lab, Brigham and Women’s Hospital), pS262 
(12E8) (1:2000, Malinow Lab, UCSD), pS202 (AT8) (1:200, Pierce). Secondaries were from 
Jackson ImmunoResearch: anti-chicken cy2/cy3/cy5, anti-rabbit cy2/cy3, anti-mouse cy2/cy3, 
anti-rat cy2/cy3 (1:1000). TOPRO3, DAPI 1:1000 Invitrogen. 
Aβ  and sAPPα /β  measurements 
Neural cells were plated in 96-well plates at various time-points up to 100 days. ELISA assays 
was carried out using the reagents, protocols, and imager manufactured by Meso Scale 
Diagnostics, LLC. Media were collected after 48-hours and analyzed using the 6E10 Abeta 
Triplex or sAPPα/sAPPβ ELISA assays (specific to human). Data were normalized to either total 
RNA or intracellular protein values, as noted.    
Inhibitor treatments 
Neural cells were plated at day 24 and allowed to differentiate until day 40-50. Conditioned 
media were collected 48-hours prior to treatment and saved for ELISA assays. Cultures were 
then treated with either 5µM DAPT or DMSO (Sigma) for 48-hours, followed by media collection 
and harvesting for either RNA or protein. RNA was purified from individual wells and processed 
through a PureLink RNA Mini Kit (Ambion). For protein, cells were lysed with standard buffer 
containing 1% NP40, 0.5M EDTA, 5M NaCl, 1M Tris and cOmplete protease inhibitors and 
phosSTOP (Roche).  
Nanostring analysis 
To analyze gene expression for a large number of genes from an individual sample, we utilized 
a custom probe set designed by NanoString Technologies (nCounter Gene Expression Assay). 
The assays were performed using the NanoString protocols, 12 samples per run. The first step 
hybridization reactions were carried out with 100-200 ng RNA. Post-hybridization samples were 
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processed with the nCounter Prep-station. Following run completion, the cartridge was scanned 
using the nCounter Digital Analyzer, at max resolution (~1000 images/sample). Data were 
analyzed using the nSolver Analysis Software and normalized to a set of 7 house-keeping 
genes or to the total gene set, as noted.  
Transfections 
HEK293 cells were transiently transfected with cDNA encoding either wild type human APP695 
or with the V717I mutation, using Fugene HD (Promega). 24-hours after transfection, media 
were changed and cells were treated with either DMSO or 5µM DAPT. 48-hours after 
transfection, conditioned media were collected and cells lysed in 1% NP40 STEN buffer. 
Statistics 
Data was analyzed using GraphPad PRISM 5 software. Values are expressed as either ±s.d or 
±s.e.m, as indicated by figure legend text. Statistical significance was tested by either an 
unpaired Student's t test (two-tailed) or by One-way ANOVA with a Tukey’s post-test. 
Statistically significant differences were determined by P values less than 0.05. 
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Appendix 3 
 
 
Effects of APOER2/VLDLR on ectodomain shedding of APP 
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Figure A3.1: Effects of APOER2/VLDLR on ectodomain shedding of APP 
HEK293 cells were co-transfected with combinations of Reelin, APOER2, and VLDLR cDNA . 
Endogenous APPsα and APPsβ levels were quantified by ELISA and shown as a percentage of 
control.   
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Effects of HSPGs on ectodomain shedding of APP 
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Figure A4.1 Effects of HSPGs on ectodomain shedding of APP  A, B) Endogenous 
APPsα levels were measured by ELISA from several wild-type CHO lines (CHO-WT1 , 2 
or 3) or CHO cells deficient in HSPGs (CHO-677) or HSPGs + chondroitin sulfate (CHO-
745) for 24 hr. Blots show the corresponding FL- and CTF levels in some of the cells. 
C, D) Ext-1 (the mutated gene in CHO-677 cells) was transfected into CHO-677 cell 
lines in an attempt to rescue the effects on APPsα.   
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Figure A4.2  HSPG-independent effects of Reelin on APP ectodomain shedding  
Ext-1  and Reelin were transfected into CHO-WT, CHO-677, CHO-745 cell lines.  
Endogenous APPsα levels were measured by ELISA .  
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APP ectodomain shedding in Reeler primary neuronal cultures 
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 Figure A5  APP ectodomain shedding in Reeler primary neuronal cultures 
Cortical neurons from WT, Het, or Reelin KO E18 mouse embryos were cultured over 
multiple days in vitro (DIV). Media was collected and APPsα was measured by ELISA. 
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